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Epidemiological Features of Central Nervous System (CNS) Infections in Taiwan and Molecular 
Investigation of CNS Infections of Unknown Cause 
Chien-Chin (Kevin) Hsu 
 
In this thesis, I explore the epidemiological features of CNS infections using a population-based 
dataset and analyze CSF samples from patients with meningitis or encephalitis of unknown cause 
using molecular methods. In the second chapter, I review the literature on the epidemiology of 
meningitis and encephalitis, and current diagnostic approaches, focusing on the strengths and 
limitations of various diagnostic methods. In the third chapter, I investigate the causes of 
meningitis and encephalitis using a population-based dataset from the National Health Insurance 
Research Dataset (NHIRD) from Taiwan, representing the interval from 1996 to 2008. The 
analysis assesses differences in the disease between known and unknown cause groups in terms 
of incidence, demographic features, seasonal and geographic distribution. In the fourth chapter, I 
analyze CSF samples from patients with meningitis or encephalitis of unknown cause using a 
tiered molecular approach to discover the undetected or novel pathogens; techniques used 
include MassTag PCR, DNA microarrays and high-throughput pyrosequencing. I conclude the 
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Chapter 1: Introduction 
 
Central Nervous System (CNS) infections remain some of the most challenging diseases to 
diagnose and treat. CNS infections can be caused by bacteria, viruses, fungi and parasites.
1
 
Pathogens may enter the CNS through several routes; for example, they may replicate outside 
the CNS, spread by the hematogenous route and invade the CNS by passing across the 
blood-brain barrier (BBB). Pathogens may also be carried across in the infected leukocytes 
(as is the case for mumps, measles or human immunodeficiency virus), and then infect 
vascular endothelial cells, or they may invade the CNS directly through peripheral nerves (as 
with rabies) and via cranial nerves (as with herpes simplex virus). 
 
CNS infections can occur sporadically, endemically (e.g., arboviruses), or in outbreaks (e.g., 
Nipah virus). Although the consequent diseases are sometimes described as unusual 
complications of common infections (e.g., influenza, herpesviruses),
2-3
 CNS infections are 
potentially fatal diseases caused by a wide variety of pathogens. More than 100 pathogens 
have been recognized as causative agents of CNS infections in immunocompetent 
individuals,
4









1.1 Meningitis and encephalitis  
Meningitis is inflammation of the meninges, a membranous tissue covering the brain and 
spinal cord. The inflamed meninges can block brain vessels, causing severe neurological 
complications. Encephalitis is characterized by inflammation of brain parenchyma, resulting 
in seizures, cognitive impairment, altered consciousness and/or focal neurologic deficits;
8
 
however, the distinction between meningitis and encephalitis is sometimes blurred, as CNS 
infections can produce a certain degree of both meningeal and brain parenchymal 
inflammation. 
 
Meningitis and encephalitis of viral origin account for the majority of CNS infections.
4, 9
 
Aseptic meningitis is defined by inflammation of the meninges, as evidenced by CSF 
pleocytosis (i.e., an increased number of white blood cells >5 cells/mm
3
) with negative 
bacterial culture. Aseptic meningitis refers to viral meningitis and culture-negative meningitis 
(e.g., meningitis of unknown cause). The cause of viral meningitis is typically identified in 
only 55%-70% of cases.
10-11
 Among identified pathogens, enteroviruses are the most common 
causative agents, accounting for 40% of aseptic cases.
11
 Other pathogens implicated include 









diagnosis can be difficult, particularly for viral infections.
1, 13
 Consequently, current practice 
often adapts empirical treatment for patients with CNS infections, using combinations of 
broad-spectrum antibiotics and acyclovir, a drug with activity against herpesviruses; these 
therapies tend to increase antimicrobial resistance as well as medical costs. For these reasons, 
rapid and accurate detection of CNS infections is crucial to improving diagnosis and 
providing the best therapies for patients. For example, improved detection could aid in 
administrating antiviral drugs in a timely manner or avoiding unnecessary prescription of 
broad-spectrum antibiotics for patients with viral CNS infections.  
 
1.2 Changing epidemiology of CNS infections 
The epidemiology of CNS infections, particularly of meningitis, has changed since the 
introduction of Haemophilus influenzae type b (Hib) vaccines and Streptococcus pneumonia 
conjugate vaccine.
14
 For example, the incidence of bacterial meningitis in the U.S. has 
decreased from 2 cases per 100,000 in 1998-1999 to 1.38 cases per 100,000 in 2006-2007, 




The incidence of CNS infections varies by geographic region, and many risk factors for CNS 
infections remain unclear, particularly for infections of unknown cause. Generalization of the 





conducted. In addition, mandatory notification of public health authorities is not required for 
most CNS infections, with a few notable exceptions (e.g., Japanese encephalitis and West 
Nile encephalitis). Therefore, epidemiological studies of CNS infections are mainly 
dependent on self-reports from clinicians or hospital records.  
 
1.3 Pathogens identified in encephalitis 
In several large epidemiological studies, 48%-75% of encephalitis cases were 
unexplained.
16-20
 A causative agent was identified in only 40%-70% of encephalitis cases.
9, 21
. 
Among the identified pathogens, common agents of viral encephalitis worldwide are 
herpesviruses, including herpes simplex-1 (HSV-1) and herpes simplex-2 (HSV-2), varicella 
zoster virus (VZV), Epstein-Barr virus (EBV) and cytomegalovirus (CMV); enteroviruses, 
mumps and measles viruses.
17-18, 22-23
 Clinical manifestations of encephalitis are typically not 
pathognomonic for specific agents, although some viruses are associated with specific 
neurologic presentations as a result of neurotropism for certain brain areas. For instance, 




1.4 Burden of disease 
CNS infections impose a substantial burden on the healthcare system. Viral meningitis 
accounts for 36,000 annual admissions in the U.S..
12





approximately 19,000 hospitalizations and 1,400 deaths annually in the U.S.,
16
 and the 
estimated annual national cost of hospitalization was $650 million. The true overall burden of 
encephalitis was even greater, as the estimate did not include subsequent rehabilitation, 
long-term care and societal costs.
16
The hospitalization rate for viral encephalitis in the UK 





Without timely and accurate identification of pathogens and proper treatment, CNS viral 
infections are potentially life-threatening. For instance, in the absence of effective antiviral 
treatment, the mortality rate for HSV encephalitis was over 70%, with only 2.5% of patients 
recovering normal function.
4
 In contrast, the mortality rate for HSV encephalitis decreased to 
19-38% after the introduction of acyclovir since 1980s.
25-26
 Rabies virus encephalitis is 
typically fatal. In the U.S., rabies cases are most likely to result from exposure to bats or wild 
mammals.
27
 In China, at least 20,000 cases of Japanese encephalitis are reported annually. 
28
 
The mortality rate for Japanese encephalitis is approximately 30%, and nearly 50% of 
survivors suffer severe neurological sequelae. In a large outbreak of enterovirus 71 in Taiwan, 
infection had a high rate of CNS complications and a 19.3% mortality rate among patients 







Given the difficulties in determining the causative agents of CNS infections and the risk of 
missing opportunities to intervene early in the course of disease, most physicians pursue 
empirical treatment, using combinations of broad-spectrum antibiotics and acyclovir. The 
inappropriate use of these drugs results in increased health care costs and promotes 
antimicrobial resistance. For example, ciprofloxacin-resistant Neisseria meningitides 
emerged in North America in 2009;
30
 in addition, a penicillin-resistant strain of S. 
pneumoniae is increasing in prevalence, and the third-generation cephalosporins (e.g., 




On a global scale, increasing human traffic and land development have facilitated the 
re-emergence of pathogens in new geographic areas and the emergence of pathogens of 
zoonotic origin.
32
 Agricultural changes may increase the incidence of co-infection with 
zoonotic viruses. In recent years, the deadly and previously unknown Nipah encephalitis 
virus appeared in Malaysia.
33-34





Moreover, the changing epidemiological patterns of arboviral CNS infections may have 
profound implications on both a local and global scale. For instance, Japanese encephalitis 
virus is expanding worldwide.
38-40





infections remain to be elucidated; clinicians and researchers are still without accurate 
estimates of incidence, cause and risk factors for CNS infections, as well as optimal methods 
for the identification of pathogens. 
 
1.5 Current diagnostic approaches for patients with CNS infections 
Cerebral spinal fluid (CSF) obtained from lumbar puncture is considered a primary specimen 
for diagnosis and identification of pathogens in meningitis and encephalitis. Although 
isolation of pathogens by culture provides unambiguous proof of the presence of a specific 
pathogen in CNS infections, identification of viruses by culture is difficult because only a 
few viruses, such as enteroviruses and herpesviruses, can be recovered from culture. Studies 




Nucleic acid amplification methods for diagnosis of meningitis and encephalitis 
Nucleic acid amplification techniques have had a profound impact on the diagnosis and 
management of infectious diseases.
41
 Molecular methods have refined diagnostic approaches 
for identifying pathogens in CNS infections and have become the method of choice for the 
diagnosis of viral encephalitis.
42-46
 A staged molecular approach has been used successfully 
for pathogen detection and discovery, incorporating a multiplex MassTag PCR platform, 
DNA microarray, and high-throughput pyrosequencing.
47-49





offer a particular advantage for exploring the cause of CNS infections, particularly infections 
of unknown origin. 
 
1.6 Advanced molecular approaches for diagnosis of CNS infections 
A staged molecular approach has been proposed; this approach employs complementary tools 
for pathogen detection and discovery that include syndrome-based multiplex PCR assays, 




Multiplex MassTag PCR method 
The MassTag PCR platform amplifies specific nucleic acid fragments, using primers labeled 
by a photocleavable link to distinct tags.
48
 The tags are released by UV light and read by 
atmospheric pressure chemical ionization mass spectrometry. The identity of the microbe in 
the clinical sample is determined by its cognate tags, which have a distinct molecular weight. 
The MassTag PCR platform can detect up to 22 respiratory pathogens in one PCR reaction.
48
 
This platform has been applied to several syndrome-based panels, such as a hemorrhagic 











Microarrays currently include up to 8 million oligonucleotide probes printed on a glass slide. 
Sample nucleic acids are first randomly amplified and labeled. In the next step, 
complementary DNA hybridization occurs between the probe and the target. The microarray 
has demonstrated potential for pathogen identification through testing for almost all known 
viruses, bacteria, fungi, or parasites.
49
 A microarray designed for identifying 13 viral 





High-throughput sequencing allows identification of any species of bacteria, viruses, fungi or 
parasites, including those that are new to science.454 Life Sciences has developed an 
emulsion PCR-based method for the amplification of a DNA library immobilized onto 
micro-beads, with subsequent massively parallel sequencing-by-synthesis in a picotiter 
plate.
53
 The unique potential of this sequencing platform has been demonstrated by its ability 
to identify a novel arenavirus that causes transplant-associated encephalopathy
54
 and a novel 
astrovirus that causes CNS disease.
55
 As a result, unbiased high-throughput sequencing shows 
promise for the investigation of CNS infections, particularly when the disease is caused by 






1.7 National Health Insurance Research Dataset in Taiwan 
Taiwan implemented a National Health Insurance program in 1995.
56
 As of December 2009, 
23.03 million people were enrolled in this universal health care system, representing over 
99% of the total Taiwanese population (23.12 million persons). The NHIRD is de-identified 
and maintained by the National Health Research Institutes and is provided to scientists in 
Taiwan for research purposes.  
 
This database includes a registry of contracted medical facilities, board-certified physicians 
and original claim data for reimbursement, including ambulatory care and inpatient medical 
benefit claims, prescriptions and treatment procedures in ambulatory and inpatient care and 
detailed hospitalization costs. Therefore, the database provides an opportunity for 
epidemiological investigation of many diseases from a nation-wide database. Several 




As almost all patients with CNS infections are hospitalized for treatment, every case with a 
diagnostic code of viral meningitis or encephalitis is recorded in the database. The NHIRD 
makes it possible to study the epidemiologic characteristics of CNS infections in Taiwan and 
determine the microbiological distribution of CNS infections. The results may provide clues 





1.8 Summary and conclusion 
CNS infections impose a substantial disease burden and represent a diagnostic challenge, 
with an infectious cause determined in less than 40 to 60% of cases. The true incidence of 
CNS infections is likely under estimated, as most CNS infections are not reported to public 
health authorities. The high proportion of cases of unknown cause is partly a result of 
insufficient understanding of the epidemiological characteristics of such infections. 
Furthermore, the currently available approaches for pathogen detection in CNS infections 
may be insufficient. Advanced nucleic acid detection methods may improve our ability to 
identify the pathogens involved in CNS infections, particularly in infections of currently 
unknown cause. 
 
In this dissertation, I review the literature regarding the epidemiology and diagnosis of CNS 
infections, with a particular focus on the strengths and limitations of various diagnostic 
methods (Chapter 2). I describe the epidemiology of CNS infections in Taiwan using a 
nation-wide NHIRD dataset. I explore risk factors for CNS infections of unknown cause 
(Chapter 3) and analyze CSF samples of unknown CNS infections using a staged molecular 
approach, with techniques including MassTag PCR, DNA microarrays and high-throughput 
pyrosequencing, to discover unrecognized or novel pathogens (Chapter 4). In the conclusion, 
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Chapter 2: Literature review: 
Epidemiology of Central Nervous System (CNS) Infections and Pathogen Discovery in CNS 








The objective of this study was to summarize the literature on the epidemiology of CNS 
infections of unknown cause and pathogen discovery in CNS infections. We focused on the 
conventional and molecular methods developed since the1990s and reviewed their 
applications in the diagnosis of CNS infections. We conducted a review of articles published 
in English in PubMed from January 1990 through December 2010, using the following 
MeSH terms: “encephalitis”, “meningitis”, “meningoencephalitis”, “central nervous system 
infections” and “molecular diagnostic techniques”. We further limited the search with MeSH 
subheadings that included “epidemiology”, “etiology”, “cerebral spinal fluid” and 
“diagnosis”. The titles of the articles were screened first; articles were excluded if they 1) 
were case reports or case series, or 2) examined non-infectious causes (e.g., encephalopathy). 
A total of 106 articles met our criteria for inclusion in the review. Several large international 
studies revealed a high proportion of encephalitis cases of unknown cause. This result may be 
in part due to insufficient knowledge of the epidemiology of CNS infections of unknown 
cause, misclassification of cases with non-infectious causes and the limited approaches 
available for pathogen discovery in CNS infections. The increasing availability of advanced 
molecular diagnostics has refined our knowledge of and approaches to CNS infections, 
particularly in infections of unknown cause. Collective results from clinical, epidemiological 





Further epidemiological studies and new developments in advanced molecular methods for 
pathogen discovery in CNS infections of unknown cause are needed to facilitate accurate 








Central Nervous System (CNS) infections may result in severe disability or death. CNS 
infections can be caused by a wide variety of pathogens, including bacteria, viruses, fungi 
and parasites.
1
 Meningitis is inflammation of the meninges, a membranous tissue covering 
the brain and spinal cord. The inflamed meninges can result in vasculitis, irritation of the 
cortex influencing consciousness or causing seizures, damage to cranial nerves or 
interference with CSF circulation resulting in hydrocephalus, causing severe neurological 
complications. Encephalitis is inflammation of the brain parenchyma; this inflammation 
causes neurologic dysfunction that may manifest as altered mental status and seizures. 
Abnormal brain function distinguishes encephalitis from meningitis; however, the distinction 
between meningitis and encephalitis is not always clear. 
 
The epidemiology of CNS infections has changed with the introduction of vaccines. 
Meningitis caused by Haemophilus influenzae, which was at one point the major cause of 
bacterial meningitis in children and infants, is now decreasing in incidence.
2
 Meningitis and 
encephalitis of viral origin, however, still account for the majority of CNS infections.
3,4
 
Nevertheless, the clinical manifestations associated with individual pathogens are nonspecific, 








Although diagnostics have improved with the introduction of advanced imaging techniques 
and polymerase chain reaction (PCR), meningitis and encephalitis remain some of the most 
challenging diseases to diagnose. The causes of most encephalitis remain unknown. In 
several large epidemiological studies, 48%-75% of encephalitis cases were unexplained,
6-10
 
indicating that current diagnostic approaches may be insufficient to identify pathogens in 
CNS infections, particularly in encephalitis. Despite these difficulties, epidemiological clues 
such as risk factors may aid in the diagnosis and management of meningitis and encephalitis; 
however, little attention has been focused on the epidemiological features of meningitis and 
encephalitis of unknown cause. 
 
The identification of microbes in brain tissue or meninges is the traditional “gold standard” 
for diagnosis; however, this is highly invasive. For this reason, cerebral spinal fluid (CSF) 
obtained via lumbar puncture is considered the best available material for diagnosis and 
identification of pathogens in CNS infections. The isolation of pathogens in culture provides 
unambiguous proof of the presence of a specific pathogen in CNS infections, but only a few 
viruses, such as enteroviruses and herpesviruses, can be recovered from culture. Studies 
showed that only 1.9% of CSF viral cultures were positive,
8
 and less than 0.1% of viral 








Nucleic acid amplification techniques have had a profound impact on diagnosis and 
management of infectious diseases.
12
 Molecular methods have refined diagnostic approaches 
for identifying pathogens in CNS infections and become the method of choice for the 
diagnosis for viral encephalitis.
13-17
 A staged molecular approach, including multiplex 
MassTag PCR, DNA microarray, and high-throughput pyrosequencing have been successfully 
used for pathogen detection and discovery.
18-20
 Advanced molecular techniques have 
particular promise for exploring the pathogenesis of CNS infections, particularly infections of 
unknown origin. 
 
The goal of this review is to examine the epidemiology of CNS infections, focusing on the 
epidemiology of CNS infections of unknown cause. This review will also explore methods 
for identifying the causes of CNS infections, highlighting their benefits and disadvantages, 
and review their applications in the diagnosis of CNS infections. Specifically, we focused on 
epidemiological studies conducted after 1990; studies conducted in the era of PCR are more 
likely to have identified CNS pathogens that are undetectable by culture-based methods. 







We used the PubMed database to search MEDLINE for relevant literature published between 
1990 and 2010. The search was restricted to human research articles written in English. We 
used the following MeSH terms: “encephalitis”, “meningitis”, “meningoencephalitis”, 
“central nervous system infections” and “molecular diagnostic techniques”. We further 
limited the search using the MeSH subheadings, such as “epidemiology”, “etiology”, 
“cerebral spinal fluid”, and “diagnosis”, for a total of 4,327 articles. Initially, we screened 
articles with respect to our eligibility criteria, as described below, by reviewing the titles of 
the articles, yielding 1,433 articles. Subsequently, we reviewed the abstracts to determine 
whether the papers were eligible for inclusion in this review.  
 
Articles that were eligible for inclusion in this review met the following criteria: 1) consisted 
of original research published after 1990; 2) performed a population-based study or a study in 
a well-defined geographic area; 3) provided information on the incidence, etiology, diagnosis 
or the proportion of cases with known and unknown cause of CNS infections; or 4) used 
molecular methods for diagnosis of CNS infections. Articles were excluded if they were 1) 
case reports or case series; or 2) studies on non-infectious causes of CNS infection (e.g., 
encephalopathy). Articles on the epidemiology or diagnosis of CNS infections were judged to 





2.4 Epidemiology of CNS infections 
Incidence of meningitis 
The incidence of bacterial meningitis ranges from 1.38 to 3.5 cases per 100,000 population in 
North America and Europe.
21-24
 The exact incidence of aseptic meningitis is unknown, as 
reporting is not mandatory in most countries. In the U.S., the incidence of aseptic meningitis 
was 3.7 per 100,000 in 1994.
25
 In one birth cohort in Finland, the incidence of aseptic 
meningitis was 27.8 per 100,000 children under age 14.
26
 One large cohort in Denmark gave 
the overall incidence of viral meningitis as 10.7 per 100,000, with the highest incidence (38.7 




Incidence of encephalitis 
The incidence of acute encephalitis varies by geographic area but was generally estimated 
between 1.4 and 7.3 per 100,000 population (Table 2.1).
6,7,9
 Only a few large epidemiological 
studies have been published. In one such study, Khetsuriani et al. analyzed representative 
sample of patient discharge records from the National Center for Health Statistics in the U.S. 
and reported that the hospitalization rate for encephalitis was 7.3 per 100,000 population 
from 1988 to 1997.
6
 David et al. analyzed hospital statistics dating from 1989 to 1998 in 
England and found that the hospitalization rate for viral encephalitis was 1.5 per 100,000 
population.
7










In Asia, however, only a few studies have examined the incidence of CNS infections, with the 
exception of Japanese encephalitis. In Thailand, one study gave an incidence of viral 
encephalitis of 6.34 per 100,000 population.
28
 A study in Japan gave an estimated incidence 




The causes of CNS infections are difficult to ascertain, especially for presumed viral 
infections.
1
 One study in England showed that 2,898 patients were diagnosed with viral 





Cause of meningitis 
Meningitis and encephalitis can be caused by a variety of bacteria, viruses, fungi and 
parasites. More than 100 pathogens have been recognized as causative agents of meningitis 
and encephalitis in immunocompetent individuals (Table 2.2). The three most common 
causes of bacterial meningitis worldwide are Haemophilus influenzae, Streptococcus 
pneumonia and Neisseria meningitides.
31





patient age. For instance, Haemophilus influenzae was the most common agent of bacterial 
meningitis among children < 5 years of age 
32
, and meningitis caused by Listeria 
moncytogenes typically occurs in neonates and people aged >50 years.
33
 With the 
introduction of the Hib vaccines, the epidemiology of bacterial meningitis has changed 
dramatically. In the U.S., the most common pathogen in cases of bacterial meningitis is now 
Streptococcus pneumoniae (Figure 2.1). 
 
Aseptic meningitis accounts for the majority of meningitis cases. Often, no pathogen is 
identified in cases of aseptic meningitis. In the U.S., the agent of aseptic meningitis was 
unspecified in most (45.9%) meningitis cases in 2006. Similarly, one study in Finland showed 
that unidentified pathogens accounted for the majority (34%) of aseptic meningitis cases.
34
 
Among aseptic meningitis cases in which a specific virus was identified, non-polio 




Cause of Encephalitis 
The majority of causes of encephalitis worldwide are unexplained. Khetsuriani analyzed 
discharge data from U.S. hospitals from 1988 to 1997 and showed that no specific agent was 
found in 60% of encephalitis cases.
6
 Similarly, 60% of viral encephalitis cases in the UK 
between 1989 and 1998 were of unexplained.
7





54% of encephalitis cases in hospitals were unexplained.
3,8
 A recent study in Australia 





Among pathogens identified, viruses are the pathogens most commonly identified in cases of 
encephalitis. Herpesviruses remain the most common pathogen of sporadic encephalitis. 
Herpes simplex virus, varicella-zoster virus and Mycobacterium tuberculosis were the most 
three commonly identified pathogens in encephalitis in the U.K. and France.
10,36
 In Australia, 
herpes simplex virus, varicella-zoster virus and Toxoplama gondii were the most common 
pathogens.
9
 Similarly, in the U.S., herpes simplex virus and Toxoplama gondii were the most 
commonly identified pathogens in cases of encephalitis.
6
 The emergence of Toxoplasma 
encephalitis during the study period was related to the HIV epidemic. With antimicrobial 





2.5 Risk Factors for CNS Infections of known or unknown cause 
Age 
CNS infections can affect patients of all ages, but they appear to be more common in young 





highest risk of encephalitis-associated hospitalization from1988 to 1997. In Australia, the 
highest rates of encephalitis admission were found for children aged 0-9 years and adults 
aged > 60 years between 1990 and 2007.
9
 In England, the rate of viral encephalitis 
hospitalizations was highest for children <1 year old in the period from 1989 to 1998.
7
    
 
The age distributions of CNS infections differ by pathogen and geographic area. For example, 
enteroviral CNS infections are predominantly seen in children. Herpes simplex virus 1 
(HSV-1) shows a bimodal age distribution, with more than 80% of cases in patients < 20 or > 
50 years of age,
38
 whereas herpes simplex virus 2 (HSV-2) is most commonly seen in 
neonatal patients when the infant contacts with maternal genital secretions at delivery.38 
Furthermore, with the introduction of Hib vaccines and the Streptococcus pneumoniae 
conjugate vaccine, the age distribution of bacterial meningitis has changed dramatically. For 
instance, the median age of patients with bacterial meningitis had increased from 15 months 





CNS infections appear to be more common in men. In one large cohort of 12,000 children 
who were followed up from birth to the age of 14 in Finland, 63% of those who developed 
CNS infections (110/174) were male.
26





was observed in Australia;
9
 a male-to-female ratio of 1.3:1 in encephalitis-related 
hospitalizations was observed in a US study.
6
 Although the reasons for the high 
male-to-female ratio in CNS infections remain unclear, the authors of the Australian and US 
studies suggested that the gender discrepancy could be due to a higher rate of toxoplasmic 
encephalitis cases in men. For example, toxoplasmic encephalitis accounted for 11.5% of all 
encephalitis-associated hospitalizations in the U.S. in 1988-1997; such cases are likely 





Many CNS infections are seasonal. Aseptic meningitis occurs more frequently in summer; 
however, some may occur sporadically year round, such as HSV encephalitis. Viral 
encephalitis shows a bimodal seasonal distribution, with a high peak in summer and a lower 
peak in winter.
39
 Such seasonal patterns are particularly prominent in regard to the infections 
transmitted by vectors that proliferate in favorable climates and seasons. For example, 
arthropod-borne viruses (arboviruses) cause CNS infections typically peak in the late summer 
and fall in the U.S., when human exposure to the vectors is highest.  
 
Some other modes of viral transmission are also seasonal. For instance, influenza incidence 







 Aseptic meningitis caused by non-polio enteroviruses is most commonly 
seen in the summer and fall.
34
 Warmer environments favor survival of enterovirus and its 
transmission through water and environmental contamination. Consequently, in Taiwan, a 
sharp increase in severe cases of enteroviral infection was observed when the average 
ambient temperature rose over 24℃ between April and May.42 Peaks of enteroviral infection 
are typically seen in the late summer and autumn in temperate climates.
43
 Similarly, 
enteroviral infections have a distinct summer-fall seasonality in the U.S., with 78% of cases 





Pathogens in CNS infections can be ubiquitous and distributed worldwide; examples include 
herpesviruses, influenza and non-polio enteroviruses, in which most infections are 
asymptomatic. On the other hand, some pathogens causing CNS infections are generally 
restricted within certain geographic area (Figure 2.2); such geographic restrictions tend 
particularly to apply to vector-borne pathogens or to those transmitted by regionally specific 
human behavior. Hence, geographic clues may provide clues to diagnosis of CNS infections. 
For example, Japanese encephalitis is endemic throughout China, Southeast Asia and India;
44
 
La Cross encephalitis is mainly seen in the central and eastern U.S.;
4
 in Bangladesh, Nipah 









Specific occupations may increase the risk of certain CNS infections, as they increase 
exposure to specific agents. For example, a forest worker has higher probability of exposure 
to tick bites and subsequent infection with tick-borne encephalitis; most cases in the 1998 
outbreaks of Nipah virus in Malaysia in 1998 were diagnosed in pig farmers, as pigs 





The spectrum of possible pathogens is even broader in immunocompromised individuals 
presenting with CNS infections. Typically innocuous pathogens may cause disease in patients 
immunocompromised by AIDS or immunosuppressive therapy. For example, fungi and 
Toxoplasma gondii are the predominant causative agents of CNS infections in patients with 
malignancies.
47
 CNS infections occurred in 3% of patients after heart transplantation and in 
3.9% of patients after kidney transplantation.
48
 Similarly, varicella zoster encephalitis is more 









2.6 Encephalitis of unknown cause 
As seen in Figure 2.3, the majority of encephalitis across countries are of unknown cause. 
Although little attention has been focused on the epidemiological features of infections of 
unknown cause, three factors may contribute to the universal phenomenon in which the 
agents of most CNS infections worldwide are unknown, as outlined below: 
 
Lack of knowledge of epidemiology of meningitis and encephalitis with unknown cause 
Our knowledge of the epidemiology of meningitis and encephalitis of unknown cause is 
insufficient. Clinical and epidemiological clues as to the identity of agents of meningitis and 
encephalitis are usually unavailable or insufficient to guide a diagnosis. Hence, identification 
of pathogens is mainly a process of informed guesswork, particularly for emerging and 
re-emerging pathogens linked to meningitis or encephalitis.  
 
Most large epidemiological studies showed a high proportion of unknown etiologies in 
encephalitis cases; however, few studies addressed the epidemiological features of 
encephalitis of unknown cause. Khetsuriani found that hospital admissions with infections of 
unknown cause had a bimodal seasonal distribution, with higher rates of admission from June 
through October and in January and lower rates in April and May. In contrast, hospital 





months of the year.
6
 One recent study suggested that new and emerging infectious agents or 
new forms of immune-mediated encephalitis may be responsible for many of the cases of 




Misclassification of encephalitis with non-infectious causes  
Clinical conditions that mimic encephalitis (Table 2.3) may be misclassified as infectious 
encephalitis. This phenomenon may account for some conditions previously classified as 
unidentified CNS infections, as is exemplified by recent studies. One study in England
36
 
found that 7.9% (16 of 203) patients with suspected infectious encephalitis in fact suffered 
from the newly described, immune-mediated anti-N-methyl-D-aspartate receptor (NMDAR) 
encephalitis.
50
 A retrospective study in one German hospital revealed that 1.4% (7 of 505) 
patients previously identified as having infectious encephalitis of unknown cause were 
ultimately diagnosed with anti-NMDAR encephalitis.
51
 Similarly, one study in the U.S. 
showed that non-infectious encephalitis was identified in 10% and a non-encephalitis 
infection was identified in 3% of patients initially diagnosed as having infectious 
encephalitis,
52
 highlighting the ways in which a treatable disease may be misclassified as 
encephalitis of unknown cause. Nevertheless, the proportion of misclassified anti-NMDAR 
encephalitis cases seems to be relatively small and cannot explain fully the large proportion 





distinguish non-infectious causes from infectious causes of CNS infections, particularly in 
treatable cases of non-infectious encephalitis. 
Current diagnostic approaches are limited 
Conventional culture-based methods usually fail to isolate viruses. Current methods for 
identifying a causative agent remain limited (as described below). The California 
Encephalitis Study in the U.S. revealed that the etiologies of 62% of encephalitis cases 
remained unknown, despite extensive laboratory testing and evaluation.
52
 Similarly, one 
Australian study showed that the proportion of patients with encephalitis of unknown cause 
remained high, despite innovations made in laboratory testing during the study period, such 
as the increased use of PCR in testing for herpes encephalitis in the 1990s.
9
 These results 
indicate that current diagnostic approaches may be insufficient to identify pathogens in CNS 
infections. 
 
2.7 Pathogen discovery in CNS infections 
Proof of causation in CNS infections 
Historically, inference of causation between agents and infections has required that Koch’s 
postulates be fulfilled: (1) the agent must be present in every organism with the disease; (2) 
the agent is not present in organisms without the disease; and (3) the agent can be isolated 
and cause the same disease in another organism.
53





infections can fulfill Koch’s postulates; this difficulty applies in particular to viral CNS 
infections. A microbe that fails to fulfill Koch’s postulates may still be the responsible agent. 
The fundamental limitation of Koch’s postulates arises when they are applied to obligate 
pathogens, as not all microbes causing disease can be isolated by culture (e.g., viruses cannot 
grow in non-living media).  
 
Additional criteria, modified by Rivers, provide virological and immunological proof of viral 
infections. The hypothesized association can be strengthened by demonstrating an 
agent-specific immune response.
54
 To prove causation, the virus need not be present in every 
case of the disease, as the possibility of a viral carrier state is recognized;
54
 however, an 
antibody specific to the causative microbe in CNS infections may still not be detected or 
generated to meet Rivers’ criteria. In particular, immunocompromised individuals may not 
generate appropriate immune responses to pathogens. For instance, up to 20% of 




Another problem with applying Koch’s postulates to these infections is that not all infections 
cause disease. Some viruses are found in healthy individuals (i.e., the infection is latent). 
Encephalitis is a rare complication of common infections.
1
 For instance, human infections 





are seropositive for HSV-1.
56
 More than 90% of adults worldwide have been infected with 
EBV.
57
 Encephalitis caused by these viruses is, however, uncommon. This discrepancy 
emphasizes the need for epidemiological data in the search for associations between prevalent 




With the advent of molecular technology, microbe identification based on nucleic acid 
sequencing methods was suggested to obviate the need for culture-based criteria
59
 (Table 2.4). 
Nevertheless, proof of causation can be difficult when classical hallmarks of infections are 
absent or mechanisms of pathogenesis are indirect or subtle.
60
 In such cases, the investigator 
must resort to statistical assessments of the strength of the epidemiological association based 
on the presence of the agent or its footprints, as identified by classical or molecular methods. 
In addition, the investigator must evaluate the biological plausibility of the hypothesis by 




Traditional diagnostic methods for pathogen detection of CNS infections 
Isolation of a pathogen in brain tissue offers the strongest proof of causation in encephalitis. 
Brain biopsy has extremely high sensitivity (95%) and specificity (>99%) for the diagnosis of 
herpes simplex encephalitis (HSE);
62
 however, biopsy is extremely invasive, and it is not 





lumbar subarachnoid space by lumbar puncture is considered a primary specimen for 
diagnosis and identification of pathogens in CNS infections. CSF is produced in the cerebral 
ventricles and circulates in the cerebral ventricles and subarachnoid space of the central 
nervous system. More than 90% of patients with meningitis and encephalitis show an 
abnormal CSF finding,
63
 including pleocytosis (i.e., an increase in white cell count in the 
CSF), elevated protein, and decreased glucose. CSF analysis is a surrogate for biopsy and 
constitutes the most practical way to diagnose CNS infections, unless a lumbar puncture is 
contraindicated by findings such as increased intracranial pressure. The presence of 
“footprints” such as nucleic acid or antigen in the CSF offers alternative evidence of 
causality. 
 
CNS infections can be identified by the following CSF analyses: 1) culture of bacteria/viruses; 
2) direct microscopic examination; 3) antigen tests; 4) chemical analyses; and 5) detection of 
pathogen-derived nucleic acids. Routine CSF tests for meningitis or encephalitis are listed in 
Table 2.5. In general, CSF analysis can help differentiate between bacterial and viral CNS 
infections. 
 
Direct microscopic examination 














 Direct microscopic examination with a 
Gram stain is reported to have a sensitivity of 56-86% for identification of bacterial 
meningitis. In one nation-wide study on community-acquired bacterial meningitis, Gram stain 
had a sensitivity of 80% and a specificity of 97%;
65
 the relatively low sensitivity means that 




Rapid antigen (Latex agglutination) tests 
Rapid antigen testing in CSF has not been shown to be clinically useful in diagnosing 
bacterial CNS infections.
69
 Exceptions include antigen tests for Streptococcu spneumoniae 
and Cryptococcus infections. The sensitivity of these tests in diagnosing pneumococcal 
meningitis can reach 95 to 100%.
70
 The sensitivity of the test for cryptococcal meningitis was 
reported to reach 94%;
71
 however, rapid antigen tests in CSF for other agents are less reliable, 






Virus-specific antibodies synthesized by infiltrating B-lymphocytes in the CSF can be useful 





CSF is evidence of West Nile virus encephalitis.
73
 Antibody levels in serum and CSF can be 
compared to distinguish peripheral from CNS infection. Based on a study of antibody 
response to Japanese encephalitis virus in serum and CSF, antibody levels in CSF higher than 
5% of the levels of serum antibody indicate intrathecal antibody production caused by CNS 
infection.
74
   
 
Serological testing, however, is usually conducted too late to indicate that an infection 
occurred in the CNS. Results from serology are generally useful retrospectively. For example, 
HSV IgG antibodies usually present in CSF after 10 or 12 days of acute infection and reach a 
peak after 20 days.
75,76
 In particular, immunocompromised patients may not be able to mount 
immune responses, leading to false negative results. Furthermore, serological testing is also 
hampered by the variety of viral serotypes. A handful of enteroviruses may co-circulate in the 
population and may be difficult to differentiate by serological testing. Additionally, antibodies 
may cross-react with antibodies produced in reaction to other viruses within the same family. 
One study showed that 48% of confirmed Japanese encephalitis cases had serum IgM 










puncture, particularly in patients presenting with neurologic abnormalities.
78
 The importance 
of imaging is that in the event of a mass lesion (like a tumor or an abscess) a lumbar puncture 
could result in fatal brain herniation. Although magnetic resonance imaging (MRI) is not 
feasible in emergent cases, it may be helpful in identifying inflammation or infection of CNS. 
Findings from an MRI may be used to guide laboratory testing for the underlying infectious 
agent. For instance, Nipah virus encephalitis yields MRI findings unlike other viral 
encephalitis, affecting primarily the white matter, with transient punctuate cortical 




Culture for pathogens 
For bacterial and fungal pathogens, CSF culture remains the cornerstone of diagnosis; culture 
is also still the best way to evaluate its antibiotic sensitivity profile. The routine clinical 
practice of initiating antibiotic treatment prior to lumbar puncture, however, may confound 
the culture result. The sensitivity of CSF culture in tests for bacterial meningitis was reported 
at 70-85% in untreated patients.
80
 Viral culture is limited as a means of isolating virus from 
CSF. The sensitivity of virus isolation from CSF was reported to be only 14-24%, using PCR 
as a standard.
81
 Few viruses that can be recovered from culture include enteroviruses (e.g., 
echoviruses, coxsackie B viruses, and polioviruses) and herpesviruses. Although the 





cyptopathic effects (CPE) in tissue culture.
82
 Some enteroviruses (e.g., coxackie A virus) 
grow poorly or are non-cultivable in tissue culture.
83
 One study reviewed 22,394 CSF viral 
cultures and found that < 0.1% of viral cultures from CSF samples recovered 
non-enteroviruses or non-herpesviruses; these results suggest that viral cultures add no 




Nucleic acid amplification methods for detection of CNS Infections 
PCR enables amplification of a specific DNA sequence to millions of copies within three 
hours, allowing sensitive detection of target sequences in clinical samples (Figure 2.4). PCR 
has been used widely used since the 1990s to detect and identify pathogens that are nonviable 
or uncultivable (like most viruses), including fastidious pathogens (e.g., Mycoplasma 
pneumoniae). Furthermore, CSF is also less prone to giving false negative PCR results 
because of the absence of PCR inhibitors such as heme (an iron-containing component of 
hemoglobin in red blood cells that carry oxygen), endonucleases and exonucleases.
84
 As a 
result, culture-based diagnosis of viral CNS infections has been largely replaced by 
PCR-based methods.
81,85,86
 PCR is widely used for the detection of CNS infections caused by 
enteroviruses and Herpesviridae (HSV 1and 2, VZV, EBV and CMV), JC virus (JCV), and 








PCR is also useful for detecting co-infections in the CNS that may be otherwise impossible to 
detect by traditional methods. For example, EBV can be present as a co-infection with other 
viruses and non-viral pathogens in CNS infections.
88
 A concurrent CNS infection with 
Borrelia burgdorferi and Bartonella henselae (a potential tick-borne pathogen) was found in 
patients with chronic Lyme disease.
89
 Additionally, molecular methods have been applied to 
detect genes encoding antimicrobial drug resistance like the methicillin-resistance-encoding 
mecA gene in methicillin-resistant Staphylococcus aureus and relevant genes in 




The most common PCR method is the singleplex assay, which can detect target genetic 
sequences at very low copy numbers -- as low as 1 to 10 copies. PCR requires prior 
knowledge of the target sequence and proper primer design. Primers may not bind to targeted 
gene regions when pathogens are characterized by high genetic variability, as in RNA viruses. 
This problem can be solved by designing degenerate primer pairs that bind to conserved 
genomic regions in related viruses; such primers can be designed with a degenerate primer 




Quantitative PCR method 





progression and treatment efficacy. For instance, quantification of human herpesvirus-6 virus 
in the CSF is useful in the follow-up of bone marrow transplant recipients, particularly when 
anti-herpetic therapy is ongoing.
93
 Monitoring of human immunodeficiency virus (HIV) load 
is clinically important in evaluating the effectiveness of anti-retroviral therapy. 
Real-time PCR is used to amplify a targeted DNA sequence and quantitate the DNA of 
interest as amplification progresses. Amplified DNA can be detected by non-specific 
fluorescent dyes (e.g., SYBR Green) that bind to double-strand DNA; however, as 
intercalating dyes can bind to any double-stranded DNA, quantitation may be confounded by 
non-specific amplification. A sequence-specific DNA probe (e.g., TaqMan probe, Applied 
Biosystems) provides more reliable quantitation of DNA amplification by utilizing the 5’ 
exonuclease activity of Taq DNA polymerase to measure the target PCR product.
94
 The probe 
consists of a fluorophore and quencher bound to sequence-specific oligonucleotides. During 
amplification, a polymerase separates the fluorophore and quencher, resulting in fluorescence. 
This method of quantitation is more specific because it allows detection only after the probe 
binds with its complementary DNA target (Figure 2.5). 
 
Although real-time PCR is a sensitive, fast method of identifying pathogens with genomic 
elements that are conserved across strains, it is limited by the specificity of primers and 










When epidemiological and clinical clues are insufficient to narrow the field of candidate 
pathogens, screening for common agents of CNS infection would require either a battery of 
singleplex reactions with a handful of primer pairs, or a multiplex PCR with several primer 
pairs in one reaction. The number of tests may be limited by the available quantities of 
clinical material, and the cost of multiple singleplex PCR assays can be prohibitive. 
Multiplex assays, in contrast, allow testing of multiple hypotheses simultaneously with 
limited specimens and resources. Multiplex PCR uses several primer pairs in one PCR to 
amplify multiple target sequences
96





A major weakness of multiplex PCR is that detection of multiple pathogens in a single 
reaction generally results in reduced sensitivity, in part because optimal reaction conditions, 
such as annealing temperature and salt concentration, can vary widely. Additionally, when 
multiple primer pairs are used in one PCR, they are more likely to form by-products (i.e., 
primer dimers) because of primer to primer interactions, which can potentially compete with 






Another limitation of this method is that the products of multiplex PCR may not be easily 
differentiated by agarose gel-based visualization which rarely distinguishes more than 8-10 
targets
100
 or by fluorescent-reporting real-time multiplex assays, which can generally 
differentiate no more than five distinct targets because of the limited number of reporting 
dyes. Hence, a detection method to differentiate among multiplex PCR products after 
amplification would simplify the problems inherent in gel-resolved or real-time assays.  
 
One approach employs flow cytometry to facilitate detection of multiplex PCR and RT-PCR 
products. This method employs a set of fluorescent polystyrene beads in 100 colors. Each 
target-sequence-specific oligonucleotide probe is coupled to a specific color bead, allowing 
for discrimination of as many as 100 discrete targets per sample.
101-103
 Another new approach 
to differentiating among multiplex PCR products is the use of mass spectrometry, which was 
first applied to single-nucleotide-polymorphism discrimination assays with primers 




2.8 Advanced molecular approaches for diagnosis of CNS infections 
Multiplex MassTag PCR method 





method can be used to simultaneously detect amplification of nucleic acid from up to 30 
pathogens by means of primers with photocleavable links to tags of unique molecular 
weight.
19
 The tags are released by UV light and read by atmospheric pressure chemical 
ionization mass spectrometry (APCI-MS, Agilent Technologies, Palo Alto, CA, USA). 
Microbes are identified by the weight of their molecular tags. A schematic representation of 
the MassTag PCR platform is shown in Figure 2.6. 
 
A syndrome-based MassTag PCR panel is designed to detect all candidate causal pathogens 
of a given syndrome; this system is a powerful tool for screening and is particularly useful 
when clinical clues are insufficient to guide testing among a wide range of candidate 
pathogens. The MassTag PCR platform can detect up to 22 respiratory pathogens in one 
PCR.
19
 It was used to determine the agent of influenza-like illness of unknown origin in 26 
out of 79 cases and to find a previously uncharacterized genetic clade of rhinoviruses in 
outbreak of an influenza-like illness.
105
 Several syndrome-based panels, including respiratory, 




One limitation of this method is that it cannot be used to quantitate agents. Additional 
methods such as real-time PCR are required to evaluate the viral load. Another limitation lies 





method is confined to specialized laboratories, and it is unlikely to be practical in laboratories 
in developing countries. Less expensive, portable instruments for use in MassTag PCR are 
being developed. Although MassTag PCR can detect up to 30 pathogens simultaneously, 
screening by MassTag PCR might not be sufficiently comprehensive for use in pathogen 
discovery. A more comprehensive method could take the guesswork out of pathogen 
screening by either implementing a platform that can cover all the known pathogens or an 
unbiased sequence of all DNA fragments present in the samples. 
 
DNA Microarray 
Microarray technology was first used to investigate differential gene expression in 1995.
108
 
Microarray has since been applied to the detection and identification of infectious diseases. 
This method involves probes immobilized on a glass slide as discrete features. Each feature 
contains millions of identical oligonucleotide probes. Microarrays can comprise up to 8 
million oligonucleotide probes printed on a 70 mm x 20 mm slide. Sample nucleic acids are 
first randomly amplified and fluorescently labeled; they are then allowed to hybridize with 
complementary probes (Figure 2.7), and the labeled targets detected by the local increase in 
fluorescent intensity. The array is then visualized with a high-resolution fluorescent scanner.  
 





microarray has the capacity for enormous multiplex testing and great potential for pathogen 
identification by testing for almost all known viruses, bacteria, fungi, or parasites.
20
 The array 
platform can detect 21 respiratory virus species and be used for subtyping of influenza A.
109
 A 









in general) as compared to PCR. Host and microbe sequences may compete with similar 
efficiency for PCR reagents, resulting in low sensitivity for microbial detection. Consequently, 
microarray methods are most useful with clinical samples that contain low levels of host 
nucleic acids, such as CSF, serum and urine. Nevertheless, depletion of host cell DNA and 










Traditionally, DNA sequencing has used the Sanger method,
112
 which is based on chain 
termination using dideoxynucleotides (ddNTPs). When these modified deoxynucleotides are 
incorporated into a growing sequence, DNA synthesis is terminated because no 
phosphodiester bond can form between the dideoxynucleotides and the next incoming 





sequencing technologies. Massively parallel sequencing based on sequencing by synthesis 
represents a paradigm shift from the Sanger method.
113
 These techniques are referred to as 
next-generation sequencing.
114
 The major commercialized platforms are pyrosequencing 
(Roche 454 GS FLX sequencer), polymerase-based sequencing-by-synthesis (Illumina, 
Solexa Genome Analyzer),
115





These methods are characterized by the ability to process millions of sequence reads in 
parallel, with a high-throughput capacity in one sequencing run. Furthermore, 
next-generation sequence reads are produced from fragment DNA libraries that have not been 
subjected to the conventional vector-based cloning and Escherichia coli-based amplification 
used in the Sanger method. Hence, some of the cloning and PCR bias issues that impact 




Sanger sequencing typically produces read lengths of 650-800 nucleotides; in contrast, 
next-generation sequencing methods yield shorter reads of 35-250 nucleotides. One of the 
next-generation sequencing methods uses a pyrosequencing platformby 454 Life Sciences 
(Bradford, CT).
118
 This platform operates on a principal based on work on continuous 
monitoring of formation of inorganic pyrophosphate (PPi), 
119





signals are detected from ATP that is formed in the ATP sulfurylase reaction using purified 
firefly luciferase (Figure 2.8). 454 Life Sciences has developed an emulsion-PCR-based 
method for the amplification of a DNA library adapted onto microbeads and subsequent 




First, a DNA library is created by shearing genomic DNA into 300-to-800-nucleotide 
fragments. The 3’ and 5’ ends of each DNA fragment are ligated with two adaptors. Then, a 
single-strand DNA fragment is captured on each microbead and amplified by emulsion PCR. 
Each bead is emulsified in a water-oil mixture with reagents; next, the beads with amplified 
single-strand DNA are distributed, together with enzyme beads (containing sulfurylase and 
luciferase in addition to a universal primer and polymerase), into a picotiter plate, such that 
each individual bead is isolated in one well 44 µm in diameter
120
 (Figure 2.9). 
 
In the sequencing step, nucleotides flow sequentially in the order T, A, C, G over the picoliter 
plate and subsequent sequencing is performed simultaneously across all wells. When a 
nucleotide is incorporated into a growing complementary strand, it triggers a cascade of 
enzymatic reactions, generating light as describe in Figure 2.8. Therefore, light generated 
from each well indicates the incorporation of nucleotides. The intensity of light is 





homopolymer runs. Light generated during sequential incorporation of nucleotides can be 
detected by a light sensitive device such as a Charge Coupled Diode (CCD) camera. The 
signals are further transformed into a pyrogram, a graph representing a peak proportional to 
the amount of lighted detected. Finally, a sequence is generated based on the peak of the 
program and the sequential nucleotides added. 
Unlike PCR and microarray methods, which are limited to the detection of known pathogens, 
high-throughput sequencing offers an unbiased method to identify any species of bacteria, 
viruses, fungi or parasites, including those that are new to science. The unique power and 
capacity of this sequencing platform were demonstrated by its role in identifying a virus 
associated with Colony Collapse Disorder in honeybees,
121
 a novel arenavirus that causes 
transplant-associated encephalopathy,
122
 and a novel astrovirus that causes CNS disease.
123
 
Thus, unbiased high-throughput sequencing shows great promise for investigation of CNS 
infections, particularly for new viral agents, which most molecular approaches would not 
detect. 
 
Implementation of next-generation sequencing techniques, however, is currently hindered by 
high costs and processing time. A single run on the 454 Life Sciences platform may cost 
$6,000. Although the reactions may complete within 7 hours, the extraordinary quantity of 





becomes more widely available, we anticipate that pyrosequencing will come to play a 
critical role in the detection of CNS infections of unknown cause. 
 
A staged molecular diagnostic approach 
A staged molecular approach that has already been used for pathogen detection and discovery 
include multiplex MassTag PCR, DNA microarray, and high-throughput pyrosequencing. 
These advanced molecular techniques have promise as complementary tools for exploring the 
cause of infectious diseases, particularly in infections of unknown origin.
18-20
 Figure 2.10 is a 
schematic depiction of a strategy for pathogen discovery in CNS infections. When there is a 
single candidate agent of infection, as in an outbreak or in follow-up after treatment, a 
singleplex PCR is desirable because of its high sensitivity/specificity and low cost. When the 
agent is unknown, however, singleplex PCR is impractical, as clinical manifestations of CNS 
infections are nonspecific. In such cases, a syndrome-based multiplex MassTag PCR is 
indicated to detect pathogens. There are usually fewer than 30 candidate agents to target. 
When a suspected pathogen is not included in the established panel, a more exploratory 
microarray platform is indicated. When a pathogen is novel or substantially divergent at the 







2.9 Conclusion and future directions 
CNS infections impose a substantial disease burden and represent a diagnostic challenge. The 
high proportion of encephalitis cases of unknown cause, seen worldwide, is in part a result of 
our insufficient knowledge of the epidemiology of such infections, misclassification of cases 
of non-infectious origin, and the limitations of the currently available methods for the 
detection of pathogens in CNS infections. Collective results from clinical, laboratory and 
epidemiological studies may aid in identifying the underlying infectious agents. Future 
studies on the epidemiological characteristics of CNS infections of unknown cause are 
needed to facilitate accurate diagnosis and proper treatment. 
 
The increasing availability of molecular diagnostic techniques for CNS infections has 
increased our understanding of these diseases and refined our approach in a clinical setting. 
Molecular methods are particularly desirable for the diagnosis of CNS infections because 
CSF is sterile and acellular. The presence of a microbe in the CSF is typically proof of 
pathogenicity. Advanced nucleic acid amplification methods may further improve our ability 
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Table 2.1: Incidence of encephalitis in selected countries 
Country Study period 






Europe     
England 1989-1998 
(n=6,414) 
All ages 1.5 7 
Finland 1967-1991 
(n=322) 
Adults 1.4  3 
Finland 1993-1994 
(n=175) 
Children 10.5  124 
Slovenia 1979-1991 
(n=170) 
Children 6.7  125 
North America     
USA 1988-1997 
(n=186,804) 
All ages 7.3 6 
Asia     
Japan 1984-1990 
(n=256) 
Children 3.3  29 
Thailand 1983-1998 
(n=3,829) 
All ages 6.3 28 
Taiwan 1996-2008 
(n=9,649) 
All ages 3.5 (This dissertation) 
Other     
Australia 1990-2007 
(n=5,026) 








Table 2.2: Important pathogens in encephalitis1 
Pathogens   
Viruses Bacteria Fungi 
Enteroviruses Streptococcus pneumoniae Cryptococcus 
Herpes simplex virus (HSV) Neisseria meningitides Aspergillosis 
Varicella-zoster virus (VZV) Hemophilus influenza Candidiasis 
Epstein-Barr virus (EBV) Listeria monocytogenes Coccidiomyosis 
Cytomegalovirus (CMV) Chlamydia spp. Histoplasmosis 
Human Herpes virus 6 and 7 (HHV 
6/7) 
Mycobacterium tuberculosis North American blastomycosis 
Mumps virus Mycoplasma pneumonia Parasites 
Measles virus Borrelia burgdorferi Toxoplasma gondii 
Rubella Leptospirosis Cerebral malaria 
Adenovirus Legionella Echinococcus granulosus 
West Nile virus Tropheryma whippeli Schistosomiasis 
Nipah virus Nocardia actinomyces Human African 
trypanosomiasis 
Rabies virus Treponema pallidum  
Lymphocytic choriomeningitis virus 
(LCMV) 
Salmonella typhi  
Tick-borne encephalitis virus Rickettsia  
Japanese encephalitis virus Rickettsia rickettsia  
St. Louis encephalitis virus Rickettsia typhi  
Murray Valley encephalitis virus Rickettsia prowazeki  
Human immunodeficiency virus (HIV) Coxiella burnetti  
Influenza virus A and B Ehrlichiosis  






Table 2.3: Conditions that mimic infectious encephalitis1 
Non-infectious conditions  
Malignancy (meningeal or brain parenchymal)  
Vascular disease  
Toxic encephalopathy  
Anti-NMDAR2 encephalitis  
Reye’s syndrome  
Subdural hematoma  
Systemic lupus erythematosus  
Adrenal leukodystrophy  
1. Adapted from reference 4. 






Table 2.4: Molecular guidelines for establishing microbial disease causation 59. 
Molecular guidelines 
1. Nucleic acids from a pathogen should be present in most cases of an infectious disease and should be found 
preferentially in anatomic sites known to be diseased. 
2. Little or no sequence of the pathogen should occur in hosts or tissue without disease. 
3. The copy number of nucleic acid sequences should decrease with resolution of disease and increase with clinical 
relapse. 
4. When sequence detection predates disease or sequence copy number correlates with severity of disease, the 
association is more likely to be a causal relationship. 
5. The nature of the microorganism inferred from the available sequence should be consistent with the known 
biological characteristics of that group of organisms. 
6. Specific in situ hybridization studies should link the microbial sequence to the area of tissue pathology and to 
visible microbes or sites where microbes are presumed to be located. 
a. The virus did not need to be present in every case of the disease. The possibility of a viral carrier state has been 
recognized. The virus should be present at the proper time in specific lesions. Disease should be produced with some 
regularity by serial inoculation of infected material into susceptible hosts. Immunological response to a viral infection 
can provide evidence of infection by a virus. 





Table 2.5: Routine CSF examinations indicating meningitis or encephalitisa 
Test Normal valuesb Abnormal results Limitation 
Opening pressure  < 200 mmH2O > 200 mmH2O Poor sensitivity & specificity 
CSF color Clear & colorless Turbid Poor sensitivity & specificity 
Protein levelc < 45 mg/dL > 45 mg/dL Poor sensitivity & specificity 
Glucose ratiod 50-60% of serum 
glucose 
< 50%  Poor sensitivity & specificity 
Lactate  < 1.0-2.9 mmol/L >2.9mmol/L Poor sensitivity & specificity 
Cell count < 5 mm3 >5 mm3 Increases in the CSF white cell count 
can occur in both infectious and 
inflammatory state 
Direct microscopic  
examinatione 
 Direct visualization of 
pathogens  
by staining 
Poor sensitivity and specificity  
Culture  Direct visualization of pathogen  Poor sensitivity, requires days to 
weeks 
a. Adapted from Guidelines on routine cerebrospinal fluid analysis. Report from the European Federation of Neurological 
Societies (EFNS) task force127. 
b. Normal values are given for CSF in adults. 
c. Protein is largely decreased in the CSF because of the CSF-brain barrier. A higher protein level in CSF is considered to be 
caused by inflammation or infection of the CNS, which leads to disruption of the cerebral venular endothelial tight junctions, 
allowing protein to leak into the CSF 
d. CSF glucose is approximately 50-65% of serum glucose. CSF glucose decreases in approximately 50% of patients with 
acute bacterial meningitis. 
e. Gram stain can be used to distinguish Gram-positive (e.g., Streptococcus) from Gram-negative bacteria (e.g., Neisseri 
meningitidis); an Indian ink stain is used to identify Cryptococcus neoformans; an acid-Fast stain is used for direct 









Figure 2.1: Changing epidemiology (per 100,000 population) of bacterial meningitis in the United States from 1977 to 2007. 






















Figure 2.2: Geographic distribution of arboviruses causing encephalitis worldwide. Adapted from CDC 
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Figure 2.4: Schematic of PCR. The PCR reaction takes place in a thermocycler. Each PCR cycle consists of three major steps: 
(1) denaturation of template DNA into single-stranded DNA; (2) primers annealing to their complementary target sequences; 
(3) extension of primers via DNA polymerase, which generates a new copy of the target DNA. At the end of each cycle, the 
newly synthesized strands act as new targets for the next cycle. By repeating the cycle multiple times, logarithmic 


























Figure 2.5: Schematic of quantitative real-time PCR. A sequence-specific DNA probe (TaqMan probe) designed 
complementary to target PCR product provides quantitation of DNA amplification via the 5’ exonuclease activity of the 
enzyme Taq DNA polymerase. The probe consists of a fluorophore, with a quencher anchored to the other end of the probe 
that absorbs the fluorophore’s photon emissions. On amplification, a polymerase separates the fluorophore and quencher, 



















Figure 2.6: Schematic representation of MassTag PCR. Adapted from Briese T. et al. Diagnostic system for rapid and 








Figure 2.7: Schematic of pathogen microarray. Sample nucleic acids are first randomly amplified and fluorescently labeled. 
The labeled nucleic acids are incubated with the slide containing millions of oligonucleotide probes, and complementary 
DNA hybridization occurs between a specific probe and the labeled target. The array is further visualized with a 
high-resolution fluorescent scanner. 
  
Dendrimer capture reagent









Figure 2.8: Schematic of an enzymatic cascade in pyrosequencing. When a nucleotide is incorporated into a growing 
complementary strand, a pyrophosphate (PPi) is released and is then converted into ATP via ATP sulfurylase. Subsequently, 





















Figure 2.9: Sample preparation for pyrosequencing. (a) Genomic DNA is isolated, fragmented, ligated to adapters and 
separated into single strands. Fragments are bound to beads under conditions that favor binding of one fragment per bead, 
and the beads are captured in the droplets of a PCR-reaction-mixture-in-oil emulsion. PCR amplification occurs for each 
DNA template within a droplet. The emulsion is broken, the DNA strands are denatured, and beads carrying single-stranded 
DNA clones are deposited into wells of a fiber-optic slide. Smaller beads carrying immobilized enzymes required for 
pyrophosphate sequencing are deposited into each well; (b) Microscope photograph of emulsion showing droplets containing 
a bead and empty droplets; (c) Scanning electronmicrograph of a portion of a ﬁber-optic slide, showing ﬁber-optic coating 
























Figure 2.10: A staged molecular approach for pathogen discovery in CNS infections. When CNS infections are associated 
with a single candidate agent, singleplex PCR is desirable because of the high sensitivity/specificity and low cost of this 
method. If singleplex PCR fails or there are multiple candidate agents (<30), a CNS-infection-based multiplex MassTag 
PCR is indicated to detect the potential pathogens. The list of candidates usually includes fewer than 30 genetic targets. 
When there is a long list of candidate agents (>30) or MassTag PCR fails, a more exploratory microarray platform is 
indicated. When microarray fails or a pathogen is novel or substantially genetically divergent at the target gene, the 
high-throughput sequencing platform is indicated for unbiased sequencing. All positive results are further sequenced for 
comparison with GenBank sequences. Adapted from reference.111 
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Chapter 3: Epidemiological Features of Central Nervous System Infections in Taiwan and the 
Search for Previously Unknown Cause:  









Background: Central Nervous System (CNS) infections impose a substantial disease burden. 
The majority of CNS infections worldwide are of unknown cause; however, little is known 
regarding the epidemiological characteristics of such infections. The aim of the present study 
was to investigate the epidemiological features of CNS infections in Taiwan as well as to 
examine risk factors for CNS infections of unknown cause. 
 
Methods: We investigated epidemiological features of CNS infections in Taiwan, including 
cases of unknown cause, data dating from 1996-2008 from the National Health Insurance 
Research Database (NHIRD) in Taiwan. We also analyzed temporal trends in CNS infections 
and risk factors for infections of unknown cause by linking the NHIRD data with 
demographic and geographic data. 
 
Results: The incidences of meningitis and encephalitis were 12.6 and 3.3 per 100,000 
population, respectively. Unknown pathogens were responsible for the majority (78.9%) of 
meningitis and the majority (78.05%) of encephalitis cases. The most commonly identified 
pathogens in meningitis were Mycoplasma tuberculosis (n=1,727) and herpesviruses were the 





pathogens among meningitis cases included female gender (OR=1.13, p=0.005), age <60 
years (highest OR=13.28 in patients aged 10-19 years, p<0.0001), patients living in a rural 
area (OR=1.49, p<0.0001) and summer season (OR=1.49, p=0.03). In contrast, for 
encephalitis cases, patients aged 0-9 years (OR=0.52, p<0.05), 40-49 years (OR=0.64, 
p<0.05), or 50-59 years (OR=0.57, p<0.05), as well as those who were hospitalized in the 
summer (OR=0.52, p<0.001) were less likely to have an unknown pathogen. 
 
Conclusion: Unknown pathogens are the etiologic agents of the majority (78%) of CNS 
infections in Taiwan. Distinct demographic, geographic and seasonal factors associated with 
these unknown pathogens may provide insight into accurate diagnosis and management of 
CNS infections in Taiwan.  
 
Key words: Central nervous system infections, meningitis, encephalitis, epidemiology, 







CNS infections may cause severe disability or death and also have the potential to result in 
disease outbreaks. CNS infections can be caused by a wide variety of pathogens, including 
bacteria, viruses, fungi and parasites.
1
 Meningitis and encephalitis of viral origin account for 
the majority of CNS infections.
2,3
 Management of CNS infections is challenging because the 
clinical manifestations of individual pathogens are nonspecific; differential diagnosis can thus 
be difficult, particularly for viral infections.
1,4
 Furthermore, the incidence and cause of CNS 
infections are thought to be underestimated, as most CNS infections are not reported, and 




The reported incidence of encephalitis ranges from 1.5 to 7.3 cases per 100,000 population in 
Western countries.
5-7
 With the exception of studies on Japanese encephalitis, few 
epidemiological studies of CNS infections in Asia are available. The incidence of viral 
encephalitis in Thailand was reported to be 6.34 per 100,000 population.
8
 By one estimate, 
the prevalence of encephalitis in Japan is 17.7 per 100,000 population.
9
 The epidemiology of 
CNS infections in Taiwan has not been well studied. 
 
Encephalitis of unknown cause accounted consistently for the majority of reported 







 Despite extensive laboratory testing, the etiologies of 62% of encephalitis cases 
remain unknown,
11
 hampering efforts at prevention and treatment. In particular, the 
epidemiological features of encephalitis of unknown cause have not been well studied.  
 
Several risk factors for CNS infections have been identified. Risk factors for bacterial 
meningitis include: age (increased at extremes of the age spectrum), male, low 
socioeconomic status, immunocompromised individuals and certain chronic diseases (such as 
alcoholism, cirrhosis, and diabetes mellitus).
12
 Viral meningitis occurs mostly in children, and 
in the summer, reflecting the peak activity of the enteroviruses as the leading cause of viral 
meningitis.
13
 Encephalitis appears to be more common in young and old patients
6
 and to be 
more common in men than in women (male-to-female ratio ranging from 1.3 to 1.4). 
Additionally, animals can transmit agents that cause encephalitis (e.g., bats and pigs can 
transmit Nipah virus) or amplify viruses (e.g., pigs are amplifiers of Japanese encephalitis 
virus). Encephalitis, particularly vector-borne infections, may be seasonal, as vectors 
proliferate in favorable climates and seasons. Some other mechanisms of viral transmission 
are also seasonal. For instance, influenza incidence typically peaks in winter in temperate 
regions, when temperature and humidity favor influenza transmission.
14
 The precise 
mechanisms are not clear; however, high atmospheric humidity levels may cause surface 
inactivation of lipid-containing virus, such as influenza. 
15





survival and transmission of enterovirus through water and environmental contamination. 
Consequently, peaks of enteroviral infection are typically seen in the late summer and autumn 
in temperate climates.
16
 Although these risk factors have been investigated in relation to 
meningitis and encephalitis, little is known regarding risk factors for infections of unknown 
cause. 
 
Taiwan implemented a National Health Insurance program in 1995, covering 90% of the 
population in the first year.
17
 As of 2009, over 99% of the total population of Taiwan was 
covered under this universal health care system. The National Health Insurance Research 
Database (NHIRD) includes original claims data on reimbursement, including ambulatory 
care and inpatient medical benefit claims, prescriptions and treatment procedures in 
ambulatory and inpatient care, and detailed hospitalization costs. The NHIRD is de-identified 
and maintained by the National Health Research Institutes and provided to scientists for 
research purposes. As almost all patients with CNS infections are hospitalized for treatment, 
every case with a diagnostic code designating meningitis or encephalitis is recorded in the 
database. The database thus provides an opportunity to study the epidemiologic 
characteristics of CNS infections in Taiwan and determine the microbiological distribution of 
CNS infections. In this study, we examined the epidemiology of CNS infections, excluding 





involved in CNS infections using a nationwide dataset. We also investigated the risk factors 
for CNS infections with unknown agents by linking the NHIRD data with geographic data, 






Source of Data 
As of December 2009, National Health Insurance in Taiwan covered over 99% of the 
population, representing 23.03 million people out of the 23.12 million living in Taiwan. We 
extracted claims data submitted for patients hospitalized with diagnoses of meningitis or 
encephalitis between1996 and 2008, using the International Classification of Diseases, 9
th
 
revision, Clinical Modification codes (ICD-9-CM). The primary diagnosis is the condition 
principally responsible for the patient’s admission. Retrieved data include an encrypted 
personal identification number, the ICD-9-CM, demographic data (age, sex, and region), 




Cases with meningitis or encephalitis are defined as hospitalizations for which the ICD-9-CM 
denotes the primary diagnosis as meningitis or encephalitis. Detailed codes for CNS 
infections are available in the Appendix-2 (Table 3.1A-B). When the principal diagnosed 
cause of a meningitis or encephalitis case cannot be specified by a single ICD-9-CM code, we 
use the underlying condition first and then follow with the symptoms or conditions due to the 





ICD-9-CM. For example, Listeria meningitis is encoded as “Listeriosis” (027.0) in 
combination with “meningitis in other bacterial diseases classified elsewhere” (320.7) in 
ICD-9-CM (in ICD-10, Listeria meningitis is identified by a new code, A32.1). 
 
To avoid duplicate counting of diseases, we used the patient as the unit of analysis. Recurrent 
meningitis or encephalitis was counted as one case. Recurrent cases were defined as having a 
period of less than 30 days between two hospitalizations (in the same or different hospitals) 
of the same patient. Likewise, multiple hospital admissions due to referral of the same patient 
were counted as single cases.  
 
Geographic Data 
Urban vs. rural 
We categorized geographic area as urban or rural at the township level, with seven 
urbanization levels derived from a cluster analysis based on population density, proportion of 
the population with a college education or higher, proportion of the population aged 65 or 
older, proportion of the population working in agriculture, and physician density.
18
 
Urbanization Level One designates the most urban areas, while Level Seven designates the 
least urban areas. We further categorized urbanization levels 1-3 (126 townships) as urban 
and levels 4-7 (232 townships) as rural, as previously described.
19





metropolitan areas in the western region of Taiwan, and most of the rural areas are located in 
the eastern and central mountainous region (Appendix-2: Figure 3.1A-B). 
 
Data of Pig Farms 
Information on the presence of pig farms and the number of pigs at the township level was 
obtained from the Annual Statistical Report of Agriculture, Council of Agriculture, Taiwan. 
The distribution of pig farms is shown in the Appendix-2 (Figure 3.2). 
 
Data of Mosquito Density 
Species of mosquitoes that can potentially transmit CNS infections in Taiwan are listed in the 
Appendix-2 (Table 3.2).The three major candidate species include Aedes aegypti, Aedes 
albopictus, and Culex annulus. In Taiwan, Culex annulus is the main vector of transmission 
of Japanese encephalitis virus. Aedes aegypti is the main vector of transmission of Dengue 
fever and can potentially transmit West Nile virus encephalitis. These species of mosquitoes 
are distributed throughout the island, with the exception of Aedes aegypti, which is found 
only in the southern part of Taiwan. Data on the distribution and density of Aedes aegypti 
were obtained from Center for Disease Control, Taiwan. The distribution of Aedes aegyptiis 







We gathered information regarding cases of meningitis and encephalitis by etiologic category, 
year of hospital discharge, age, sex, and geographic area. We used census population data 
collected by the Department of Household Registration Affairs, Ministry of Interior, 
Executive Yuan, Taiwan, from 1996 to 2008 as the denominator in calculating the annual 
incidence rates of CNS infections. We estimated age-specific incidence rates by calculating 
the number of cases of CNS infection in each age group by age-specific population 
(Appendix-2: Table 3.3). 
 
We used SAS (version 9.2) for data analysis, including demographic features of all cases and 
the frequencies of known and unknown pathogens, which were stratified by age group, sex 
and geographic area, and seasons. We used a chi-square test to examine whether there are 
significant differences between the known and unknown cause groups with regard to age 
group, sex, and geographic area. The results were further adjusted for age group, sex, and 
geographic area by means of a multivariate logistic regression model. We used negative 
binomial regression models to determine temporal trends in the incidence rates of CNS 
infections caused by known and unknown pathogens. Detailed regression models and 
statistical considerations are listed in the Appendix-2. A p-value ≤0.05 was considered 






Cases of identified causes 
A total of 25,554,182 hospital admission records were retrieved from the NHIRD in Taiwan, 
dating from January 1996 to December 2008. In this period, 49,482 hospitalizations for 
meningitis or encephalitis with infectious cause were identified. After removing cases that 
were duplicated, recurrent, or involved patients of unknown sex or unknown geographical 
origin, as well as cases with missing values in demographic and geographic variables, 46,410 
cases of meningitis or encephalitis remained for further analysis (Figure 3.1). Of these cases, 
36,761 (79.2%) were identified as meningitis, for an average of 2,828 meningitis cases per 
year (range: 1,900-7,706). A further 9,649 (20.8%) cases were identified as encephalitis, for 
an average of 742 cases per year (range: 482-945). Most cases of CNS infection occurred on 
the west coast of Taiwan, which includes the most populous area in Taiwan.  
 
The overall incidence of CNS infections in Taiwan from 1996-2008 was 15.9 cases per 
100,000 population. The incidence of meningitis was 12.6 per 100,000 population (range: 
8.4-34.4). The incidence of encephalitis was 3.3 cases per 100,000 population (range: 2.2-4.2) 
(Table 3.1). The incidence of meningitis and encephalitis in each year was listed in 
Appendix-2: Figure 3.4. The incidence of meningitis in men (15.1 per 100,000) was higher 





1.5. Similarly, the incidence of encephalitis was higher in men (3.6 per 100,000) than in 
women (3.0 per 100,000). The male-to-female ratio among encephalitis patients ratio was 
1.2.  
 
The age-specific incidences of meningitis and encephalitis are also shown in (Table 3.1; 
Figure 3.2). The incidence of meningitis was highest (51.6 per 100,000) in the 0-9-year-old 
age group and lowest in the 40-49-year-old age group (4.2 per 100,000). For encephalitis, the 
age-specific incidence was also highest (11.1 per 100,000) in the 0-9-year-old age group, but 
lowest in the 20-29-year-old age group (1.5 per 100,000). Figure 3.3 shows the distribution of 
pediatric cases (age:≦17 years) of CNS infections. Meningitis cases constituted the majority 
of CNS infections in pediatric patients, with the exception of 2-year-olds. The incidence of 
meningitis was highest in children less than 1year old (153 per 100,000), declining sharply 
after age one and reaching a second peak in 6-7-year-olds. In contrast, the incidence of 







Overall, CNS infections appear to be most common in the summer (Figure 3.4). Meningitis 
occurred most frequently in the summer (May-July, 39.2% of meningitis cases), followed by 
autumn (22.5%) and spring (22.3%); cases occurred least frequently in the winter (16.1%). 
Similarly, encephalitis occurred most frequently in the summer (28.9%); however, cases of 
encephalitis occurred least frequently in the spring (23.0%). In 2001, there was an outbreak 
of meningitis, with a total of 8,628 cases. Meningitis accounted for the majority of these 
cases (7,706 meningitis cases, 89.3% of CNS infections in 2001), of which most were aseptic 
meningitis (7,062 aseptic meningitis cases, or 91.6% of meningitis cases in 2001). There was 
also an outbreak of encephalitis in 1998, with a total of 781 encephalitis cases; this outbreak 
corresponded to a large-scale outbreak of enterovirus 71, with severe neurological 





We applied negative binomial regression to model the temporal trends in the annual incidence, 
as the Poisson regression model yielded over-dispersed variance in the data (statistical 
description in the Appendix-2). The average annual incidence of meningitis from 1996 to 
2008 did not change (p=0.40); this stable trend applies to meningitis cases with both known 





meningitis from the 2001 outbreak were removed (p=0.33, 0.18 and 0.24 for all meningitis 
cases and those with known and unknown pathogens, respectively). Similarly, the annual 
incidence did not differ between all encephalitis cases (p=0.57) and encephalitis caused by 
known pathogens (p=0.85). For encephalitis cases caused by unknown pathogens, however, 
the trend showed a statistically significant increase of 2.5% per year (p=0.03) (statistical 
description and Table 3.19 in the Appendix-2). 
 
Cause identified 
Of a total of 46,412 CNS infections, specific pathogens were identified in only 22% of cases. 
Among meningitis cases, the incidence of bacterial meningitis was 1.9 per 100,000 
population (range: 1.6-2.5), and the incidence of aseptic meningitis was 10.0 per 100,000 
population (range: 5.8-30.7). Unknown cause was the largest (78.9%) cause group in 
meningitis cases, followed by bacterial meningitis (15.1%), viral meningitis (3.7%) and 
fungal/parasitic meningitis (2.3%) (Table 3.2). Among 9,649 encephalitis cases, unknown 
pathogenic agents were the most common (78%) cause, followed by viruses (21%), bacterial 
pathogens (0.8%), and parasitic pathogens (0.6%). Yearly distributions of the cause groups of 
meningitis and encephalitis are shown in Figure 3.5A-B. No distinct trend was observed for 






Figure 3.6 shows the proportions of CNS infection etiologies by agent across different age 
groups. Unknown pathogens accounted for the largest proportion of the meningitis cases in 
patients<50 years old. In contrast, known pathogens accounted for the majority of meningitis 
cases in patients> 50 years old. The proportion of bacterial meningitis cases is higher in older 
age groups, and fungal/parasitic meningitis is less common in younger age groups. For 
encephalitis cases, unknown pathogens remained the most common cause of encephalitis in 
all age groups. The proportion of cases of bacterial encephalitis was higher in the middle age 
groups (30-79); however, parasitic encephalitis was not identified in patients aged 0-20 years 
or in patients older than 60 years (Figure 3.6). 
 
Pathogens identified in meningitis 
Of all meningitis cases, 78.90% were associated with unknown pathogens. Among bacterial 
meningitis cases, unspecified bacterial meningitis composed the largest proportion of 
diagnoses (43%). Tubercular, streptococcal, and pneumococcal meningitis were the three 
most common diagnoses, accounting for 44% of all bacterial meningitis cases and 78% of 
cases in which a pathogen was reported (Table 3.3A and Figure 3.7A). The most common 
viral pathogens in meningitis cases were enterovirus (3.06%), herpes zoster virus (0.38%), 
and herpes simplex virus (0.31%). Cryptococcal meningitis was the most common fungal 






Pathogens identified in encephalitis 
As with meningitis, 78.1% of encephalitis cases were associated with unknown pathogens. 
The most commonly identified pathogens in encephalitis cases were viruses (21.1%). Of 
these viruses, herpesviruses were the most common, accounting for 7.86% of all encephalitis 
cases and 37% of cases of viral encephalitis in which a virus was identified. The next-most 
common viruses identified were enteroviruses (7.0%) and Japanese encephalitis virus (2.1%) 
(Table 3.3B and Figure 3.7B). Among bacterial encephalitis cases, Listeria monocytogenes 
encephalitis occurred most frequently (0.38%), followed by meningococcal encephalitis 
(0.23%) and tubercular encephalitis (0.07%).  
 
We further explored the possible co-infections of agents in the same patients with meningitis 
or encephalitis (Appendix-2, Table 3.4). Viral or bacterial agents may be identified in 
concurrent primary viral or bacterial meningitis and encephalitis; however, co-infections were 
not common seen in both meningitis cases of known cause (0.4%, or 29/7751) and 
encephalitis case of known cause (0.5%, or 11/2118).  
 
Unknown vs. Known pathogens 





the analogous number for encephalitis cases (78.05%). Women tend to have slightly higher 
odds of diagnosis with meningitis associated with an unknown pathogen than men (OR=1.05, 
p=0.06) (Table 3.4). This association was not found in encephalitis cases (p=0.83). Patients 
aged 0-29 and 40-49 years appear to have greater odds (OR=1.62 to 13.22) of diagnosis with 
meningitis associated with an unknown pathogen, as compared with patients >80 years old. 
In contrast, for encephalitis cases, patients aged 0-9 and 40-49 years had lower odds 
(OR=0.53, p<0.0001 and OR=0.64, p=0.03, respectively) of having encephalitis associated 
with an unknown pathogen as compared with patients >80 years old; however, there were no 
statistically significant differences between patients aged 50-79 years and patients >80 years 
old. 
 
Meningitis associated with an unknown pathogen occurred more commonly in rural than in 
urban areas (OR=1.28, p<0.0001). For encephalitis cases associated with an unknown 
pathogen, no difference between rural and urban areas was observed (OR=1.09, p=0.35) 
(Table 3.4). Patients living in townships in which pig farms were present had lower odds of 
having meningitis associated with an unknown pathogen than patients in areas in which no 
pig farms were present (OR=0.84, p<0.0001). For encephalitis cases, in contrast, there was no 
difference observed in the frequency of infections with unknown pathogens between 





however, not correlated with the total numbers of pigs (Pearson correlation, p= 0.32 and 
p=0.20 for meningitis and encephalitis, respectively). Interestingly, patients living in 
townships in which Aedes aegypti mosquitoes were present had lower odds of having 
meningitis associated with an unknown pathogen (OR=0.93, p=0.014) and encephalitis 
associated with an unknown pathogen (OR=0.67, p<0.0001) than those living in townships 
without Aedes aegypti (Table 3.4). 
 
As seen in Figure 3.8A, meningitis associated with an unknown pathogen was more common 
in summer; however, no obvious seasonal pattern was observed for meningitis cases 
associated with a known pathogen. For encephalitis cases, no clear seasonal pattern was 
observed for cases associated with known or unknown pathogens (Figure 3.8B). There was 
one large outbreak of encephalitis from May to July, 1998; at the peak of the outbreak, in 
June, enteroviruses accounted for 97.4% (74 out of 76) of identified pathogens. 
 
The results seemed consistent when the associations of CNS infections of unknown 
pathogens and demographic, seasonal and geographic factors were analyzed in each 
individual year (Appendix-2: Table 3.5-3.17). Furthermore, the multivariate logistic 
regression model showed similar results regarding risk factors for meningitis associated with 





had significant effect of slightly higher odds (OR=1.2, p<0.01) of having meningitis 
associated with an unknown pathogen as compared with patients in the >80-year-old age 
group (Table 3.5). For encephalitis cases, the results were consistent with the multivariate 






In this study, we described the epidemiological features of all infectious etiologies of 
meningitis and encephalitis in Taiwan over a 13-year period, using a nationwide dataset. 
Overall, the annual incidences of both meningitis and encephalitis in Taiwan were stable 
throughout the study period. Our results include a large outbreak of encephalitis from April to 
August, 1998 (Figure 3.8B), which was mainly caused by enterovirus 71 infections and 
characterized by rapid onset of encephalitis and fatal outcome. During this outbreak, 129,106 
cases of hand-foot-mouth disease (HFMD) and herpangina were reported. Of these cases, 405 
were hospitalized with CNS manifestations, and 78 patients died. Among the patients who 
died, 71 (91%) were < 5 years old.
20
 There was also a large meningitis outbreak in 2001 
(Figure 3.8A), in which aseptic meningitis accounted for the majority of the cases. 
 
The incidence of bacterial meningitis was 1.9 per 100,000 population in Taiwan, which is 
similar to the rates in North America and Europe (1.38 to 3.5 cases per 100,000 
population).
21-24
 The incidence of aseptic meningitis was 10 per 100,000 population in 
Taiwan; however, the exact incidence of aseptic meningitis is usually unknown, as it is not a 
notifiable disease in most countries. In one birth cohort in Finland, the incidence of aseptic 
meningitis was 27.8 per 100,000 population in children under age 14.
25
 Another study in 





people aged 16 or over.
26





The incidence of encephalitis (3.3 per 100,000 population) in Taiwan was lower than the 
incidences found in the U.S., in Australia, or in Thailand (7.3, 5.2, and 6.3 per 100,000 
population, respectively), but higher than the 1.5 per 100,000 population found in England 
(Table 3.6). This discrepancy may be due in part to differences in cases enrolled and study 
methods. For instance, the U.S. study investigated encephalitis-related hospitalizations in 
which encephalitis was included in any discharge diagnosis (primary, secondary or other). 
The hospitalization rates included both incidence and prevalence data. Therefore, the 
incidence of encephalitis was probably lower than the reported encephalitis-related 
hospitalization rate. Although the Australian study estimated annual hospitalization rate using 
only the primary discharge diagnosis from hospital discharge records as the incidence rate, 
the data still represents hospital admissions, rather than cases of encephalitis. Consequently, 
the true incidence might be lower than hospitalization rate, as some patients had repeated 
hospital admissions,
6
 and the England study enrolled only viral encephalitis cases. 
 
Our results showed a high male-to-female ratio in CNS infections: 1.5:1 for meningitis and 





male-to-female ratio of 1.2:1 in encephalitis cases was observed in Australia 
6
; a ratio of 1.3:1 
was observed in encephalitis-related hospitalizations in the US.
7
 Although the Australian and 
US studies showed that the gender discrepancy was mainly due to a higher rate of 
toxoplasmosis encephalitis cases in men (likely associated with HIV infection), only six cases 
of toxoplasmosis encephalitis were identified in our study; thus, toxoplasmosis cannot 
explain the gender difference observed in our study. The cause of the observed gender 
disparities remains to be determined. 
 
Cause identified  
We found that unknown pathogens accounted for the 78.9% of total meningitis cases and 
95% of aseptic meningitis cases. Clinically, aseptic meningitis is a broad term used to 
describe meningitis with negative routine CSF bacterial cultures, including both viral 
meningitis and unknown pathogens. Often, no pathogen is identified in cases of aseptic 
meningitis. One study in Finland showed that unidentified pathogens accounted for the 
greatest proportion (34%) of aseptic meningitis cases.
26
 Among aseptic meningitis cases in 
which a specific virus was identified, our results showed that enteroviruses accounted for 









Our data showed that the largest proportion of bacterial meningitis cases was diagnosed as 
unspecified bacterial meningitis. This result could be due in part to cases of purulent 
meningitis with negative or undetermined bacterial culture, particularly in the case of prior 
antibiotic treatment. Negative CSF cultures were reported in 44% of initial lumbar punctures 
performed after administration of parenteral antibiotics in children with bacterial 
meningitis.
31
 Another potential cause is that final microbiological results may not have been 
available at the time of ICD-9-CM coding. Regardless of its origins, such a misclassification 
would underestimate the incidence of pathogen-specific bacterial meningitis. 
 
Common causes of bacterial meningitis worldwide include Haemophilus influenza, 
Streptococcus pneumoniae and Neisseria meningitides, which were also among the most 
commonly seen pathogens in many Asian countries.
32-35
 With the introduction of 
Haemophilus influenzae type b (Hib) vaccines and Streptococcus pneumoniae conjugate 
vaccine, the epidemiology of bacterial meningitis changed dramatically.
36
 For instance, in the 
United States, the most common pathogens associated with bacterial meningitis are 
Streptococcus pneumoniae, group B Streptococcus (GBS), Neisseria meningitides, 
Haemophilus influenzae, and Listeria monocytogenes.
24
 Our study showed that the three most 
common types of bacterial meningitis identified in Taiwan during 1996-2008 were tubercular, 





Significantly, our results showed that, in Taiwan, tubercular meningitis was the most common 
known pathogen among bacterial meningitis cases in which a causative agent was identified 
(Figure 3.7A). In contrast, we found only 7 (0.07% of total) cases of tubercular encephalitis. 
The incidence of extrapulmonary tuberculosis is increasing because of the increasing 
prevalence of HIV infection.
37
 In the United States, nearly 20% of tuberculosis cases are 
extrapulmonary, and tubercular meningitis accounted for 2.9% of extrapulmonary 
tuberculosis cases in 2009.
38
 In Germany, extrapulmonary tuberculosis accounted for 21.6% 
of tuberculosis cases.
39
 Nevertheless, international comparison of the epidemiology of 
tubercular meningitis is difficult because the incidence of tubercular meningitis is unknown 
in most countries. The incidence of tubercular meningitis in France was estimated at 0.16 
cases per 100,000 population.
40
 One study in Hong Kong reported that Mycobacterium 





Although Mycobacterium tuberculosis meningitis was the most common cause of bacterial 
meningitis in Taiwan, this incidence is not surprisingly high, as the incidence of tuberculosis 
in Taiwan was 54-62 per 100,000 from 1996-2008,
42,43
 substantially higher than the 3.6 cases 
per 100,000 population in the United States in 2010,
44
 15 per 100,000 population in the U.K. 
in 2009,
45
 and 19.4 per 100,000 population in Japan in 2007.
46





estimated to account for approximately 1% of all new tuberculosis cases annually.
47
 By this 
estimate, the incidence of tuberculosis of CNS was 0.54 to 0.62 per 100,000 population in 
Taiwan; this range accords with our results (0.58 per 100,000 population), suggesting that 
tubercular meningitis could be a leading cause of bacterial meningitis in areas where the 
incidence of tuberculosis remains high. 
 
In contrast to our findings on meningitis, viruses are the most common pathogens identified 
in cases of encephalitis. In this study, herpesviruses and enteroviruses were the three most 
commonly identified pathogens in encephalitis cases. The rank order of causative pathogens 
of encephalitis varies across countries; however, herpesviruses remain the most common 
pathogens in cases of sporadic encephalitis. Herpes simplex virus, varicella-zoster virus, and 
Mycobacterium tuberculosis were the most three commonly identified pathogens in 
encephalitis cases in the U.K. and France.
48,49
 In Australia, herpes simplex virus, 
varicella-zoster virus, and Toxoplama gondii were the most common pathogens identified in 
encephalitis cases.
6
 Similarly, in the U.S., herpes simplex virus and Toxoplama gondii were 
the most common pathogens identified in encephalitis cases.
7
 The emergence of Toxoplasma 
encephalitis during the study period was related to the HIV epidemic. With antimicrobial 









Interestingly, only six cases of Toxoplasma encephalitis were identified in our study and only 
one of them was HIV positive. Meningitis and encephalitis associated with HIV positive 
cases in Taiwan were shown in Appendix-2: Table 3.18. The lower incidence of Toxoplasma 
encephalitis in Taiwan could be due to a lower seroprevalence of Toxoplasma gondii infection 




Known vs. unknown pathogens 
Our study underscores the fact that CNS infections of unknown cause account for the 
majority (nearly 78%) of CNS infections for both meningitis and encephalitis cases. This 
high proportion of encephalitis cases associated with an unknown pathogen was observed 
across countries (Figure 3.9) The incidence of both meningitis and encephalitis remained 
stable throughout the study period; however, we found that cases of encephalitis associated 
with an unknown pathogen in Taiwan increased by 2.5% per year during the study period 
(p=0.03). It remains unclear whether the observed increase was due to a true increase in the 
incidence of encephalitis associated with an unknown pathogen. This finding highlights the 
need to monitor trends in encephalitis cases in Taiwan and to improve diagnostic approaches 







Our results showed that meningitis associated with an unknown pathogen was more common 
(OR=1.28, p<0.0001) in rural areas, although the effect was not statistically significant for 
encephalitis (OR=1.09, p=0.35). This result could be explained in part by the fact that 
hospitals in rural areas lack the laboratory resources to identify pathogens. Alternatively, 
these numbers could represent the true, elevated incidence of diseases in rural areas, where 
human exposures to vector-borne viruses are thought to be more common than in urban areas. 
 
Meningitis associated with unknown pathogens were seen most frequently in summer 
(OR=1.49, p=0.03), followed by autumn (OR=1.13, p<0.0001) and spring (OR=1.10, 
p=0.0001) (Table 3.5), suggesting that pathogens active in summer, such as enteroviruses and 
arboviruses, may contribute to the high proportion of meningitis cases associated with 
unknown pathogens. Our results showed that young patients, in particular those aged 0-19 
years, had greater odds (9.7-13.2) of diagnosis with meningitis associated with an unknown 
pathogen. Children are known to be more susceptible to enteroviral infections.
28
 Collectively, 
our results suggest that pathogens active in the summer and predominantly seen in children, 
such as enterovirus, may play a key role in meningitis associated with unknown pathogens. 
 





pattern, in that cases associated with unknown pathogens were less frequently seen in 
summer (OR=0.52, p<0.0001), followed in increasing order of incidence by autumn 
(OR=0.69, p<0.0001) and spring (OR=0.81, p=0.006), suggesting that pathogens active in 
winter (e.g., influenza) may contribute to the incidence of encephalitis associated with 
unknown pathogens. In support of this theory, encephalitis associated with unknown 
pathogens was less common in rural areas, where human exposures to vector-borne viruses 
are thought to be more common. Our findings are consistent with the findings of the 
Australian study, in which the encephalitis cases of unknown cause were also not found to be 




The incidence of encephalitis cases associated with unknown pathogens did not differ 
between townships with and without pig farms (OR=0.97, p=0.6). Although meningitis 
associated with unknown pathogens seemed to be less common (OR=0.88, p<0.0001) in 
townships with pig farms, this finding may be confounded by the fact that 69.4% of 
townships with pig farms are located in urban areas (Appendix-2: Figure 3.2), where 
meningitis associated with unknown pathogens was less common. In fact, we found that CNS 
infections associated with unknown pathogens were not correlated with the number of pigs in 
the area (Pearson correlation: γ= -0.09 with p=0.32 andγ= -0.13 with p=0.2 for meningitis 





infections associated with unknown pathogens in Taiwan. 
 
Interestingly, cases of both meningitis and encephalitis associated with unknown pathogens 
were less common in geographic areas where Aedes aegypti mosquitoes were present. Aedes 
aegypti is the main transmission vector of Dengue fever in Taiwan and can potentially 
transmit West Nile virus encephalitis. This finding suggests that Aedes aegypti may not play a 
key role in CNS infections associated with unknown pathogens in Taiwan. Alternatively, 
patients and physicians living in the area where Aedes aegypti and Dengue are prevalent 
might have a heightened awareness of mosquito bite-related diseases; thus, extensive clinical 
and laboratory examinations are more likely to be performed, and pathogens are more likely 
to be detected. Indeed, we found that mosquito-borne viral encephalitis was more likely to be 
detected (OR=2.0, p<.001) in an area of Taiwan with endemic Aedes aegypti (Table 
3.7).Taiwan does, however have other endemic mosquitoes but distributed in the whole island, 
such as Aedes albopictus and Culex annulus, and we cannot exclude the possibility that these 
species have roles in transmitting unknown pathogens associated with CNS infections. 
 
Strengths and limitations 
This nationwide dataset from the NHIRD may provide a more accurate estimate of the 





study. First, case ascertainment was based exclusively on ICD-9-CM coding from insurance 
claims data. Administrative data is subject to coding errors and thus might lead to 
misclassification of diseases. Second, laboratory data on CNS infections are not available. We 
cannot distinguish between pathogens that are not specified by ICD-9-CM. For example, 
there is only one code (053.4) for all causes of herpetic encephalitis. Therefore, we cannot 
distinguish HSV-1 or HSV-2 from herpetic encephalitis using ICD-9-CM. Further, meningitis 
or encephalitis associated with specific pathogens may be classified as unspecified meningitis 
or encephalitis if confirmatory laboratory data were not available at the time of coding, as is 
exemplified by 2001 outbreak in which 5,105 (66.3%) cases were coded as “unspecified viral 
meningitis”, and 1,722 (22.4%) cases were coded as “unspecified meningitis”. Consequently, 
the cause of the CNS infections categorized by claims data may be misclassified and 
underestimated for specific pathogens. Thirdly, no other risk factors, such as vaccination and 
travel history, are available from the claims data; thus, we cannot adjust for these risk factors 
in calculating the incidence of CNS infections. 
 
Despite these limitations, the study’s main strengths are the internal and external validity of 
the data. Selection bias and recall bias are avoided by using the nationwide dataset. Second, 
in contrast to other epidemiological studies that use hospitalizations as the unit of analysis 





the patient as the unit of analysis via the NHIRD, generating a more accurate estimate of 
cases of CNS infection. Thirdly, a large sample size provides sufficient statistical power to 
detect differences between CNS infections of known and unknown cause after adjusting for 
confounding variables, such as sex, age, and geographic factors. Fourth, using the same 
ICD-9-CM code throughout the study period ensures the validity of the temporal trend 
analyses. Finally, the results of the study based on the nationwide dataset can be generalized 








CNS infections may impose a substantial disease burden and have the potential to cause 
disease outbreaks. Reliable identification of pathogens is critical for individual case 
management and effective outbreak control. Among identified pathogens, Mycoplasma 
tuberculosis and herpesviruses were the most common causes of meningitis and encephalitis 
in Taiwan, respectively. Both infections are potentially preventable or treatable causes of 
CNS infections. 
 
Our findings may provide a better understanding of epidemiological characteristics of CNS 
infections in Taiwan, particular of those associated with an unknown pathogen. Consistent 
with the high proportion of CNS infections of unknown cause seen across countries, our 
results underscore the diagnostic challenge of CNS infections, for which an infectious cause 
is determined in only 22% of cases. Demographic and geographic factors may be associated 
with CNS infections with unknown pathogens in Taiwan. Meningitis and encephalitis 
associated with unknown pathogens showed distinct seasonal patterns, indicating that 
pathogens active in summer, spring, and autumn may play a role in meningitis associated 
with an unknown pathogen, whereas pathogens active in winter may contribute to cases of 
encephalitis associated with an unknown pathogen. The findings may facilitate accurate 
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Table 3.1: Gender and age-specific incidence of CNS infections in Taiwan from 1996-2008 








Total No. (%) Incidence 
/100,000 
Total No. (%) Incidence/
100,000 
Total No. (%) 
Total 15.93 46410 (100) 12.62 36761 (100) 3.31 9649 (100) 
Gender       
 Male 18.70 27794 (59.89) 15.06 22374 (60.86) 3.64 5420 (56.17) 
Female 13.03 18616 (40.11) 10.08 14387 (30.14) 2.95 4229 (43.83) 
Age 
group 
      
0-9 62.72 23864 (51.42) 51.59 19707 (53.61) 11.13 4157 (43.08) 
10-19 13.36 5850 (12.61) 10.36 4537 (12.34) 3.00 1313 (13.61) 
20-29 7.54 3710 (7.99) 6.06 2983 (8.11) 1.48 727 (7.53) 
30-39 6.90 3371 (7.26) 5.41 2642 (7.19) 1.49 729 (7.56) 
40-49 5.74 2643 (5.69) 4.19 1925 (5.24) 1.55 718 (7.44) 
50-59 7.73 2289 (4.93) 5.54 1624 (4.42) 2.19 665 (6.89) 
60-69 10.47 1997 (4.30) 7.61 1447 (3.94) 2.86 550 (5.70) 
70-79 14.96 1919 (4.13) 10.59 1352 (3.68) 4.37 567 (5.88) 








Table 3.2: Infectious cause of CNS infections in Taiwan from 1996-2008 
Cause  No. of cases (%)  Incidence (per 100,000) 
Meningitis 36,761 (100) 12.62 
Unknown meningitis1 29,010 (78.91)  9.96 
Viral meningitis1 1,382 (3.76)  0.47 
Bacterial meningitis 5,535 (15.06) 1.90 
Fungal/parasitic meningitis 834 (2.27) 0.29 
   
Encephalitis 9,649 (100) 3.50 
Unknown encephalitis 7,531 (78.05) 2.73 
Viral encephalitis 2,038 (21.12) 0.74 
Bacterial encephalitis 74 (0.77) 0.03 
Parasitic encephalitis 6 (0.06) 0.00 






Table 3.3A: Diagnosis identified in meningitis cases in Taiwan from 1996-2008 
Pathogen identified by ICD-9-CM Cases (%) 
Meningitis cases 36761 (100) 
Unknown pathogens1 29010 (78.92) 
Known pathogen 7751 (21.08) 
Unspecified bacterial meningitis 2306 (6.20) 
Tuberculous meningitis 1727 (4.64) 
Enteroviral meningitis 1137 (3.06) 
 Cryptococcal meningitis 792 (2.13) 
Streptococcal meningitis 440 (1.18) 
 Pneumococcal meningitis 224 (0.60) 
 Meningitis due to gram-negative bacterium 215 (0.58) 
Hemophilus meningitis 154 (0.41) 
 Staphylococcal meningitis 149 (0.40) 
 Herpes zoster meningitis 140 (0.38) 
Meningococcal meningitis 116 (0.31) 
 Herpes simplex meningitis 114 (0.31) 
Salmonella meningitis 50 (0.13) 
Syphilitic meningitis 13 (0.03) 
Leptospiral meningitis 10 (0.03) 
 Lymphocytic choriomeningitis 10 (0.03) 
Candidal meningitis 7 (0.02) 
Meningitis due to adenovirus 5 (0.01) 
Anaerobic meningitis 5 (0.01) 
Mumps meningitis 4 (0.01) 
Gonococcal meningitis 1 (0.00) 
Other pathogen2 146 (0.40) 
1. “Unknown pathogen” includes 3 codes: “Unspecified viral meningitis” (047.9), “Nonpyogenic meningitis” (322.0), and 
“Meningitis, unspecified” (322.9). 
2. “Other pathogen” includes the following codes: “Meningitis in other bacterial diseases classified elsewhere” (320.7), 
meningitis due to other specified bacteria (320.89), “Meningitis due to other nonbacterial organisms classified 







Table 3.3B: Diagnosis identified in encephalitis cases in Taiwan from 1996-2008 
Primary discharge diagnosis Cases (%) 
Encephalitis cases 9649 (100) 
Unknown pathogens 7531 (78.05) 
Herpetic meningoencephalitis 725 (7.51) 
Enteroviral encephalitis 677 (7.02) 
Other specified non-arthropod-borne viral disease of the CNS  227 (2.35) 
Japanese encephalitis 200 (2.07) 
Varicella encephalitis 117 (1.21) 
Listeria meningoencephalitis 37 (0.38) 
Epstein-Barr virus encephalitis 30 (0.31) 
Meningococcal encephalitis 22 (0.23) 
Encephalitis, myelitis, and encephalomyelitis in viral diseases classified elsewhere 18 (0.19) 
Encephalitis following immunization procedure 12 (0.12) 
Tuberculous encephalitis  7 (0.07) 
Meningoencephalitis due to toxoplasmosis 6 (0.06) 
Post-infectious encephalitis 6 (0.06) 
Syphilitic encephalitis 5 (0.05) 
Measles encephalitis 4 (0.04) 
Cytomegalovirus encephalitis 3 (0.03) 
Other pathogens† 22 (0.23) 
†”Other pathogens” includes 13 etiologies: “Other encephalitis, myelitis, and encephalomyelitis due to infection classified 
elsewhere” (323.4); “Congenital syphilitic encephalitis” (090.41); “Mosquito-borne viral encephalitis, unspecified” (062.9); 
“Rubella with neurological complications” (056.0); “Rubella with unspecified neurological complication” (056.00); 
“Encephalomyelitis due to rubella” (056.01); “Western equine encephalitis” (062.1); "Eastern equine encephalitis” (062.2); 
“St. Louis encephalitis” (062.3); “Other specified mosquito-borne viral encephalitis” (062.8); “Louping ill” 063.1); 









Table 3.4: Comparison of CNS infections associated with known vs. unknown pathogens between groups in Taiwan from 1996-2008 
 Meningitis Odds ratio p-value Encephalitis Odds ratio p-value 
 Unknown (%) Known (%) (95% CI)  Unknown (%) Known (%) (95% CI)  
Sex         
Female 11426 (39.39) 2961 (38.20) 1.05 (1.00-1.11) 0.06 3305 (43.89) 924 (43.63) 1.01 (0.92-1.11) 0.83 
Male 17584 (60.61) 4790 (61.80) referent  4226 (56.81) 1194 (56.37) referent  
Age         
0-9 17450 (60.15) 2257 (29.12) 9.72 (8.16-11.58) <0.01 3069 (40.75) 1088 (51.37) 0.53 (0.36-0.76) <0.01 
10-19 4143 (14.28) 394 (5.08) 13.22 (10.84-16.12) <0.01 1149 (15.26) 164 (7.74) 1.30 (0.88-1.94) 0.19 
20-29 2324 (8.01) 659 (8.50) 4.43 (3.67-5.36) <0.01 586 (7.78) 141 (6.66) 0.77 (0.52-1.16) 0.21 
30-39 1838 (6.34) 804 (10.37) 2.87 (2.38-3.47) <0.01 593 (7.87) 136 (6.42) 0.81 (0.54-1.22) 0.31 
 40-49 1083 (3.73) 842 (10.86) 1.62 (1.34-1.96) <0.01 556 (7.38) 162 (7.65) 0.64 (0.43-0.95) 0.03 
 50-59 764 (2.63) 860 (11.10) 1.12 (0.92-1.36) 0.27 500 (6.64) 165 (7.79) 0.56 (0.38-0.84) 0.01 
 60-69 627 (2.16) 820 (10.58) 0.96 (0.79-1.17) 0.70 441 (5.86) 109 (5.15) 0.73 (0.50-1.14) 0.18 
 70-79 540 (1.86) 812 (10.48) 0.84 (0.68-1.02) 0.08 449 (5.96) 118 (5.57) 0.71 (0.47-1.07) 0.10 
>80 241 (0.83) 303 (3.91) referent  188 (2.50) 35 (1.65) referent  
Seasonality         
Spring 6360 (21.92) 1828 (23.59) 1.32 (1.22-1.43) <0.01 1784 (23.69) 432 (20.40) 0.80 (0.68-0.93) <0.01 
Summer 12100 (41.71) 2296 (29.63) 2.00 (1.86-2.15) <0.01 2007 (26.65) 781 (36.87) 0.50 (0.43-0.57) <0.01 
Autumn 6271 (21.62) 2001 (25.82) 1.19 (1.10-1.28) <0.01 1825 (24.23) 536 (25.31) 0.66 (0.57-0.76) <0.01 
Winter 4279 (14.75) 1625 (20.97) referent  1915 (25.43) 369 (17.42) referent  
Geographic area         
Rural 11426 (39.39) 2961 (38.20) 1.28 (1.17-1.39) <0.01 521 (6.92) 159 (7.51) 1.09 (0.91-1.31) 0.35 







Pig farm           
Present 21631 (74.56) 6021 (77.68) 0.84 (0.79-0.89) <0.01 5650 (75.02) 1610 (76.02) 0.95 (0.85-1.06) 0.35 
Absent 7379 (25.44) 1730 (22.32) referent  1881 (24.98) 508 (23.98) referent  
Mosquito1         
Present 8636 (29.77) 2419 (31.21) 0.93 (0.89-0.99) 0.01 1694 (22.49) 638 (30.12) 0.67 (0.60-0.75) <0.01 
 Absent 20374 (70.23) 5332 (68.79) referent  5837 (77.51) 1480 (69.88) referent  







Table 3.5: Multivariate logistic regression of CNS infections associated with unknown pathogens by demographic, seasonal 
















Sex (F:M) 1.13 (1.07-1.19) <0.01 1.02 (0.92-1.12) 0.76 
Age       
0-9 9.74 (8.17-11.62) <0.01 0.52 (0.36-0.75) <0.01 
10-19 13.28 (10.88-16.22) <0.01 1.23 (0.82-1.83) 0.31 
20-29 4.51 (3.73-5.46) <0.01 0.75 (0.50-1.13) 0.17 
30-39 2.96 (2.44-3.57) <0.01 0.80 (0.53-1.20) 0.28 
 40-49 1.67 (1.38-2.03) <0.01 0.64 (0.43-0.95) 0.03 
 50-59 1.16 (0.95-1.41) <0.01 0.57 (0.38-0.85) 0.01 
 60-69 1.00 (0.82-1.22) 0.14 0.74 (0.49-1.13) 0.16 
 70-79 0.86 (0.70-1.05) 0.99 0.69 (0.46-1.05) 0.08 
Seasonality       
Spring 1.10 (1.01-1.20) <0.01 0.81 (0.69-0.94) 0.01 
Summer 1.49 (1.38-1.62) 0.03 0.52 (0.45-0.60) <0.01 
Autumn 1.13 (1.04-1.23) <0.01 0.69 (0.59-0.80) <0.01 
Geographic 
area 
      
Rural vs. 
Urban 
1.49 (1.35-1.64) <0.01 0.92 (0.76-1.11) 0.38 
Pig farms 
present 
0.88 (0.82-0.94) <0.01 0.97 (0.86-1.09) 0.60 









Table 3.6: Comparison of incidence of encephalitis among studies from different countries. 








7.3 N=186,804 All ages All causes  National Hospital Discharge Survey Data 
(NHDS). Any ICD code for 
encephalitis-related admissions. 





5.2  N=5,926 All ages All causes  Hospital discharges from Health Outcomes, 






1.5  N=6,414 All ages Viruses only  Hospital episode statistics in National 







6.3  N=3,777 All ages All causes  Monthly encephalitis data from the Ministry 





?  N=262 All ages All causes  Nationwide questionnaire-based survey 





3.3 N=9,649 (for 
encephalitis) 




















Aedes aegypti      
Presence 79 (3.4) 2253 (96.6) 2332 (100) 2.0 (1.50-2.66) <<0.01 
Absence 126 (1.7) 7191 (98.3) 7317 (100)   
Total 205 (2.1) 9444 (97.9) 9649 (100)   








Figure 3.1: Flow chart for data analysis of the NHIRD 
 
 
7,531 cases of 
unknown cause 
2,118 cases of 
known cause 
7,751 cases of 
known cause 
29,010 cases of 
unknown cause 
9,649 cases of encephalitis 36,761 cases of meningitis 
Delete cases with age>110, unknown sex and 
geographic area* 
Delete duplicated and transferred cases 
49,484 cases of CNS infection 
46,698 cases of CNS infection 
46,410 cases of CNS infection 
Total of 25,554,182 hospitalizations in Taiwan 
from 1996-2008 
Retrieve cases by ICD-9-CM 
Statistical analysis with chi-square, logistic regression, Poisson and 
negative binomial regression models 
 
* Demographic and geographic variables with missing data 








Figure 3.2: The incidence of CNS infections among different age groups in Taiwan from 1996-2008. The incidence of all CNS 
infections was highest in patients aged 0-9 years or >80 years. For meningitis cases, the incidence was highest in patients aged 
0-9and decreased thereafter, with a slight increase after age 50. For encephalitis cases, the incidence was highest in patients aged 
0-9, declined after age 10, and increased after age 40. 
 
 
Figure 3.3: The incidence of CNS infections among pediatric patients in Taiwan from 1996-2008. The incidence of meningitis 
was highest in patients younger than one year old, declining sharply after age one and reaching a second peak in patients aged 6-7 
years. In contrast, the incidence of encephalitis peaked at age 2 (with even more cases of encephalitis than of meningitis) among 






































































Figure 3.4: Total CNS infection cases in Taiwan by month,1996-2008. Meningitis accounted for the majority of CNS infections 



































































































Figure 3.5A: Yearly distribution of meningitis grouped by cause in Taiwan from 1996-2008. Unknown cause accounted for the 
majority of etiologies throughout the 13-year study period, followed by bacterial, viral, and fungal/parasitic cause. One large 
outbreak of meningitis in 2001 was noted. Aseptic meningitis (unknown and viral meningitis) accounted for the majority (91.6%) 

























Figure 3.5B: Yearly distribution of encephalitis grouped by cause in Taiwan from 1996-2008. Unknown cause accounted for the 
majority of etiologies throughout the 13-year study period, followed by viral and parasitic cause. The total number of encephalitis 




























Figure 3.6: (A) Proportions of meningitis cases (n=37,203) by cause and age groups in Taiwan, from 1996-2008. Meningitis 
associated with unknown pathogens accounted for the majority of meningitis cases in all age groups, but the proportion decreased 
in older age groups, except in patients older than 80 years. The proportion of patients with bacterial meningitis was higher in 
older age groups. Fungal/parasitic meningitis was less common in younger age groups. (B) Proportions of encephalitis cases by 
cause and age groups. Encephalitis associated with an unknown pathogen was the most common cause of encephalitis cases. The 
proportion of viral encephalitis cases was highest in the 0-9-year age group. The proportion of bacterial encephalitis was higher 










































Figure 3.7A: Distribution of pathogens associated with bacterial meningitis in Taiwan from 1996-2008. Unspecified bacteria 
accounted for the largest proportion (45%) of bacterial meningitis cases. Tuberculous meningitis, streptococcal meningitis, and 
pneumococcal meningitis were the three most commonly identified pathogens in cases of bacterial meningitis in which a 
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Figure 3.7B: Distribution of viruses identified in encephalitis cases in Taiwan from 1996-2008. Herpesviruses accounted for the 
majority (37%) of viral encephalitis cases, followed by enteroviruses (33%).  
1. Encephalitis cases associated with other viruses include 1) other specified non-arthropod-borne viral disease of the CNS, 2) 
encephalitis, myelitis, and encephalomyelitis in viral diseases classified elsewhere, 3) mumps encephalitis, 4) other 
encephalitis, myelitis, and encephalomyelitis due to infection classified elsewhere, 5) rubella with neurological 
complications, with unspecified neurological complication, and encephalomyelitis due to rubella. 
2. Mosquito-borne viruses included Japanese encephalitis virus (n=200), Eastern equine encephalitis virus (n=1), Western 





























Figure 3.8A: Seasonal patterns of meningitis associated with known and unknown pathogens in Taiwan,1996-2008. Meningitis 
associated with unknown pathogens occurred more frequently in summer, consistent with the seasonal patterns of total meningitis 

























































































































Figure 3.8B: Seasonal patterns of encephalitis associated with known and unknown pathogens in Taiwan,1996-2008. No clear 
seasonal pattern was observed for encephalitis cases in cases associated with known or unknown pathogens. One large outbreak 























































































































Figure 3.9: Comparison of the proportion of encephalitis cases associated with an unknown pathogen in selected countries. 
Study populations and case ascertainment varied from studies; however, the majority of cause of encephalitis across 
countries was unexplained. References, study populations and case enrollment were listed in Appendix-1, Table 1. 
  
66.8 























Chapter 4: Pathogen Discovery in CNS Infections of Unknown Cause:  













Background: CNS infections remain some of the most challenging diseases to diagnose and 
treat. Conventional methods for identifying pathogens are limited, as few viruses can be 
recovered by culture. Molecular techniques have promise for exploring the cause of 
infectious diseases. In this study, we employed a staged molecular approach to investigate 
CNS infections of unknown cause. 
 
Methods: We analyzed 131 CSF samples collected between 2006-2008 from adult patients 
with meningitis (n=94) and encephalitis (n=37) of unknown cause using multiplex MassTag 
PCR assays, 16S ribosomal RNA (rRNA) PCR, DNA microarray and high-throughput 
pyrosequencing. Positive results were confirmed by sequencing. 
 
Results: A total of 31 (23.7%) pathogens were identified from 131 CSF samples collected 
from adult patients with meningitis or encephalitis of unknown cause. Candidate pathogens 
were identified in 27% (25/94) of unexplained meningitis cases and in 16% (6/37) of 
unexplained encephalitis cases. Epstein-Bar virus (EBV) (n=16) accounted for the majority of 
the identified pathogens in unexplained meningitis cases, followed by Escherichia coli 
(E.coli) (n=5), enterovirus (n=2), human herpes virus 2 (HSV-2) (n=1) and Mycobacterium 







varicella zoster virus (VZV) (n=3), human herpes virus 1 (HSV-1) (n=2), and 
cytomegalovirus (n=1). 
 
Conclusion: Rapid and accurate detection of meningitis and encephalitis is crucial to 
providing individual disease management and preventing disease outbreaks. Our study 
demonstrated that a staged molecular approach, incorporating techniques including multiplex 
MassTag PCR, 16S rRNA PCR, DNA microarray and high-throughput pyrosequencing, may 
facilitate the detection of pathogens in CSF samples from meningitis or encephalitis of 
unknown cause. This approach may thus reveal the pathogens involved in meningitis or 
encephalitis of unknown cause. 
 












CNS infections represent a diagnostic challenge because clinical manifestations are not 
typically pathognomonic for specific pathogens, and a wide range of agents can cause these 
diseases. An infectious cause of encephalitis was determined in less than 40% to 60% of 
cases worldwide.
1-5
 Significantly, this difficulty remains even in the era of polymerase chain 
reaction (PCR)-based approaches to the diagnosis of CNS infections, particularly of 
encephalitis. One recent Australian study showed that the proportion of patients with 
encephalitis of unknown cause was 69.5%, given the increasing use (since the 1990s) of 
PCR-based testing for herpes encephalitis.
4
 These results indicate that current diagnostic 
approaches may be insufficient to identify pathogens in CNS infections. 
 
Rapid and accurate detection of agents in CNS infections is crucial to improving diagnosis 
and providing the best therapies for patients. Although isolation of pathogens by culture 
provides unambiguous proof of the presence of a specific pathogen in CNS infections, the 
identification of viruses by culture is limited and impractical because only a few viruses (e.g., 
enteroviruses and herpesviruses) can be recovered from culture. Studies show that only 1.9% 
of CSF viral cultures were positive,
3











PCR allows sensitive detection of target genetic sequences in clinical samples, which may be 
useful in identifying pathogens that are nonviable, uncultivable (e.g., most viruses) or 
fastidious (e.g., Mycoplasma pneumoniae). PCR is particularly useful in detecting the agents 
of CSF infections because CSF is normally acellular and sterile; thus, evidence of a pathogen 
in the CSF is usually a proof of infection. 
 
A syndrome-based MassTag PCR system has been used for differential diagnosis.
7-10
 
MassTag PCR enables inexpensive, sensitive and simultaneous detection of multiple 
pathogens. The MassTag PCR platform can detect up to 22 respiratory pathogens in one 
reaction.
7
 This system was used to determine the cause of influenza-like illness for 26 out of 
79 previously unknown cases and to detect a previously uncharacterized genetic clade of 
rhinoviruses causing that was responsible for an increased case load of influenza-like illness.
8
 
The platform has been applied to several syndrome-based panels, such as a hemorrhagic fever 




Amplification and sequencing of the highly conserved regions of the 16S ribosomal RNA 
(rRNA) gene is a well-established technique for identification of bacterial pathogens.
12
 Broad 
range 16S rRNA PCR, with subsequent sequencing is superior to bacterial culture for 
detecting bacterial meningitis, with a sensitivity of 86% and a specificity of 97%.
13







particularly useful for slow-growing bacteria (e.g., Mycobacteria tuberculosis) and for 
diagnosis in the case of CSF that is culture-negative as a result of antibiotic treatment prior to 
lumbar puncture. 
 
Microarray has been applied to the detection and identification of infectious diseases.
10, 14
 
This approach can include up to 8million oligonucleotide probes printed on a 70 mm x 20 
mm glass slide and may offer an advantage for the detection of rapidly evolving agents (e.g., 
RNA viruses). Sample nucleic acids are randomly amplified and fluorescently labeled, then 
allowed to hybridize with complementary probes. Microarray analysis has shown its potential 





The advent of high-throughput pyrosequencing affords unique opportunities to identify 
pathogens in CNS infections of unknown cause. Unlike PCR and microarray methods, which 
are limited to detection of known pathogens, high-throughput pyrosequencing allows 
identification of any species of bacteria, viruses, fungi or parasites, including those that are 
new to science. The unique potential of this sequencing platform has been demonstrated by 
its use in identifying a novel arenavirus that causes transplant-associated encephalopathy,
16
 
and a novel astrovirus that causes CNS disease.
17







proposed; this approach employs complementary tools for pathogen detection and discovery 





In this study, we employed complementary molecular tools, including syndrome-based 
multiplex MassTag PCR assays, 16S ribosomal RNA gene PCR, DNA microarray and 










We applied a staged molecular approach to the detection of potential pathogens in CNS 
infections of unknown cause, including multiplex MassTag PCR, 16S rRNA-gene PCR, DNA 
microarray and high-throughput sequencing. The study flow chart is shown in Figure 4.1. 
 
Case definition and CSF samples 
Because clinical presentations of meningitis and encephalitis can overlap, a narrow case 
definition (i.e., meningitis only or encephalitis only) might result in under-recognition of 
cases. Thus, we used a broad case definition for meningitis and encephalitis of unknown 
cause in an effort to capture all relevant cases of CNS infections and to avoid clinical 
misclassifications of specific CNS infections (e.g., meningitis misclassified as encephalitis 
and meningoencephalitis). Eligibility criteria for case enrollment are listed in Table 4.1. A 
total of 131 CSF samples were collected from patients with meningitis (n=94) and 
encephalitis (n=37) of unknown cause between 2006 and 2008 in Kaohsiung Veterans 
General Hospital, a tertiary care hospital in southern Taiwan. CSF was initially analyzed by a 
standard procedure, including CSF chemistry, antigen-antibody tests and bacterial/viral 
cultures. CSF samples with negative microbiological results from cultures and 









CSF samples (250 μL of CSF in 750 μL NucliSENSE lysis buffer) were shipped to the Center 
for Infection and Immunity, Columbia University, U.S.A. for molecular analysis. Total 
nucleic acids (DNA and RNA) were extracted from 250 μL of CSF by the NucliSENS Easy 
Mag Extraction Method (bioMerieux) and were eluted in 35μL of water. The total nucleic 
acids were enriched for RNA with a DNase I treatment (DNA-free; Ambion, Austin, TX). 
Reverse transcription PCR (RT-PCR) was performed using random hexamers with the 
Invitrogen Superscript II Kit (Invitrogen, Carlsbad, CA). 
 
Multiplex MassTag PCR  
We first employed a multiplex MassTag PCR platform designated for a range of potential 
pathogens in CNS infections. The assay targets 26 pathogens of CNS infections, including 18 
viruses, 5 bacteria, 2 fungi and 1 parasite. Detailed gene targets and primer sequences were 
listed in Table 4.2. 
 
Total nucleic acids (4 μL) were added to MassTag PCR reaction mixes with the DNA 
pathogens primer mix and were amplified by a standard cycling protocol, as follows: 
denaturation at 94°C for 20 seconds, annealing with a temperature reduction in 1°C 







50°C for 20 sec, then extension 72°C for 30 sec in an MJ PTC200 thermal cycler (MJ 
Research, Waltham, MA, USA). For detection of RNA pathogens, 4 μL of 
reverse-transcription products were added to MassTag PCR reactions with the primer mix for 
RNA pathogens and were amplified by the same protocol. 
 
PCR products were purified using QIAquick 96 PCR purification cartridges (Qiagen, Hilden, 
Germany) to remove unincorporated primers before the tags were released from PCR 
products by UV irradiation in a flow cell. Tags were analyzed in a single quadrapole mass 
spectrometer using positive-mode atmospheric-pressure chemical ionization (Agilent 
Technologies).
7
 The identity of the pathogens in the CSF was determined by the appearance 
and the signal intensity of its cognate tags. A positive sample was defined by both tags as one 
in which an agent was consistently detected above a threshold. Positivity was assessed using 
a non-parametric method utilizing the inter-quartile range of the negative control distribution. 
 
16S ribosomal RNA gene PCR 
For those samples that were negative by MassTag PCR, we performed broad-range bacterial 
16S rRNA PCR assays to detect bacterial pathogens that are not included in the MassTag 
panel; however, amplification of this universal bacterial gene is much more vulnerable to 







DNase I (Ambion DNA-free; Austin, TX, USA) pretreatment as described
19
 to the PCR 
master mix, including the incubation of AmpliTaq Gold polymerase (Applied Biosystems, 
Weiterstadt, Germany), MgCl2, PCR 10X buffer and dNTPs with 0.1 IU DNases I; the mix 
was incubated for 30 min at 37°C, then for 10 min at 95°C. Primers and templates were 
added subsequently. The 16S rRNA gene was amplified (899-bp length) with two universal 
primers, 8UA (5’-AGAGTTTGATCCTGGCTCAG-3’) and 907B 
(5’-CCGTCAATTCMTTTAGTTT-3’).20 Cycling conditions were as follows: 95°C for 5 min, 
followed by 35 cycles at 95°C for 30 sec, 45°C for 30 sec and 72°C for 60 sec, with a final 




RNA is obtained by removing DNA from total nucleic acids via DNase I treatment 
(DNA-free; Ambion, Austin, TX) to eliminate human chromosomal DNA. First-strand 
reverse transcription is initiated using Superscript II (Invitrogen, Carlsbad, CA, USA), with a 
random octamer linked to a specific primer (5’-GTT TCC CAG TAG GTC TCN NNN NNN 
N-3’).14 After digestion with RNase H (Invitrogen, Carlsbad, CA), the cDNA is amplified 
using a 1:9 mixture of the sequence independent amplification (SIA) primer
15, 23
 and a primer 







annealing temperature (25°C) is used for the initial PCR amplification cycle; a stringent 
annealing temperature (55°C) is used thereafter to favor priming through the specific 
sequence.
15
 The products of the first PCR are labeled with the specific primer sequence, 
which is linked to a capture sequence for 3DNA dendrimers containing more than 300 
fluorescent reporter molecules (Genisphere Inc., Hatfield, PA).
15
  
Microarray hybridization and processing 
Hybridization is performed by adding 30 μL of sodium dodecyl sulfate-based hybridization 
buffer (Genisphere Inc., Hatfield, PA, USA) to the products of the labeled PCR, heating for 
10 min at 80C, and transferring the solution to the Greenchip microarray15 for hybridization 
for 16 hr at 65C. The reaction is washed with 6X SSC (0.15 M NaCL plus 0.015 M sodium 
citrate), 0.005% Triton X-100 and 0.1X SSC-0.005% Triton X-100 for 10 min at room 
temperature. Then, Cy3 3DNA dendrimers (Genisphere Inc., Hatfield, PA) are added for a 





Microarray scanning and analysis 
The microarrays are scanned by the NimbleGen MS 200 Microarray scanner (Roche 
NimbleGen; WI, USA), and are analyzed with GreenLamp software (version 2.0). A ranked 







Alignment Search Tool (BLAST) data
22
 and used to connect probe sequences on the array in 
a viral sequence database. Each of those sequences corresponds to a taxonomic identifier 
(NCBI Taxon ID, TaxID). The individual TaxIDs are mapped to nodes in the phylogenetic 




For the remaining negative samples, RNA preparations are amplified by reverse-transcriptase 
PCR (RT-PCR), using Superscript II (Ambion DNA-free; Austin, TX, USA) with SIA 
primers. cDNA was treated with RHase H before random PCR amplification with a 9:1 
mixture of a specific 17-mer primer and a SIA primer. Products >70 bp long were purified 
using a MinElute kit (QIAGEN, Valencia, CA, USA). Purified products were pooled and 
sequenced with the use of the GSL FLX platform (454 Life Sciences, Branford, CT, USA). 
Raw sequence reads from high-throughput pyrosequencing are trimmed to remove sequences 
from the primers and highly repetitive sequences. After the human sequences were removed, 
reads were clustered and assembled into contiguous fragments for comparison with the 
GenBank database of nucleic acids and proteins via the BLAST.
24
 We analyzed the resulting 
alignments with a custom software application written in Perl (BioPerl 5.8.5) and programs 








Confirmation of pathogens 
All positive results from MassTag PCR, 16S rRNA PCR, microarray and pyrosequencing 








A total of 131 CSF samples were collected between 2006 and 2008. All had previously tested 
negative for pathogens. We identified 31 (23.7%) pathogens in 131 CSF samples from 
patients with meningitis and encephalitis of unknown cause. Candidate pathogens were 
identified in 27% (25/94) of unexplained meningitis cases and in 16% (6/37) of unexplained 
encephalitis cases. (Table 4.3). Epstein-Bar virus (EBV) (n=16) accounted for the majority of 
the identified pathogens in unexplained meningitis cases, followed by Escherichia coli 
(E.coli) (n=5), enterovirus (n=2), human herpes virus 2 (HSV-2) (n=1) and Mycobacterium 
tuberculosis (n=1). Herpesviruses were identified in unexplained encephalitis cases, including 
varicella zoster virus (VZV) (n=3), human herpes virus 1 (HSV-1) (n=2), and 
cytomegalovirus (n=1). 
 
Among these 31 pathogens, 25 were identified by MassTag PCR. A signal on the MassTag 
PCR was considered positive when it was above a threshold determined by the negative 
control distribution (Figure 4.2). Six bacterial pathogens were identified by 16S rRNA PCR, 
including E. coli (n=5) (Figure 4.3). Among those samples that were negative by MassTag 
PCR and 16S rRNA PCR, we identified one HSV-1-positive-sample by microarray. Detailed 
results of the microarray are shown in Appendix (Figure 4.1). We pursued unbiased 







samples (screened previously by MassTag PCR, 16S rRNA PCR and microarrays); however, 
no specific pathogen was identified by pyrosequencing. All positive samples detected by 
MassTag PCR, 16S rRNA PCR and microarray were verified by sequencing. 
 
Among 16 EBV positive meningitis cases, 56.3% (9/16) of them were HIV-infected patients. 
To differentiate EBV latent infection from lytic infection, we further measured EBV specific 
antibodies in EBV DNA positive CSF samples, including antibodies in 8 paired CSF and 
serum (Table 4.4). Antibodies against EBV viral capsid antigens (VCA) IgG were found in 
68.8% (11/16) of CSF samples; however, no CSF sample was positive for VCA IgM, and 
only one CSF sample was positive for both EBV early antigens (EA) and nuclear antigens 
(NA), indicating a current or recent EBV infection. Eight serum samples, which were paired 
with 8 CSF samples, were all positive for both VCA-IgG and EBV-NA, but negative for 











We presented a comprehensive, a staged approach to the detection of pathogenic agents in 
CNS infections of unknown cause. We identified etiologies in 23.7% (31 of 131) of the CSF 
samples from meningitis or encephalitis of previously unknown cause. Most (24/31) of these 
pathogens were identified by MassTag PCR. Our findings, together with other 
syndrome-based multiplex MassTag PCR,
7-9, 11
 confirm the power of multiplex MassTag PCR 
for detecting pathogens in CNS infections. 
 
Interestingly, 16 EBV were identified in CSF samples from meningitis of unknown cause. 
EBV is a ubiquitous human herpesvirus that infects 90% adult individuals worldwide.
25
 
Similarly, in Taiwan, most people were infected with EBV in early childhood, and EBV 
capsid antigen IgG antibodies persist for decades or for a lifetime.
26
 Because EBV is a 
lymphotropic virus and is latent in B cells for a lifetime after primary infection, EBV may be 
carried into the CSF by the B cells during inflammatory responses induced by other agents, 
resulting in spurious association between CNS infection and the presence of EBV DNA, as 
detected by PCR. 
 
The detection of antibody against EBV in 8 paired sera is suggestive of past EBV infections; 







was detected in all EBV-positive CSF samples. One study showed that CSF samples from all 
five patients contained EBV DNA and EBV-specific antibodies in the neurologic stage of 
infectious mononucleosis, but not during convalescence. In contrast, EBV DNA and 
anti-EBV antibody were not detected in the CSF of 17 EBV-seropositive patients with other 




Furthermore, false positives rarely occur in EBV-seropositive individuals who develop 
non-EBV meningoencephalitis.
28
 For instance, EBV was not detected by CSF PCR in 
patients with bacterial meningitis, and more lymphocytes/monocytes were present in the CSF 
of control patients with bacterial meningitis than in the CSF of the EBV-positive patients.
29
 
Likewise, in our study, we did not detect EBV in the CSF of patients with meningitis of 
bacterial origin, such as Mycobacterium tuberculosis and Escherichia coli. 
 
On the other hand, given that seropositivity of EBV approaches 90-95% in adults, a 
considerable amount of EBV would be detected if the EBV is carried via peripheral 
lymphocytes into the CSF during inflammatory responses triggered by other agents; however, 
EBV PCR in CSF is rarely positive in patients with CNS infections. One study showed that 
only 11 of 2,233 specimens from 2,162 patients were EBV-positive by PCR.
30
 Another study 
detected EBV in the CSF of 7.4% (4 of 56) of patients with CNS disorders.
31







results revealed that only 16 of 131 CSF samples tested positive for EBV. Therefore, the 
hypothesis that EBV DNA is carried into the CSF by B-cells in the inflammatory process 
seems unlikely to be correct.  
 
Significantly, 56.3% of our EBV-positive cases were HIV-infected. EBV has been reported to 
be associated with primary CNS lymphomas (PCNSL) in HIV-infected individuals,
32-33
 and 
EBV DNA can be detected in the CSF in 80-100% of HIV-infected patients with PCNSL;
34-36
 
however, EBV may also be detected in the CSF of 12% of HIV-infected patients with 
neurological symptoms but without lymphoma.
37
 Similarly, none of our EBV-positive cases 
had CNS lymphoma. As EBV is a ubiquitous virus, the incidence of CNS infections caused 
by EBV may be underestimated. Our results suggest that EBV should be considered in all 
patients with meningitis, especially in immunocompromised patients. 
 
We used the 16S rRNA PCR to screen for any possible bacteria in CSF prior to analysis by 
microarray and pyrosequencing. E. coli was detected in 5 CSF samples. E. coli meningitis is 
common cause of neonatal meningitis,
38
 but it is a rare cause of acute bacterial meningitis in 
adults.
39-40
 In Taiwan, E. coli meningitis has been reported in adults with chronic underlying 
conditions, such as chronic liver disease, diabetes mellitus or HIV infection.
41-42
 Among five 







pulmonary tuberculosis (n=2) and HIV infection (n=1).  
Broad-range 16S rRNA PCR provides an additional advantage in the detection of bacterial 
pathogens that are not covered by the MassTag PCR panel. PCR is particularly useful for 
detecting slow-growing bacteria (e.g., Mycobacteria tuberculosis) or bacteria in CSF that is 
culture-negative as a result of antibiotic treatment prior to testing, as is demonstrated in our 
study; meningitis with E. coli may not have been previously identified by bacterial cultures 
because of prior treatment with antibiotics, which may confound the results of bacterial 
culture. Indeed, CSF may become sterile rapidly after antibiotic treatment, with 
meningococci and pneumococci disappearing within two and four hours, respectively.
43
 One 
study also showed that 49% (21 of 43) of CSF samples from patients with partially treated 




Notably, one HSV-1 positive CSF sample was not positive by MassTag PCR but was positive 
by the DNA microarray, despite MassTag PCR is more sensitive than DNA microarrays.
21
 
one reason for this discrepancy may be that signals in the MassTag PCR were confounded by 
high levels of background noise from clinical samples or from the purification process. These 
results highlight the need for complementary tools for the detection of pathogens in infections 








There are some limitations in this study. First, samples were collected from only one referral 
hospital, which may not reflect the case distribution of meningitis and encephalitis in Taiwan. 
Instead, they may represent some of the more difficult cases to diagnose. Secondly, CSF 
samples were stored for three years after collection, and nucleic acid degradation, particularly 
of RNA, might have occurred prior to laboratory analysis, which may explain why no RNA 
viruses were detected by microarray and high-throughput pyrosequencing. Thirdly, we cannot 
rule out misclassification of encephalitis with non-infectious causes, such as the newly 
described immune-mediated anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis 
45
, 
as we did not test for NMDAR encephalitis. The above limitations may help explain why 










Diagnosis of CNS infections has been revolutionized by the advent of molecular diagnostic 
methods, which are particularly useful in the detection of uncultivable, fastidious or 
slow-growing organisms. Rapid and accurate identification of the causative agent of 
meningitis and encephalitis can affect individual clinical management. On the scale of 
populations, agent identification is crucial to determining the burden of meningitis and 
encephalitis caused by specific agents, allowing researchers to prioritize targets for public 
health intervention and to prevent outbreaks of disease. 
 
Our study confirms the power of multiplex MassTag PCR as a diagnostic tool for the 
identification of pathogens in meningitis and encephalitis. Viral and bacterial candidate 
pathogens were detected in CSF from patients with meningitis or encephalitis of unknown 
cause. Additionally, a staged molecular approach incorporating complementary tools may 
allow detection of pathogens in meningitis and encephalitis of previously unrecognized cause 
that would otherwise have been missed. This approach may aid in explaining the high 
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Table 4.1: Eligibility criteria for meningitis or encephalitis without known cause 
Eligibility criteria 
Inclusion criteria 
 Patients diagnosed as having acute CNS infections (≦3 weeks), with clinical presentations of fever (≧
38°C), headache, with or without neurological manifestations (e.g., altered level of consciousness, 
paralysis or seizure) 
 Adult patients (aged 18 years or older) 
 Cerebrospinal fluid pleocytosis (>4 white blood cells/μL CSF) 
 Negative microbiological results, including CSF cultures, blood cultures and antigen-antibody tests 
 Brain image finding or electroencephalogram (EEG) compatible with meningitis or encephalitis 
Exclusion criteria 
• Non-infectious diagnosis, including traumatic, metabolic, malignant, vascular, surgical, hypoxic and toxic 
causes. 
• Post-infectious meningitis and encephalitis, e.g., meningitis and encephalitis following a recent vaccination 









Table 4.2: Primers for MassTag encephalitis panel 
Pathogen Target 
Gene 
Primer sequence  Mass 
code 
RNA encephalitis panel    
Eastern equine encephalitis 
virus   
E1  Fwd: ACACTAAATTCACCCTAGTTCGAT 
Rev: GTGTATAAAATTACTTAGGAGCAGCATTATG 383/650 
Nipah/Hendra virus Phos Fwd: GGGGGAATGYCTAAGRATGATG 
Rev: TCCGGTACATTCTCCTCCATG 519/566 
Japanese encephalitis virus NS5   Fwd: TCAACCTAGGGAGCGGAACA 
Rev: GGCTGAGCCAGTAGCCTTCA 582/698 
Parecho virus 5UTR Fwd: ACACTAGTTGTAAGGCCCACGAA 
Rev: GGTBTGGCCCACTAGACGTTTT 690/606 
Powassan virus NS5 Fwd: CATCCGACCATGCACCTAGA 
Rev: CCAAAGTGAGGATGTGTACCAAAG 622/375 
Lacrosse virus S Fwd: CTCAACCTTGCTGCAGTTAGGA 
Rev: CCACCTGCCACTCTCCAAA 686/590 
Lymphocytic choriomeningitis 
virus 
pol Fwd: CCACTYTTGTCTGCACTGTCTAT 
Rev: CTTTTTGATGCGCAATGGAT 614/654 
St. Louis encephalitis virus NS5 Fwd: CATTTGTTCAGCTGTCCCAGTC 
Rev: CTCACCCTTCCCATGAATTGA 658/423 
Enterovirus 5UTR Fwd: TCCTCCGGCCCCTGAATGCGGCTAATCC 
Rev: GAAACACGGWCACCAAAGTASTCG 495/702 
West Nile virus DF3 Fwd: CCACCGGAAGTTGAGTAGACG 
Rev: GCTTTGTTCACCCAGTCCTCCT 499/539 
Western equine encephalitis 
virus 
E1  Fwd: ACATCGAGCCCACAAGCA 
Rev: GCATAGAGCTGCAGACCAACAC 598/678 
Venezuelan equine encephalitis 
virus 
E1  Fwd: CTACGCGCCACTCCCTATCA 
Rev: TGGCAGGTGACGTACTCCAA 602/646 
Rabies virus N Fwd: GGGTTYATAAAVCAGATWAATCTCAC 
Rev: GAAGTGRATGAAATARGAGTGAGG 475/558 
Influenza A virus M Fwd: CATGGAATGGCTAAAGACAAGACC 
Rev: AAGTGCACCAGCAGAATAACTGAG 618/690 
DNA encephalitis panel    
Adenovirus Hexon Fwd: CCCMTTYAACCACCACCG  
  Rev: ACATCCTTBCKGAAGTTCCA 503/630 
Cytomegalo virus Pol Fwd: CATGCGCGAGTGTCAAGAC  







Epstein-Barr virus EBER Fwd: AAACCTCAGGACCTACGCTGC  
  Rev: AGACACCGTCCTCACCAC 570/463 
Varicella zoster virus Gp 31 Fwd: CCGATTCTGGATTTTCGTTGTT  
  Rev: AAAGTCGATTTCCCCCCAAA 471/515 
Human herpes virus 6 U7 Fwd: AAAATTTCTCACGCCGGTATTC  
  Rev: CCTGCAGACCGTTCGTCAA 357/718 
Herpes simplex virus 1 Gp C1 Fwd: GATGCCGGTTTCGGAATTC  
  Rev: CCCATGGAGTAACGCCATATCT 706/666 
Herpes simplex virus 2 UL3 Fwd: GGTCCCCTCTGCGTTTACTA  
  Rev: TCGACTCTATGGGCGTCGTA 527/642 
Haemophilus influenzae Plysin Fwd: CGCTGGAAAGAGAACAAGCAA  
  Rev: TTTCAGCTTGACGTAATCCATC 726/734 
Streptococcus pneumoniae CTRA Fwd: GACTCCTAAGGCTTGGGACAGAAAT  
  Rev: TTCATAAACCGTACGCCACCATTC 694/714 
Neisseria meningitides cap59 Fwd: TTCTGATGCGCGTGGTGTGT  
  Rev: CGCATCAGCCATATTCACACGA 439/730 
Cryptococcus neoformans flaB wd: GCGAGGCAGCACAAGTACTT  
  Rev: TTGTCTGGTCGTTGGAMCCGTT 650/638 
Leptospira interrogans pncA Fwd: GATCATGAAGCAGAGRGCGGATATG  
  Rev: CCATATCGGCGTCYCGAATTC 634/383 
Mycobacterium tuberculosis B1 Fwd: ACGTCAGGCCCACGACATTGA  
  Rev: CCTGGGCAAGCTGAACCTCGAA 395/475 
Toxoplasma gondii CaAG Fwd: GAAGAGATCCAGCAGATCTCGT  
  Rev: TGAGAGGAGGCAGCACAAG 548/562 
Candida albicans M1 Fwd: ACCAGTAGGAGTACAACGAACAGGAA  
  Rev: ATTTCATTGAATATTGGTGTGGTTCA 602/670 









Table 4.3: Pathogens identified by a staged molecular approach 






No. of HIV 
positive 
Molecular methods 
Virus      
Enterovirus1 2 (6.5) 2 (8) 0 (0) 0 MassTag PCR 
Herpes simplex virus-1 2 (6.5) 0 (0) 2 (33) 0 MassTag 
PCR/Microarray2 
Herpes simplex virus-2 1 (3.2) 1 (4) 0 (0) 0 MassTag PCR 
Varicella zoster virus 3 (9.7) 0 (0) 3 (50) 0 MassTag PCR 
Epstein-Barr virus 16 (51.6) 16 (64) 0 (0) 9 MassTag PCR  
Cytomegalovirus 1 (3.2) 0 (0) 1 (17) 0 MassTag PCR 
Bacteria      
Mycobacterium tuberculosis 1 (3.2) 1 (4) 0 (0) 0 MassTag PCR 
Escherichia coli 5 (16.1) 5 (20) 0 (0) 1 16S rRNA PCR 
Total 31 (100) 25 (100) 6 (100) 10   
1. Sequences of enteroviruses revealed echovirus 11 (n=1) and echovirus 30 (n=1). 
2. One herpes simplex virus-1 was identified by DNA microarray. 









Table 4.4: Epstein-Barr virus (EBV) antibody1 in cerebrospinal fluid (CSF) and serum in patients identified with EBV 
infections by MassTag PCR 
Case CSF Serum 
 VCA2-IgM VCA-IgG EBV-EA3 EBV-NA4 VCA-IgM VCA-IgG EBV-EA EBV-NA 
1 - - - - - + - + 
2 - - - - - + - + 
3 - - - - ND5 ND ND ND 
4 - + - - ND ND ND ND 
5 - + + + ND ND ND ND 
6 - + - - - + - + 
7 - + - - - + - + 
8 - + - - ND ND ND ND 
9 - + - - ND ND ND ND 
10 - + - - - + - + 
11 - - - - - + - + 
12 - + - - - + - + 
13 - + - - ND ND ND ND 
14 - + - - ND ND ND ND 
15 - + - - ND ND ND ND 
16 - - - - - + - + 
1. EBV antibody was measured using commercial kit Euroimmun (Medizinische Labordiagnostika AG, Lübeck, 
Germany). Results were evaluated semiquantitatively by calculating a ratio of the extinction value of the control or 
patient samples over the extinction value of calibrator. Ratio <0.8: negative and ratio ≧1.1: positive. 
2. VCA=Viral capsid antigen. 
3. EBV-NA=Epstein-Barr virus nuclear antigen, indicating past EBV infections. 
4. EBV-EA=Epstein-Barr virus early antigen, indicating current or recent EBV infections. 











































Figure 4.1: Flow chart of the molecular approaches for the investigation of CNS infections of unknown cause. 
* Routine CSF study includes chemistry, direct microbial examinations, antigen tests, and bacterial/viral cultures. 
Patients with clinical presentations of 




Identify pathogens by routine CSF study* 
 
No pathogen identified 
131 CSF from cases of unexplained 
meningitis (n=94) and encephalitis 
(n=37) 



















Figure 4.2: Signal abundance data obtained by mass spectrometry. Pathogens (varicella zoster virus) are detected by the 
appearance and the signal intensity of the two cognate tags (indicated by blue and green bars). Positivity is defined by both 
tags for an agent being consistently detected above a threshold, as seen in sample DDM-6, 14 and 17. Positivity is assessed 









Chapter 5: Conclusion 
 
CNS infections impose a substantial disease burden associated with significant mortality and 
morbidity and represent a diagnostic challenge; an infectious cause is determined in less than 
40 to 70% of encephalitis cases. The high proportion of CNS infections of unknown cause 
exists across countries.
1-5
 More importantly, this phenomenon endures even in the era of 
PCR-based methods for the diagnosis of CNS infections; in the California Encephalitis Study, 
the etiologies of 62% of encephalitis cases remained unknown, despite extensive laboratory 
testing and evaluation.
6
 Similarly, one Australian study showed that the proportion of 
encephalitis patients with encephalitis of unknown cause was 69.5%, despite the increasing 
use of PCR testing for herpes encephalitis since the1990s,
4
 which indicates that current 
diagnostic approaches may be insufficient to identify pathogens in meningitis and 
encephalitis. Despite the high proportion of encephalitis of unknown cause observed in 
epidemiological studies worldwide, there are currently few studies exploring the causes of 
this phenomenon.  
 
In this dissertation, I aim to fill these research gaps. I begin by reviewing the published 
literature on the epidemiology of meningitis and encephalitis of known and unknown cause, 







review molecular methods for the identification of CNS infections in the era of PCR, 
specifically focusing on the strengths and limitations of various diagnostic methods (Chapter 
2). Secondly, I investigate the epidemiological features of meningitis and encephalitis in 
Taiwan by utilizing a nation-wide health insurance dataset dating from 1996 to 2008, 
examining clues to the epidemiology of meningitis and encephalitis of unknown cause 
(Chapter 3). Finally, I analyze CSF samples from patients with meningitis and encephalitis of 
unknown cause using a staged molecular approach that included MassTag PCR, DNA 
microarrays and high-throughput pyrosequencing to discover the potential agents of these 
infections (Chapter 4). 
 
In Chapter 2, I summarize the existing literature on the incidence, cause and risk factors for 
meningitis and encephalitis of both known and unknown cause. Several risk factors have 
been associated with meningitis and encephalitis, including male sex, young and old age, 
specific seasonal and geographic distribution and immune status; however, little attention has 
been focused on the epidemiology of meningitis and encephalitis of unknown cause. 
Epidemiological studies across countries revealed a high proportion of cases without known 
cause; this pattern may be due in part to insufficient knowledge of epidemiology of 
meningitis and encephalitis of unknown cause, misclassification of diseases with 







discovery in meningitis and encephalitis.  
 
The invention of molecular diagnostic methods has improved our ability to identify 
pathogens that are nonviable, uncultivable (e.g., most viruses) or fastidious (e.g., 
Mycoplasma pneumoniae). Nevertheless, the major limitation of conventional molecular 
methods is the requirement for clinical and epidemiological clues to narrow the field of 
candidate agents. Clinical clues are particularly impractical because the symptoms and signs 
of individual pathogens are not typically pathognomonic. The search for candidate agents is 
further hindered by insufficient epidemiological clues, especially for infections of unknown 
cause. Consequently, screening for common pathogens in meningitis and encephalitis by the 
conventional singleplex molecular assay is cumbersome, as it requires a battery of singleplex 
assays, which are expensive in terms of resources, time and sample. A staged molecular 
approach has been successfully used for pathogen detection and discovery;
7
 this approach 
includes multiplex MassTag PCR platform, DNA microarray, and high-throughput 
pyrosequencing. These advanced molecular techniques offer complementary tools for 
exploring the cause of infectious diseases, particularly for meningitis and encephalitis of 
unknown origin. 
 







in Taiwan over a 13-year period, using a nationwide dataset. Overall, the annual incidences of 
both meningitis and encephalitis in Taiwan were stable throughout the study period. The 
incidences of meningitis and encephalitis were 12.6 and 3.3 per 100,000 population, 
respectively. Unknown pathogens were responsible for the majority (78%) of both meningitis 
and encephalitis. The most commonly identified pathogens in meningitis and encephalitis 
cases were Mycoplasma tuberculosis (n=1727) and herpesviruses (n=725), respectively. 
Significantly, our results showed that, in Taiwan, tuberculous meningitis was the most 
common known pathogen among the bacterial meningitis cases in which an etiologic agent 
was identified, suggesting that tuberculous meningitis could be a leading cause of bacterial 
meningitis in areas where the incidence of tuberculosis remains high. 
 
Risk factors for CNS infection of unknown pathogens among meningitis cases included male 
gender (OR=1.13, p=0.005), age <60 years (highest OR=13.28 in patients aged 10-19 years, 
p<0.0001), living in a rural area (OR=1.49, p<0.0001) and summer season (OR=1.49, 
p=0.03). In contrast, among encephalitis cases, patients aged 0-9 years (OR=0.52, p<0.05), 
40-49 years (OR=0.64, p<0.05), or 50-59 years (OR=0.57, p<0.05), as well as those who 









To my knowledge, this is the first epidemiological study to investigate a link between risk 
factors and meningitis and encephalitis of unknown cause. The results suggested that 
pathogens active in the summer and predominantly seen in children, such as enterovirus, may 
play a key role in meningitis associated with unknown pathogens, whereas pathogens active 
in winter (e.g., influenza or mumps) may contribute to the incidence of encephalitis 
associated with unknown pathogens. Understanding risk factors for meningitis and 
encephalitis of unknown cause may aid in narrowing a search for candidate agents in 
infections of unknown cause in future studies. 
 
In Chapter 4, I attempt to explain the high proportion of meningitis and encephalitis of 
unknown cause by analyzing CSF samples from patients with meningitis and encephalitis of 
unknown cause utilizing a staged molecular approach, including multiplex MassTag PCR 
assays, 16S ribosomal RNA gene PCR, DNA microarray and high-throughput 
pyrosequencing. A total of 31 (23.7%) pathogens were identified from 131 CSF samples 
taken from adult patients in Taiwan with meningitis or encephalitis of unknown cause. 
Candidate pathogens were identified in 27% (25/94) of unexplained meningitis cases and in 
16% (6/37) of unexplained encephalitis cases. Epstein-Bar virus (EBV) (n=16) accounted for 
the majority of the identified pathogens in unexplained meningitis cases, followed by 







Mycobacterium tuberculosis (n=1). Herpesviruses were identified in unexplained encephalitis 
cases, including varicella zoster virus (VZV) (n=3), human herpes virus 1 (HSV-1) (n=2), and 
cytomegalovirus (n=1). 
 
Significantly, 54% (9/16) of EBV-positive cases were HIV-infected. EBV has been reported 
to be associated with primary CNS lymphomas (PCNSL) in HIV-infected individuals,
8-9
 and 
EBV DNA can be detected in the CSF of 80-100% of HIV-infected patients with PCNSL;
10-12
 
however, none of the EBV-positive patients in this study had CNS lymphoma. As EBV is a 
ubiquitous virus, the incidence of meningitis caused by EBV may be underestimated. If this 
supposition is true, EBV should be considered in all patients with CNS infections, especially 
in immunocompromised patients. 
 
Additionally, E. coli was detected in five previously culture-negative CSF samples. E. coli 
meningitis is a rare cause of acute bacterial meningitis in adults
13-14
 and may be associated 
with chronic underlying conditions.
15-16
 Culture-based methods may be confounded by 
antibiotic treatment prior to CSF culture. This study highlighted an advantage of PCR-based 
methods for the identification of bacterial pathogens in CSF from patients under antibiotic 
treatment. Finally, a staged molecular approach incorporating complementary tools may 







that would otherwise have been missed. By this approach, we explained some of the 
unknown cause of meningitis and encephalitis cases, decreasing the proportion of unknown 
cause from 57% (94/170) to 40% (69/170) in meningitis cases, and from 73% (37/51) to 61% 
(31/51) in encephalitis cases in one tertiary hospital in Taiwan. 
 
Although no definitive treatment is currently available for most viral CNS infections, 
attempts to identify the causative agents are critical for individual case management as well 
as for effective outbreak control. This last point is particularly true in the global context, as 
emerging and re-emerging pathogens, increasing global traffic and climate change increase 
the probability that CNS infections will be globally distributed. Advanced nucleic acid 
amplification methods have shown their potential to identify pathogens from CSF in CNS 
infections. If widely adopted, such a staged molecular approach could improve identification 
of the etiologic agents of CNS infections. 
 
In this dissertation, I review the literature regarding the epidemiology of CNS infections of 
both known and unknown cause and the currently available diagnostic methods for CNS 
infections. I summarize the incidence, cause and risk factors for CNS infections and offered 
explanations for the high proportion of CNS infections of unknown cause worldwide. I 







nation-wide dataset dating over a 13 year period. I also identify risk factors for CNS 
infections of unknown cause, which may have implications for future studies. Finally, I 
confirm the power of multiplex MassTag PCR as a useful diagnostic tool for identifying 
pathogens in CNS infections of unknown cause, which may guide future epidemiological 
studies of CNS infections.  
 
Collective results from clinical, laboratory and epidemiological studies are needed to identify 
the underlying infectious agents of CNS infections. Future studies on the epidemiological 
characteristics of CNS infections of unknown cause and advanced molecular diagnostics for 
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Appendix 1: Supplemental Table for Chapter 2 
 
Table 2.1: Articles selected for literature review on the incidence and cause of CNS infections from 1990-2010 
Author Country Study year 
No of cases 
Study population, 
age 




Europe        
Koskiniemi et al.[1] Finland 1968-1987 
(n=405) 
1 month-16 years;  
One university 
hospital 
Encephalitis Review medical 
records and laboratory 
data 
31% 1.0-16.7 (varies 
by age) 
Koskiniemi et al.[2] Finland 1993-1994 
(n=175) 
1 month-15 years; 
Prospective study in 
two hospitals 
Encephalitis Clinical criteria and 
laboratory data 
37% 10.5 





Encephalitis Review medical 
records and laboratory 
data 
41-64% 1.4 
Koskiniemi et al.[4] Finland 1995-1996 
(n=1,014 in 
encephalitis) 




25-100 (all CNS 
infections) 
Ckizman et al.[5] Slovenia 1979-1991 
(n=170) 
1 month-15 years Encephalitis Medical records; 
clinical criteria 
32% 6.7 
Davidson, et al.[6] England 1989-1998 
(n=6,414) 
All ages Viral encephalitis Hospital episode 
statistics, using ICD-9 
or 10 coding 
60% 1.5 







(n=93) laboratory data 
Galanakis et al.[8] Greece 2005-2007 
(n=42) 
1 month-15 years; 
prospective enrolled 
cases in three 
hospitals 
Encephalitis Clinical and 
laboratory data 
42.9% 4.5 
North America        




of discharge records 
from nonfederal, 
general and children’s 
hospitals in the U.S. 
Encephalitis National Hospital 
Discharge Survey 
Data using ICD-9-CM  
60% 7.3 
Glaser et al.[10] USA 1998-2000 
(n=334) 
> 6 months; 
patients referred from 
95 institutions in 
California 
Encephalitis Clinical criteria and 
laboratory data 
62% N/A 
Trevejo [11] USA 1990-1999 
(n=13,807) 
All ages;  
all acute care 
hospitals in California 
Encephalitis Hospital discharge 
data using ICD-9-CM 
56% 4.3 
Glaser et al.[12] USA 1998-2005 
(n=1,570) 
≧ 6 months; 
patients referred from 
195 institutions in 
California 
Encephalitis Clinical criteria and 
laboratory data 
63% N/A 








Asia        
Ishikawa, et al.[14] Japan 1984-1990 
(n=256) 
≦15 years 
36 departments of 
pediatrics in Aichi 
prefecture 
Encephalitis Questionnaires to 
pediatricians; cases 
ascertained using 
clinical and laboratory 
data 
59%  3.3 




data from Ministry of 
Public Health 
Viral encephalitis Clinical criteria N/A 6.34 
Chhour, et al. [16] Cambodia 1996-1998 
(n=50) 
≦14 years 
One pediatric referral 
hospital 
Encephalitis Clinical criteria; only 
Japanese encephalitis 
was tested for 
82% N/A 
Lowry et al.[17] Vietnam June-August 1995 
(n=79) 
All ages;  
one hospital in Hanoi 
Encephalitis Clinical criteria 58% N/A 
Lee et al.[18] Taiwan 2000-2001 
(n=127) 
Age ≧1 year; 
prospective enrolled 
cases in 30 hospitals 
Encephalitis Clinical criteria 31% N/A 
Other        
Huppatz et al.[19] Australia 1990-2007 
(n=5,926) 
All ages Encephalitis Hospital discharge 
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Table 3.1A: Detailed ICD-9-CMcodes defining meningitis in Taiwan from 1996-2008 
Discharge diagnosis of meningitis ICD-9-CM code 
Bacterial meningitis  
Hemophilus meningitis 320.0 
Pneumococcal meningitis 320.1 
Streptococcal meningitis 320.2 
Staphylococcal meningitis 320.3 
Meningitis in other bacterial diseases classified elsewhere1 320.7 
Anaerobic meningitis 320.81 
Meningitis due to gram-negative bacteria, not elsewhere classified 320.82 
Meningitis due to other specified bacteria 320.89 
Meningitis due to unspecified bacterium 320.9 
Tuberculous meningitis2 013.00-013.06 
Meningococcal meningitis 036.0 
Congenital syphilitic meningitis 090.42 
Acute syphilitic meningitis (secondary) 091.81 
Syphilitic meningitis 094.2 
Gonococcal meningitis 098.82 
Leptospiral meningitis 100.81 
Salmonella meningitis 003.21 
Fungal/parasitic Meningitis  
Candidal meningitis 112.83 
Coccidioidal meningitis 114.2 
Meningitis, infection by Histoplasma capsulatum 115.01 
Meningitis, infection by Histoplasma duboisii 115.11 
Meningitis, infection by Histoplasmosis, unspecified 115.91 
Cryptococcal meningitis3 321.0 
Meningitis in other fungal disease 321.1 
Meningitis due to trypanosomiasis 321.3 
Meningitis due to other nonbacterial organisms classified elsewhere 321.8 
Aseptic meningitis  
Known pathogen  
 Enteroviral meningitis (3 codes)4 047.0-047.1 
Other specified viral meningitis 047.8 
 Meningitis due to adenovirus 049.1 
Lymphocytic choriomeningitis 049.0 
Herpes zoster with meningitis 053.0 






Mumps meningitis 072.1 
Meningitis due to viruses not elsewhere classified 321.2 
Unknown pathogen  
 Unspecified viral meningitis 047.9 
Nonpyogenic meningitis 322.0 
Eosinophilic meningitis 322.1 
 Chronic meningitis 322.2 
 Meningitis, unspecified 322.9 
1. Include Listeria meningitis (027.0+ 320.7); actinomycosis meningitits (039.8+ 320.7); meningitis in typhoid fever 
(002.0+ 320.7) and meningitis due to whooping cough (033.0-033.9+ 320.7). 
2. Six codes for tuberculous meningitis: tuberculous meningitis (013.0);tuberculous meningitis, unspecified 
(013.00);tuberculous meningitis, bacteriological or histological examination not done (013.01); tuberculous meningitis, 
bacteriological or histological examination unknown (013.02);tuberculous meningitis, tubercle bacilli found (in sputum) 
by microscopy (013.03); tuberculous meningitis, tubercle bacilli not found (in sputum)by microscopy, but found by 
bacterial culture (013.04); tuberculous meningitis, tubercle bacilli not found by bacteriological examination, but 
confirmed histologically (013.05); tuberculous meningitis, tubercle bacilli not found by bacteriological or histological 
examination, but confirmed by other methods (inoculation of animals)(013.06). 
3. Cryptococcal meningitis is encoded as 321.0 as a primary diagnosis, or cryptococcosis (117.5) as a primary diagnosis 
pluscryptococcal meningitis (321.0) as a secondary diagnosis. 
4. Enteroviral meningitis includes meningitis due to coxsackie virus (047.0), meningitis due to ECHO virus (047.1), and 







Table 3.1B: Detailed ICD-9-CM codes defining encephalitis in Taiwan from 1996-2008 
Discharge diagnosis Code 
Bacterial origin  
Meningococcal encephalitis 036.1 
Congenital syphilitic encephalitis 090.41 
Syphilitic encephalitis 094.81 
Tuberculous encephalitis 1 013.2-013.6 
Listeria meningoencephalitis2 027.02 
  
Fungal/parasitic origin  
Encephalitis, myelitis, and encephalomyelitis in protozoal diseases classified elsewhere 323.2 
Meningoencephalitis due to toxoplasmosis 130.0 
Meningoencephalitis due to Naegleria 136.29 
  
Known viral origin  
  Enteroviral encephalitis3  
Other specified non-arthropod-borne viral disease of the CNS 049.8 
Varicella encephalitis 052.0 
Herpes viral meningoencephalitis 054.3 
Other human herpesvirus encephalitis 058.2 
Human herpesvirus 6 encephalitis 058.21 
Human herpesvirus 7 encephalitis 058.29 
Mumps encephalitis 072.2 
Rubella with neurological complications 056.0 
Rubella with unspecified neurological complication 056.00 
Encephalomyelitis due to rubella 056.01 
Mosquito-borne viral encephalitis  
Japanese encephalitis 062.0 
Western equine encephalitis 062.1 
Eastern equine encephalitis 062.2 
St. Louis encephalitis 062.3 
Australian encephalitis 062.4 
California virus encephalitis 062.5 
Other specified mosquito-borne viral encephalitis 062.8 
Mosquito-borne viral encephalitis, unspecified 062.9 
Tick-borne viral encephalitis  
Russian spring-summer (taiga) encephalitis 063.0 






Central European encephalitis 063.2 
Other specified tick-borne viral encephalitis 063.8 
Viral encephalitis transmitted by other and unspecified arthropods 064 
Venezuelan equine encephalitis 066.2 
West Nile encephalitis 066.41 
Encephalitis, myelitis, and encephalomyelitis in viral diseases classified elsewhere 323.0 
Encephalitis, myelitis, and encephalomyelitis in rickettsial diseases classified elsewhere 323.1 
Encephalitis and encephalomyelitis in viral diseases classified elsewhere 323.01 
Other encephalitis, myelitis, and encephalomyelitis due to infection classified elsewhere 323.4 
Postmeasles encephalitis 055.0 
Encephalitis following immunization procedures 323.5 
Encephalitis and encephalomyelitis following immunization procedures 323.51 
Postinfectious encephalitis 323.6 
Other postinfectious encephalitis and encephalomyelitis 323.62 
  
Unknown causes  
Viral encephalitis not otherwise specified 049.9 
Mosquito-borne viral encephalitis, unspecified 062.9 
Unspecified tick-borne encephalitis 063.9 
Other encephalitis and encephalomyelitis due to infection classified elsewhere 323.41 
Unspecified cause of encephalitis 323.8 
Unspecified cause of encephalitis, myelitis and encephalomyelitis 323.9 
1. Tuberculous encephalitis includes 5 codes: “Tuberculoma of brain” (013.2), “Tuberculous abscess of brain” (013.3), 
“Tuberculous encephalitis or myelitis” (013.6), “Other specified tuberculosis of central nervous system” (013.8), 
“Unspecified tuberculosis of central nervous system” (013.9). 
2. Listeria meningoencephalitis is encoded as Listeriosis (027.0), plus any of “other specified”, “classified elsewhere”, or 
“unspecified causes of encephalitis” (049.8, 049.9, 323.0, 323.4, 323.6, 323.8, 323.9, 348.3). 
3. Enteroviral encephalitis includes other enterovirus-related diseases of central nervous system (048) or Hand-foot-mouth 
disease (074.3), plus any of “other specified”, “classified elsewhere” or “unspecified causes of encephalitis” (049.8, 







Table 3.2: Mosquitoes in Taiwan that can potentially transmit encephalitis1 
Pathogen Potential vectors in Taiwan 
Flaviviradae  
Dengue virus Aedes aegypti 
Aedes albopictus 
Japanese encephalitis virus Culex annulus 
Culex vishinui 
Culex fuscocephalus 
 Culex tritaeniorhynchus 






St. Louise encephalitis Culex quinqefasciatus 
Yellow fever encephalitis Aedes aegypti 
Togaviridae (genus Alphavirus)  
Eastern Equine encephalitis Aedes albopictus 
Aedes vexans 
Venezuelan equine encephalitis Culex quinquefasciatus 
Chikungunya encephalitis Aedes aegypti 
Bunyaviridae  




1. Modified from: Teng, Hwa-Jen, 2007. Arbovirus mosquito surveillance program in Taiwan (Chinese version). 








Table 3.3: Age-specific population in Taiwan through 1996-2008
1 
Year Age 0-9 10~19 20~29 30~39 40~49 50~59 60~69 70~79 > 80 Total 
1996 3,206,352  3,775,800  3,675,929  3,831,527  2,979,587  1,655,345  1,380,753  783,959  236,181  21,525,433  
1997 3,226,109  3,700,424  3,694,243  3,838,449  3,125,309  1,687,645  1,391,517  828,272  250,847  21,742,815  
1998 3,159,561  3,645,117  3,721,097  3,848,383  3,266,399  1,747,136  1,398,405  876,646  265,847  21,928,591  
1999 3,132,499  3,542,349  3,754,816  3,840,748  3,383,661  1,825,370  1,410,902  920,315  281,727  22,092,387  
2000 3,104,400  3,474,056  3,780,665  3,828,978  3,484,626  1,914,115  1,427,566  960,791  301,475  22,276,672  
2001 3,045,723  3,384,508  3,821,115  3,802,330  3,538,240  2,051,260  1,445,062  989,984  327,346  22,405,568  
2002 2,972,207  3,307,811  3,861,042  3,761,111  3,602,206  2,185,676  1,464,925  1,012,859  352,939  22,520,776  
2003 2,870,949  3,256,719  3,878,662  3,712,874  3,663,790  2,322,498  1,488,513  1,033,826  376,719  22,604,550  
2004 2,764,954  3,214,793  3,886,690  3,674,659  3,710,150  2,476,340  1,505,453  1,052,965  403,118  22,689,122  
2005 2,647,291  3,202,012  3,867,021  3,651,771  3,733,796  2,671,372  1,495,578  1,066,929  434,613  22,770,383  
2006 2,530,102  3,224,197  3,759,284  3,686,248  3,759,995  2,863,417  1,503,448  1,078,172  471,664  22,876,527  
2007 2,412,365  3,238,606  3,692,612  3,712,173  3,766,698  3,004,151  1,537,526  1,092,570  501,659  22,958,360  
2008 2,346,076  3,165,079  3,636,872  3,740,257  3,774,360  3,138,123  1,596,563  1,104,437  535,264  23,037,031  





Table 3.4: Possible co-infections in meningitis or encephalitis cases in Taiwan from 1996 to 2008 
ICD-9-CM primary diagnosis (case number) Co-infections1 Number 
Meningitis of known cause (n=7751)   
Enteroviral meningitis (n=1137) Unspecified bacterial meningitis 5 
 Herpetic encephalitis 5 
 Tuberculous meningitis 2 
 Japanese encephalitis 2 
Tuberculous meningitis (n=1727) Herpetic encephalitis 5 
 Pneumococcal meningitis 1 
 Syphilitic meningitis 1 
 Encephalitis due to rubella 1 
Pneumococcal meningitis (n=224) Herpetic encephalitis 1 
Staphylococcal meningitis (n=149) Tuberculous meningitis 1 
Herpes simplex meningitis (n=114) Tuberculous meningitis 1 
 Japanese encephalitis 1 
Herpes zoster with meningitis (n=140) Syphilitic meningitis 1 
Meningitis due to adenovirus (n=5) Herpetic encephalitis 1 
Lymphocytic choriomeningitis (n=10) Tuberculous meningitis 1 
  Subtotal=29 
   
Encephalitis of known cause (n=2118)   
Herpetic encephalitis (n=725) Unspecified Bacterial meningitis 2 
 Japanese encephalitis  1 
 Syphilitic meningitis 1 
Japanese encephalitis (n=200) Herpetic encephalitis 3 
 Unspecified bacterial meningitis 2 
 Enteroviral CNS infections 1 
 Tuberculous meningitis 1 
  Subtotal=11 
1. Co-infection is defined by the secondary diagnosis of ICD-9-CM codes in meningitis or encephalitis, with additional 









Table 3.5: Comparison of CNS infections associated with known vs. unknown pathogens between groups in Taiwan in 1996 
 Meningitis Crude odds ratio p-value Encephalitis Crude odds ratio p-value 
 Unknown (%) Known (%) (95% CI)  Unknown (%) Known (%) (95% CI)  
Sex         
Female 629 (39.14) 212 (39.04) 1.05 (0.87-1.26) 0.61 171 (42.22) 47 (52.22) 1.50 (0.95-2.37) 0.08 
Male 978 (60.86) 331 (60.96) referent  234 (57.78) 43 (47.78) referent  
Age         
0-9 1095 (68.14) 209 (38.49) 4.84 (2.18-10.75) <0.01 147 (36.30) 29 (32.22) 1.13 (0.23- 5.49) 0.88 
10-19 131 (8.15) 30 (5.52) 4.03 (1.67-9.71) <0.01 73 (18.02) 12 (13.33) 1.35 (0.26- 7.03) 0.72  
20-29 101 (6.29) 31 (5.71) 3.01 (1.25- 7.26) 0.01  36 (8.89) 7 (7.78) 1.14 (0.20- 6.47) 0.88  
30-39 85 (5.29) 55 (10.13) 1.43 (0.61-3.35) 0.41  46 (11.36) 10 (11.11) 1.02 (0.19- 5.47) 0.98  
 40-49 60 (3.73) 49 (9.02) 1.13 (0.47-2.70) 0.78 28 (6.91) 8 (8.89) 0.78 (0.14- 4.35) 0.77  
 50-59 40 (2.49) 55 (10.13) 0.67 (0.28-1.63) 0.38  18 (4.44) 10 (11.11) 0.40 (0.07- 2.23) 0.29  
 60-69 41 (2.55) 57 (10.50) 0.66 (0.28-1.60) 0.36  24 (5.93) 4 (4.44) 1.33 (0.21- 8.58) 0.76  
 70-79 41 (2.55) 45 (8.29) 0.84 (0.34-2.05) 0.70  24 (5.93) 8 (8.89) 0.67 (0.12- 3.75) 0.64  
>80 13 (0.81) 12 (2.21) referent  9 (2.22) 2 (2.22) referent  
Seasonality         
Spring 323 (20.10) 123 (22.65) 1.48 (1.09- 2.00) <0.01 100 (24.69) 28 (31.11) 0.81 (0.43-1.49) 0.49 
Summer 627 (39.02) 145 (26.07) 2.43 (1.83- 3.23) <0.01 120 (29.63) 26 (28.89) 1.04 (0.56-1.93) 0.90  
Autumn 433 (26.94) 149 (27.44) 1.63 (1.23- 2.18) <0.01 83 (20.49) 13 (14.44) 1.44 (0.69-3.02) 0.33  
Winter 224 (13.94) 126 (23.20) referent  102 (25.19) 23 (25.56) referent  
Geographic area         









Urban 1483 (92.28) 511 (94.11) referent  390 (96.30) 83 (92.22) referent  
Pig farm           
Present 1120 (69.70) 408 (75.14) 0.76 (0.61-0.95) 0.02 304 (75.06) 73 (81.11) 0.70 (0.39-1.24) 0.22 
Absent 487 (30.30) 135 (24.86) referent  101 (24.94) 17 (18.89) referent  
Mosquito1         
Present 412 (25.64) 163 (30.02) 0.80 (0.65-1.00) 0.05 95 (23.46) 27 (30.00) 0.72 (0.43-1.19) 0.19 
 Absent 1195 (74.36) 380 (69.98) referent  310 (76.54) 63 (70.00) referent  












Table 3.6: Comparison of CNS infections associated with known vs. unknown pathogens between groups in Taiwan in 1997 
 Meningitis Crude odds ratio p-value Encephalitis Crude odds ratio p-value 
 Unknown (%) Known (%) (95% CI)  Unknown (%) Known (%) (95% CI)  
Sex         
Female 620 (39.57) 220 (39.43) 1.01 (0.83-1.23) 0.95 168 (41.48) 33 (42.86) 1.06 (0.65-1.73) 0.82 
Male 947 (60.43) 338 (60.57) referent  237 (58.52) 44 (57.14) referent  
Age         
0-9 1025 (65.41) 178 (31.90) 5.42 (2.69-10.92) <0.01 151 (37.28) 23 (29.87) 1.46 (0.30-7.18) 0.64 
10-19 182 (11.61) 27 (4.84) 6.34 (2.87-14.03) <0.01 59 (14.57) 11 (14.29) 1.19 (0.23-6.28) 0.84 
20-29 96 (6.13) 41 (7.35) 2.20 (1.02-4.78) 0.04 43 (10.62) 7 (9.09) 1.37 (0.24-7.68) 0.72 
30-39 80 (5.11) 52 (9.32) 1.45 (0.67-3.12) 0.34 33 (8.15) 6 (7.79) 1.22 (0.21-7.12) 0.82 
 40-49 53 (3.38) 64 (11.47) 0.78 (0.36-1.69) 0.53 35 (8.64) 4 (5.19) 1.94 (0.31-12.35) 0.48 
 50-59 32 (2.04) 64 (11.47) 0.47 (0.21-1.05) 0.06 23 (5.68) 11 (14.29) 0.46 (0.09-2.52) 0.37 
 60-69 43 (2.74) 66 (11.83) 0.61 (0.28-1.34) 0.22 29 (7.16) 5 (6.49) 1.29 (0.21-7.82) 0.78 
 70-79 39 (2.49) 50 (8.96) 0.73 (0.33-1.64) 0.45 23 (5.68) 8 (10.39) 0.64 (0.11-3.61) 0.61 
>80 17 (1.08) 16 (2.87) referent  9 (2.22) 2 (2.60) referent  
Seasonality         
Spring 373 (23.80) 145 (25.99) 1.30 (0.97-1.73) 0.08 106 (26.17) 15 (19.48) 1.21 (0.58-2.56) 0.61  
Summer 561 (35.80) 137 (24.55) 2.06 (1.55-2.75) <0.01 97 (23.95) 23 (29.87) 0.72 (0.36-1.44) 0.36  
Autumn 391 (24.95) 154 (27.60) 1.28 (0.96-1.70) 0.09  103 (25.43) 22 (28.57) 0.80 (0.40-1.60) 0.54  
Winter 242 (15.44) 122 (21.86) referent  99 (24.44) 17 (22.08) referent  
Geographic area         









Urban 1393 (88.90) 538 (96.42) referent  385 (95.06) 74 (96.10) referent  
Pig farm           
Present 1156 (73.77) 421 (75.45) 0.92 (0.73-1.14) 0.44 311 (76.79) 54 (70.13) 1.41 (0.82-2.42) 0.21 
Absent 411 (26.23) 137 (24.55) referent  94 (23.21) 23 (29.87) referent  
Mosquito1         
Present 459 (29.29) 166 (29.75) 0.98 (0.79-1.21) 0.84 75 (18.52) 28 (36.36) 0.40 (0.23-0.67) <0.01 
 Absent 1108 (70.71) 392 (70.25) referent  330 (81.48) 49 (63.64) referent  












Table 3.7: Comparison of CNS infections associated with known vs. unknown pathogens between groups in Taiwan in 1998 
 Meningitis Crude odds ratio p-value Encephalitis Crude odds ratio p-value 
 Unknown (%) Known (%) (95% CI)  Unknown (%) Known (%) (95% CI)  
Sex         
Female 738 (41.77) 224 (40.73) 0.86 (0.79-1.16) 0.67 294 (43.36) 98 (40.83) 0.90 (0.67-1.22) 0.50 
Male 1029 (58.23) 326 (59.27) referent  384 (56.64) 142 (59.17) referent  
Age         
0-9 1071 (60.61) 185 (33.64) 6.15 (3.05-12.39)     <0.01 375 (55.31) 184 (76.67) 0 (N/A) 0.94  
10-19 237 (13.41) 28 (5.09) 8.99 (4.09-19.76) <0.01 96 (14.16) 9 (3.75) 0 (N/A) 0.95  
20-29 110 (6.23) 43 (7.82) 2.72 (1.26-5.86) 0.01  42 (6.19) 10 (4.17) 0 (N/A) 0.94  
30-39 120 (6.79) 60 (10.91) 2.13 (1.00-4.50) 0.05  47 (6.93) 5 (2.08) 0 (N/A) 0.95  
 40-49 70 (3.96) 50 (9.09) 1.49 (0.69-3.22) 0.31  35 (5.16) 10 (4.17) 0 (N/A) 0.94  
 50-59 44 (2.49) 56 (10.18) 0.83 (0.38-1.84) 0.65  19 (2.80) 12 (5.00) 0 (N/A) 0.94  
 60-69 54 (3.06) 61 (11.09) 0.94 (0.43-2.04) 0.88  19 (2.80) 5 (2.08) 0 (N/A) 0.94  
 70-79 45 (2.55) 50 (9.09) 0.96 (0.43-2.11)  0.91  34 (5.01) 5 (2.08) 0 (N/A) 0.95  
>80 16 (0.91) 17 (3.09) referent  11 (1.62) 0 (0.00) referent  
Seasonality         
Spring 508 (28.75) 134 (24.36) 1.43 (1.06-1.93) 0.02 159 (23.45) 41 (17.08) 0.78 (0.45-1.36) 0.38  
Summer 695 (39.33) 165 (30.00) 1.59 (1.19-2.12) <0.01  238 (35.10) 117 (48.75) 0.41 (0.25-0.67) <0.01  
Autumn 299 (16.92) 151 (27.45) 0.75 (0.55-1.01) 0.06  157 (23.16) 57 (23.75) 0.56 (0.33-0.94) 0.03  
Winter 265 (15.00) 100 (18.18) referent  124 (18.29) 25 (10.42) referent  
Geographic area         









Urban 1587 (89.81) 517 (94.00) referent  649 (95.72) 227 (94.58) referent  
Pig farm           
Present 1312 (74.25) 434 (78.91) 0.77 (0.61-0.97) 0.03  504 (74.34) 183 (76.25) 0.90 (0.64-1.27) 0.56  
Absent 455 (25.75) 116 (21.09) referent  174 (25.66) 57 (23.75) referent  
Mosquito1         
Present 504 (28.52) 199 (36.18) 0.70 (0.58-0.86) <0.01 184 (27.14) 65 (27.08) 1.00 (0.72-1.40) 0.99 
 Absent 1263 (71.48) 351 (63.82) referent  494 (72.86) 175 (72.92) referent  













Table 3.8: Comparison of CNS infections associated with known vs. unknown pathogens between groups in Taiwan in 1999 
 Meningitis Crude odds ratio p-value Encephalitis Crude odds ratio p-value 
 Unknown (%) Known (%) (95% CI)  Unknown (%) Known (%) (95% CI)  
Sex         
Female 798 (38.78) 195 (36.04) 1.12 (0.92-1.37) 0.24 214 (44.49) 49 (49.00) 1.20 (0.78-1.85) 0.41 
Male 1260 (61.22) 346 (63.96) referent  267 (55.51) 51 (51.00) referent  
Age         
0-9 1374 (66.76) 158 (29.21) 8.32 (4.53-15.27) <0.01 208 (43.24) 45 (45.00) 1.54 (0.30-7.88) 0.60  
10-19 274 (13.31) 21 (3.88) 12.48 (5.99-26.00) <0.01 87 (18.09) 8 (8.00) 3.63 (0.63-20.99) 0.15  
20-29 94 (4.57) 34 (6.28) 2.64 (1.31-5.35) 0.01  31 (6.44) 12 (12.00) 0.86 (0.15-4.87) 0.87  
30-39 92 (4.47) 50 (9.24) 1.76 (0.89-3.47) 0.10  36 (7.48) 6 (6.00) 2.00 (0.32-12.33) 0.46  
 40-49 55 (2.67) 75 (13.86) 0.70 (0.36-1.38) 0.31  33 (6.86) 12 (12.00) 0.92 (0.16-5.18) 0.92  
 50-59 49 (2.38) 58 (10.72) 0.81 (0.40-1.62) 0.55  32 (6.65) 6 (6.00) 1.78 (0.29-11.00) 0.54  
 60-69 59 (2.87) 63 (11.65) 0.90 (0.45-1.78) 0.75  26 (5.41) 5 (5.00) 1.73 (0.27-11.19) 0.56  
 70-79 38 (1.85) 60 (11.09) 0.61 (0.30-1.23) 0.17  22 (4.57) 4 (4.00) 1.83 (0.27-12.54) 0.54  
>80 23 (1.12) 22 (4.07) referent  6 (1.25) 2 (2.00) referent  
Seasonality         
Spring 443 (21.53) 131 (24.21) 1.59 (1.19-2.14) <0.01 127 (26.40) 25 (25.00) 0.99 (0.54-1.80) 0.96  
Summer 983 (47.76) 157 (29.02) 2.95 (2.23-3.90) <0.01 115 (23.91) 22 (22.00) 1.01 (0.55-1.89) 0.96  
Autumn 390 (18.95) 139 (25.69) 1.32 (0.98-1.78) 0.06  105 (21.83) 27 (27.00) 0.76 (0.42-1.37) 0.35  
Winter 242 (11.76) 114 (21.07) referent  134 (27.86) 26 (26.00) referent  
Geographic area         









Urban 1855 (90.14) 505 (93.35) referent  467 (97.09) 89 (89.00) referent  
Pig farm           
Present 1487 (72.25) 416 (76.89) 0.78 (0.63-0.98) 0.03  344 (71.52) 64 (64.00) 1.41(0.90-2.22)  0.13  
Absent 571 (27.75) 125 (23.11) referent  137 (28.48) 36 (36.00) referent  
Mosquito1         
Present 478 (23.23) 174 (32.16) 0.64 (0.52-0.79) <0.01 120 (24.95) 20 (20.00) 1.33 (0.78- 2.26) 0.29  
 Absent 1580 (76.77) 367 (67.84) referent  361 (75.05) 80 (80.00) referent  













Table 3.9: Comparison of CNS infections associated with known vs. unknown pathogens between groups in Taiwan in 2000 
 Meningitis Crude odds ratio p-value Encephalitis Crude odds ratio p-value 
 Unknown (%) Known (%) (95% CI)  Unknown (%) Known (%) (95% CI)  
Sex         
Female 1088 (37.87) 201 (35.64) 1.10 (0.91-1.33) 0.32 279 (44.08) 101 (41.22) 1.12 (0.83-1.52) 0.44 
Male 1785 (62.13) 363 (64.36) referent  354 (55.92) 144 (58.78) referent  
Age         
0-9 2104 (73.23) 159 (28.19) 19.85 (11.30-34.85) <0.01 316 (49.92) 169 (68.98) 0.23 (0.03-1.89) 0.05  
10-19 291 (10.13) 35 (6.21) 12.47 (6.55-23.73) <0.01 86 (13.59) 18 (7.35) 0.60 (0.07-5.08) 0.17  
20-29 125 (4.35) 39 (6.91) 4.81 (2.51-9.19) <0.01 46 (7.27) 19 (7.76) 0.30 (0.04-2.59) 0.64  
30-39 119 (4.14) 56 (9.93) 3.19 (1.70-5.96) <0.01  43 (6.79) 7 (2.86) 0.77 (0.08-7.12) 0.28  
 40-49 75 (2.61) 69 (12.23) 1.63 (0.87-3.06) 0.13  37 (5.85) 6 (2.45) 0.77 (0.08-7.32) 0.82  
 50-59 41 (1.43) 55 (9.75) 1.12 (0.57-2.19) 0.75  32 (5.06) 7 (2.86) 0.57 (0.06-5.34) 0.82  
 60-69 54 (1.88) 61 (10.82) 1.33 (0.69-2.55) 0.39  33 (5.21) 8 (3.27) 0.52 (0.06-4.74) 0.62  
 70-79 42 (1.46) 57 ()10.11 1.11 (0.57-2.16) 0.77  32 (5.06) 10 (4.08) 0.40 (0.04-3.60) 0.56  
>80 22 (0.77) 33 (5.85) referent  8 (1.26) 1 (0.41) referent  
Seasonality         
Spring 507 (17.65) 129 (22.87) 1.17(0.89-1.55) 0.27 134 (21.17) 41 (16.73) 0.74 (0.45-1.22) 0.24  
Summer 1279 (44.52) 172 (30.50) 2.22 (1.72-2.860 <0.01 177 (27.96) 91 (37.14) 0.44 (0.29-0.68) <0.01  
Autumn 671 (23.36) 139 (24.65) 1.44 (1.10-1.89) 0.01  159 (25.12) 76 (31.02) 0.48 (0.30-0.74) <0.01  
Winter 416 (14.48) 124 (21.99) referent  163 (25.75) 37 (15.10) referent  
Geographic area         









Urban 2512 (87.43) 515 (91.31) referent  591 (93.36) 229 (93.47) referent  
Pig farm           
Present 2101 (73.13) 452 (80.14) 0.67 (0.54-0.84) <.01 464 (73.30) 175 (71.43) 1.10 (0.79-1.53) 0.58  
Absent 772 (26.87) 112 (19.86) referent  169 (26.70) 70 (28.57) referent  
Mosquito1         
Present 1053 (36.65) 176 (31.21) 1.28 (1.05-1.55) 0.01  154 (24.33) 102 (41.63) 0.45 (0.33-0.62 <0.01 
 Absent 1820 (63.35) 388 (68.79) referent  479 (75.67) 143 (58.37) referent  













Table 3.10: Comparison of CNS infections associated with known vs. unknown pathogens between groups in Taiwan in 2001 
 Meningitis Crude odds ratio p-value Encephalitis Crude odds ratio p-value 
 Unknown (%) Known (%) (95% CI)  Unknown (%) Known (%) (95% CI)  
Sex         
Female 2645 (38.37) 312 (38.38) 1.00 (0.86-1.16) 1.00 273 (42.99) 124 (43.21) 0.99 (0.75-1.31) 0.95 
Male 4248 (61.63) 501 (61.62) referent  362 (57.01) 163 (56.79) referent  
Age         
0-9 4720 (68.48) 315 (38.75) 21.73 (12.15-38.84) <0.01 282 (44.41) 202 (70.38) 0.22 (0.05-0.96) 0.04  
10-19 1071 (15.54) 68 (8.36) 22.84 (12.28-42.46) <0.01 109 (17.17) 14 (4.88) 1.20 (0.24-5.87) 0.82  
20-29 490 (7.11) 77 ()9.47 9.23 (4.97-17.12) <0.01 49 (7.72) 11 (3.83) 0.69 (0.14-3.48) 0.65  
30-39 300 (4.35) 69 (8.49) 6.30 (3.37-11.80) <0.01 44 (6.93) 16 (5.57) 0.42 (0.09-2.09) 0.29  
 40-49 127 (1.84) 67 (8.24) 2.75 (1.45-5.22) <0.01  42 (6.61) 14 (4.88) 0.46 (0.09-2.30) 0.35  
 50-59 79 (1.15) 56 (6.89) 2.05 (1.05-3.98) 0.03  39 (6.14) 16 (5.57) 0.38 (0.08-1.85) 0.23  
 60-69 44 (0.64) 62 (7.63) 1.03 (0.52-2.05) 0.94  28 (4.41) 3 (1.05) 1.44 (0.21-9.66) 0.71  
 70-79 42 (0.61) 70 (8.61) 0.87 (0.44-1.73) 0.69  29 (4.57) 9 (3.14) 0.50 (0.09-2.62) 0.41  
>80 20 (0.29) 29 (3.57) referent  13 (2.05) 2 (0.70) referent  
Seasonality         
Spring 1454 (21.09) 216 (26.57) 1.19(0.94-1.51) 0.15 158 (24.88) 50 (17.42) 0.84 (0.52-1.34) 0.46  
Summer 3617 (52.47) 294 (36.16) 2.18 (1.74-2.73) <0.01 178 (28.03) 108 (37.63) 0.44 (0.29-0.67) <0.01  
Autumn 1133 (16.44) 181 (22.26) 1.11 (0.86-1.42) 0.42  148 (23.31) 89 (31.01) 0.44 (0.29-0.68) <0.01  
Winter 689 (10.00) 122 (15.01) referent  151 (23.78) 40 (13.94) referent  
Geographic area         









Urban 6109 (88.63) 692 (85.12) referent  584 (91.97) 269 (93.73) referent  
Pig farm           
Present 5096 (73.93) 664 (81.67) 0.64 (0.53-0.77) <0.01 494 (77.80) 202 (70.38) 1.47 (1.08-2.02) 0.02  
Absent 1797 (26.07) 149 (18.33) referent  141 (22.20) 85 (29.62) referent  
Mosquito1         
Present 2496 (36.21) 223 (27.43) 1.50 (1.28-1.77) <0.01 151 (23.78) 92 (32.06) 0.66 (0.49-0.90) 0.01  
 Absent 4397 (63.79) 590 (72.57) referent  484 (76.22) 195 (67.94) referent  













Table 3.11: Comparison of CNS infections associated with known vs. unknown pathogens between groups in Taiwan in 2002 
 Meningitis Crude odds ratio p-value Encephalitis Crude odds ratio p-value 
 Unknown (%) Known (%) (95% CI)  Unknown (%) Known (%) (95% CI)  
Sex         
Female 1102 (38.61) 236 (37.94) 0.97 (0.81-1.16) 0.76 237 (44.22) 78 (43.09) 0.96 (0.68-1.34) 0.79 
Male 1752 (61.39) 386 (62.06) referent  299 (55.78) 103 (56.91) referent  
Age         
0-9 1654 (57.95) 157 (25.24) 9.22 (5.41-15.71) <0.01 244 (45.52) 101 (55.80) 0.56 (0.16- 2.00) 0.37  
10-19 451 (15.80) 31 (4.98) 12.73 (6.82-23.76) <0.01 84 (15.67) 18 (9.94) 1.08 (0.28- 4.17) 0.91  
20-29 245 (8.58) 63 (10.13) 3.40 (1.91-6.06) <0.01 38 (7.09) 14 (7.73) 0.63 (0.16- 2.53) 0.51  
30-39 188 (6.59) 76 (12.22) 2.16 (1.22-3.84) 0.01  40 (7.46) 10 (5.52) 0.92 (0.22- 3.87) 0.91  
 40-49 103 (3.61) 73 (11.74) 1.23 (0.68-2.23) 0.48  39 (7.28) 13 (7.18) 0.69 (0.17- 2.82) 0.61  
 50-59 67 (2.35) 70 (11.25) 0.84 (0.46-1.54) 0.57  21 (3.92) 7 (3.87) 0.69 (0.15- 3.16) 0.64  
 60-69 67 (2.35) 63 (10.13) 0.93 (0.50-1.72) 0.82  29 (5.41) 11 (6.08) 0.61 (0.15- 2.55) 0.50  
 70-79 47 (1.65) 61 (9.81) 0.67 (0.36-1.27) 0.22  28 (5.22) 4 (2.21) 1.62 (0.32- 8.29) 0.57  
>80 32 (1.12) 28 (4.50) referent  13 (2.43) 3 (1.66) referent  
Seasonality         
Spring 849 (29.75) 165 (26.53) 1.29(1.01-1.65) 0.04 123 (22.95) 38 (20.99) 0.82 (0.48- 1.38) 0.44  
Summer 924 (32.38) 155 (24.92) 1.50 (1.16-1.92) <0.01  146 (27.24) 55 (30.39) 0.67 (0.41- 1.09) 0.11  
Autumn 515 (18.04) 160 (25.72) 0.81 (0.63-1.04) 0.10  132 (24.63) 54 (29.83) 0.62 (0.38- 1.01) 0.05  
Winter 566 (19.83) 142 (22.83) referent  135 (25.19) 34 (18.78) referent  
Geographic area         









Urban 2555 (89.52) 565 (90.84) referent  497 (92.72) 171 (94.48) referent  
Pig farm           
Present 2165 (75.86) 497 (79.90) 0.79 (0.64-0.98) 0.03  394 (73.51) 138 (76.24) 0.86 (0.58- 1.28) 0.47  
Absent 689 (24.14) 125 (20.10) referent  142 (26.49) 43 (23.76) referent  
Mosquito1         
Present 676 (23.69) 170 (27.33) 0.83 (0.68-1.00) 0.05  122 (22.76) 61 (33.70) 0.58 (0.40- 0.84) <0.01 
 Absent 2178 (76.31) 452 (72.67) referent  414 (77.24) 120 (66.30) referent  














Table 3.12: Comparison of CNS infections associated with known vs. unknown pathogens between groups in Taiwan in 2003 
 Meningitis Crude odds ratio p-value Encephalitis Crude odds ratio p-value 
 Unknown (%) Known (%) (95% CI)  Unknown (%) Known (%) (95% CI)  
Sex         
Female 564 (40.17) 186 (36.9) 1.25 (0.93-1.42) 0.20 203 (43.38) 62 (49.60) 1.28 (0.87-1.91) 0.21 
Male 840 (59.83) 318 (63.1) referent  265 (56.62) 63 (50.40) referent  
Age         
0-9 744 (52.99) 115 (22.82) 14.12 (6.73-29.59) <0.01 184 (39.32) 41 (32.80) 1.12 (0.23- 5.48) 0.89  
10-19 176 (12.54) 14 (2.78) 27.43 (11.18-67.29) <0.01 65 (13.89) 13 (10.40) 1.25 (0.24- 6.57) 0.79  
20-29 132 (9.40) 45 (8.93) 6.40 (2.91-14.10) <0.01 39 (8.33) 19 (15.20) 0.51 (0.10- 2.66) 0.43  
30-39 110 (7.83) 51 (10.12) 4.71 (2.14-10.34) <0.01 38 (8.12) 10 (8.00) 0.95 (0.17- 5.19) 0.95  
 40-49 93 (6.62) 59 (11.71) 3.44 (1.57-7.54) <0.01  45 (9.62) 11 (8.80) 1.02 (0.19- 5.51) 0.98  
 50-59 54 (3.85) 64 (12.70) 1.84 (0.83-4.10) 0.13  37 (7.91) 9 (7.20) 1.03 (0.19- 5.70) 0.98  
 60-69 36 (2.56) 67 (13.29) 1.17 (0.52-2.66) 0.70  31 (6.62) 8 (6.40) 0.97 (0.17- 5.48) 0.97  
 70-79 48 (3.42) 65 (12.90) 1.61 (0.72-3.60) 0.24  21 (4.49) 12 (9.60) 0.44 (0.08- 2.41) 0.34  
>80 11 (0.78) 24 (4.76) referent  8 (1.71) 2 (1.60) referent  
Seasonality         
Spring 279 (19.87) 121 (24.01) 0.86 (0.64-1.16) 0.32 102 (21.79) 29 (23.20) 0.89 (0.52- 1.54) 0.68  
Summer 386 (27.49) 124 (24.60) 1.16 (0.87-1.55) 0.31  89 (19.02) 36 (28.80) 0.63 (0.37- 1.06) 0.08  
Autumn 409 (29.13) 136 (26.98) 1.12 (0.84-1.49)  0.43  127 (27.14) 22 (17.60) 1.46 (0.82- 2.60) 0.20  
Winter 330 (23.50) 123 (24.40) referent  150 (32.05) 38 (30.40) referent  
Geographic area         









Urban 1250 (89.03) 469 (93.06) referent  433 (92.52) 114 (91.20) referent  
Pig farm           
Present 1054 (75.07) 383 (75.99) 0.95 (0.75-1.21) 0.68  348 (74.36) 99 (79.20) 0.76 (0.47- 1.23) 0.26  
Absent 350 (24.93) 121 (24.01) referent  120 (25.64) 26 (20.80) referent  
Mosquito1         
Present 455 (32.41) 160 (31.75) 1.03 (0.83-1.28) 0.79  106 (22.65) 29 (23.20) 0.97 (0.61- 1.55)  0.90  
 Absent 949 (67.59) 344 (68.25) referent  362 (77.35) 96 (76.80) referent  














Table 3.13: Comparison of CNS infections associated with known vs. unknown pathogens between groups in Taiwan in 2004 
 Meningitis Crude odds ratio p-value Encephalitis Crude odds ratio p-value 
 Unknown (%) Known (%) (95% CI)  Unknown (%) Known (%) (95% CI)  
Sex         
Female 536 (39.88) 215 (38.67) 0.95 (0.78-1.16) 0.62 267 (45.33) 58 (45.31) 1.00 (0.68-1.47) 1.00 
Male 808 (60.12) 341 (61.33) referent  322 (54.67) 70 (54.69) referent  
Age         
0-9 614 (45.68) 106 (19.06) 5.79 (2.97-11.30) <0.01 232 (39.39) 50 (39.06) 0.62 (0.14-2.79) 0.53  
10-19 203 (15.10) 24 (4.32) 8.46 (3.94-18.15) <0.01 79 (13.41) 7 (5.47) 1.50 (0.28-7.96) 0.63  
20-29 149 (11.09) 84 (15.11) 1.77 (0.89-3.54) 0.10  48 (8.15) 8 (6.25) 0.80 (0.15-4.18) 0.79  
30-39 122 (9.08) 59 (10.61) 2.07 (1.02-4.20) 0.04 47 (7.98) 13 (10.16) 0.48 (0.10-2.38) 0.37  
 40-49 92 (6.85) 66 (11.87) 1.39 (0.69-2.84) 0.36  53 (9.00) 12 (9.38) 0.59 (0.12-2.93) 0.52  
 50-59 50 (3.72) 68 (12.23) 0.74 (0.35-1.53) 0.41  38 (6.45) 17 (13.28) 0.30 (0.06-1.45) 0.13  
 60-69 52 (3.87) 53 (9.53) 0.98 (0.47-2.06) 0.96  40 (6.79) 11 (8.59) 0.49 (0.10-2.45) 0.38  
 70-79 43 (3.20) 77 (13.85) 0.56 (0.27-1.17) 0.12  37 (6.28) 8 (6.25) 0.62 (0.12-3.25) 0.57  
>80 19 (1.41) 19 (3.42) referent  15 (2.55) 2 (1.56) referent  
Seasonality         
Spring 352 (26.19) 128 (23.02) 1.37(1.02-1.84) 0.04 128 (21.73) 18 (14.06) 1.53 (0.83-2.84) 0.18  
Summer 429 (31.92) 160 (28.78) 1.34 (1.01-1.77) 0.05  141 (23.94) 41 (32.03) 0.74 (0.45-1.23) 0.25  
Autumn 318 (23.66) 146 (26.26) 1.08 (0.81-1.45) 0.59  162 (27.50) 35 (27.34) 1.00 (0.59-1.68) 0.99  
Winter 245 (18.23) 122 (21.94) referent  158 (26.83) 34 (26.56) referent  
Geographic area         









Urban 1196 (88.99) 501 (90.11) referent  555 (94.23) 115 (89.84) referent  
Pig farm           
Present 1036 (77.08) 437 (78.60) 0.92 (0.72- 1.16) 0.47  464 (78.78) 104 (81.25) 0.86 (0.53-1.39) 0.53  
Absent 308 (22.92) 119 (21.40) referent  125 (21.22) 24 (18.75) referent  
Mosquito1         
Present 354  (26.34) 176 (31.65) 0.77 (0.62- 0.96) 0.02  150 (25.47) 40 (31.25) 0.75 (0.50-1.14) 0.18  
 Absent 990 (73.66) 380 (68.35) referent  439 (74.53) 88 (68.75) referent  














Table 3.14: Comparison of CNS infections associated with known vs. unknown pathogens between groups in Taiwan in 2005 
 Meningitis Crude odds ratio p-value Encephalitis Crude odds ratio p-value 
 Unknown (%) Known (%) (95% CI)  Unknown (%) Known (%) (95% CI)  
Sex         
Female 749 (41.24) 241 (37.36) 0.85 (0.71-1.02) 0.08 303 (40.78) 78 (38.61) 1.09 (0.80-1.51) 0.58 
Male 1067 (58.76) 404 (62.64) referent  440 (59.22) 124 (61.39) referent  
Age         
0-9 933 (51.38) 195 (30.23) 5.29 (2.79-10.02) <0.01 302 (40.65) 108 (53.47) 0.80 (0.31-2.03) 0.64  
10-19 265 (14.59) 31 (4.81) 9.45 (4.58-19.48) <0.01 113 (15.21) 11 (5.45) 2.93 (0.98-8.80) 0.05  
20-29 189 (10.41) 56 (8.68) 3.73 (1.87-7.43) <0.01 49 (6.59) 9 (4.46) 1.56 (0.49-4.93) 0.45  
30-39 163 (8.98) 64 (9.92) 2.82 (1.42-5.58) <0.01  51 (6.86) 18 (8.91) 0.81 (0.28-2.32) 0.69  
 40-49 83 (4.57) 66 (10.23) 1.39 (0.69-2.80) 0.36  60 (8.08) 13 (6.44) 1.32 (0.44-3.91) 0.62  
 50-59 74 (4.07) 74 (11.47) 1.11 (0.55-2.22) 0.78  61 (8.21) 14 (6.93) 1.25 (0.42-3.66) 0.69  
 60-69 48 (2.64) 68 (10.54) 0.78 (0.38-1.61) 0.50  45 (6.06) 12 (5.94) 1.07 (0.35-3.25) 0.90  
 70-79 42 (2.31) 70 (10.85) 0.66 (0.32-1.37) 0.27  41 (5.52) 11 (5.45) 1.07 (0.35-3.28) 0.91  
>80 19 (1.05) 21 (3.26) referent  21 (2.83) 6 (2.97) referent  
Seasonality         
Spring 387 (21.31) 154 (23.88) 1.08 (0.81-1.43) 0.60 192 (25.84) 47 (23.27) 0.53 (0.32-0.89)  0.02  
Summer 736 (40.53) 224 (34.73) 1.41 (1.09-1.83) 0.01  193 (25.98) 103 (50.99) 0.24 (0.15-0.39) <0.01 
Autumn 409 (22.52) 145 (22.48) 1.21 (0.91-1.61) 0.19  158 (21.27) 26 (12.87) 0.79 (0.44-1.41) 0.43  
Winter 284 (15.64) 122 (18.91) referent  200 (26.92) 26 (12.87) referent  
Geographic area         









Urban 1619 (89.15) 566 (87.75) referent  677 (91.12) 186 (92.08) referent  
Pig farm           
Present 1363 (75.06) 524 (81.24) 0.69 (0.56-0.87) <0.01 560 (75.37) 153 (75.74) 0.98 (0.68-1.41) 0.91  
Absent 453 (24.94) 121 (18.76) referent  183 (24.63) 49 (24.26) referent  
Mosquito1         
Present 456 (25.11) 215 (33.33) 0.67 (0.55-0.82)  <0.01 166 (22.34) 52 (25.74) 0.83 (0.58-1.19) 0.31  
 Absent 1360 (74.89) 430 (66.67) referent  577 (77.66) 150 (74.26) referent  














Table 3.15: Comparison of CNS infections associated with known vs. unknown pathogens between groups in Taiwan in 2006 
 Meningitis Crude odds ratio p-value Encephalitis Crude odds ratio p-value 
 Unknown (%) Known (%) (95% CI)  Unknown (%) Known (%) (95% CI)  
Sex         
Female 819 (40.17) 185 (33.76) 0.76 (0.62-0.93) 0.01 306 (46.72) 57 (45.60) 0.96 (0.65-1.40) 0.82 
Male 1220 (59.83) 363 (66.24) referent  349 (53.28) 68 (54.40) referent  
Age         
0-9 985 (48.31) 121 (22.08) 13.96 (7.03-27.70) <0.01 239 (36.49) 27 (21.60) 0 (N/A) 0.13 
10-19 390 (19.13) 23 (4.20) 29.07 (13.30-63.53) <0.01 104 (15.88) 16 (12.80) 0 (N/A) 0.08 
20-29 234 (11.48) 43 ()7.85 9.33 (4.47-19.46) <0.01 42 (6.41) 8 (6.40) 0 (N/A) 0.06 
30-39 163 (7.99) 75 (13.69) 3.73 (1.83-7.61) <0.01  49 (7.48) 12 (9.60) 0 (N/A) 0.03 
 40-49 94 (4.61) 61 (11.13) 2.64 (1.27-5.50) 0.01  39 (5.95) 22 (17.60) 0 (N/A) <0.01 
 50-59 75 (3.68) 75 (13.69) 1.71 (0.82-3.57) 0.15  59 (9.01) 19 (15.20) 0 (N/A) 0.01 
 60-69 48 (2.35) 64 (11.68) 1.29 (0.60-2.74) 0.52  52 (7.94) 11 (8.80) 0 (N/A) 0.04 
 70-79 36 (1.77) 62 (11.31) 1.00 (0.46-2.16) 0.99  51 (7.79) 10 (8.00) 0 (N/A) 0.05 
>80 14 (0.69) 24 (4.38) referent  20 (3.05) 0 (0.00) referent  
Seasonality         
Spring 360 (17.66) 108 (19.71) 1.54(1.13-2.10) 0.01 161 (24.58) 32 (25.60) 0.61 (0.33-1.11) 0.11  
Summer 911 (44.68) 160 (29.20) 2.62 (1.98-3.47) <0.01 185 (28.24) 41 (32.80) 0.54 (0.30-0.97) 0.04  
Autumn 525 (25.75) 168 (30.66) 1.44 (1.08-1.91) 0.01  151 (23.05) 33 (26.40) 0.55 (0.30-1.01) 0.05  
Winter 243 (11.92) 112 (20.44) referent  158 (24.12) 19 (15.20) referent  
Geographic area         









Urban 1801 (88.33) 496 (90.51) referent  606 (92.52) 112 (89.60) referent  
Pig farm           
Present 1588 (77.88) 408 (74.45) 1.21 (0.97-1.50) 0.09  490 (74.81) 96 (76.80) 0.90 (0.57-1.41) 0.64  
Absent 451 (22.12) 140 (25.55) referent  165 (25.19) 29 (23.20) referent  
Mosquito1         
Present 618 (30.31) 177 (32.30) 0.91 (0.74-1.12) 0.37  136 (20.76) 36 (28.80) 0.65 (0.42-1.00) 0.05  
 Absent 1421 (69.69) 371 (67.70) referent  519 (79.24) 89 (71.20) referent  














Table 3.16: Comparison of CNS infections associated with known vs. unknown pathogens between groups in Taiwan in 2007 
 Meningitis Crude odds ratio p-value Encephalitis Crude odds ratio p-value 
 Unknown (%) Known (%) (95% CI)  Unknown (%) Known (%) (95% CI)  
Sex         
Female 610 (41.70) 229 (40.39) 0.95 (0.78-1.15) 0.60 320 (45.26) 68 (43.31) 1.08 (0.76-1.53) 0.66 
Male 853 (58.30) 338 (59.61) referent  387 (54.74) 89 (56.69) referent  
Age         
0-9 635 (43.40) 80 (14.11) 9.53 (5.34-17.00) <0.01 216 (30.55) 34 (21.66) 1.47 (0.56-3.82) 0.43  
10-19 249 (17.02) 30 (5.29) 9.96 (5.19-19.12) <0.01 126 (17.82) 15 (9.55) 1.94 (0.69-5.47) 0.21  
20-29 177 (12.10) 53 (9.35) 4.01 (2.17-7.40) <0.01 73 (10.33) 9 (5.73) 1.87 (0.61-5.77) 0.28  
30-39 129 (8.82) 70 (12.35) 2.21 (1.21-4.05) 0.01  49 (6.93) 14 (8.92) 0.81 (0.28-2.35) 0.70  
 40-49 81 (5.54) 75 (13.23) 1.30 (0.70-2.40) 0.41  59 (8.35) 24 (15.29) 0.57 (0.21-1.55) 0.27  
 50-59 82 (5.60) 86 (15.17) 1.14 (0.62-2.11) 0.67  66 (9.34) 23 (14.65) 0.66 (0.24-1.81) 0.42  
 60-69 40 (2.73) 67 (11.82) 0.72 (0.37-1.39) 0.32 40 (5.66) 17 (10.83) 0.54 (0.19-1.56) 0.26  
 70-79 45 (3.08) 76 (13.40) 0.71 (0.37-1.36)  0.30  52 (7.36) 15 (9.55) 0.80 (0.28-2.30) 0.68  
>80 25 (1.71) 30 (5.29) referent  26 (3.68) 6 (3.82) referent  
Seasonality         
Spring 209 (14.29) 109 (19.22) 1.11 (0.82-1.51) 0.50 147 (20.79) 35 (22.29) 0.65 (0.38-1.11) 0.11  
Summer 474 (32.40) 144 (25.40) 1.91 (1.45-2.50) <0.01 162 (22.91) 55 (35.03) 0.46 (0.28-0.74) <0.01  
Autumn 514 (35.13) 160 (28.22) 1.86 (1.43-2.43) <0.01 204 (28.85) 37 (23.57) 0.85 (0.51-1.43) 0.55  
Winter 266 (18.18) 154 (27.16) referent  194 (27.44) 30 (19.11) referent  
Geographic area         









Urban 1282 (87.63) 503 (88.71) referent  632 (89.39) 141 (89.81) referent  
Pig farm           
Present 1130 (77.24) 429 (75.66) 1.09 (0.87-1.37) 0.45  529 (74.82) 130 (82.80) 0.62 (0.39-0.97) 0.03  
Absent 333 (22.76) 138 (24.34) referent  178 (25.18) 27 (17.20) referent  
Mosquito1         
Present 361 (24.68) 155 (27.34) 0.87 (0.70-1.08) 0.22  131 (18.53) 47 (29.94) 0.53 (0.36-0.79) <0.01 
 Absent 1102 (75.32) 412 (72.66) referent  576 (81.47) 110 (70.06) referent  














Table 3.17: Comparison of CNS infections associated with known vs. unknown pathogens between groups in Taiwan in 2008 
 Meningitis Crude odds ratio p-value Encephalitis Crude odds ratio p-value 
 Unknown (%) Known (%) (95% CI)  Unknown (%) Known (%) (95% CI)  
Sex         
Female 528 (39.85) 305 (41.22) 0.94 (0.79-1.13) 0.54 270 (45.3) 71 (44.10) 1.05 (0.74-1.49) 0.79 
Male 797 (60.15) 435 (58.78) referent  326 (54.7) 90 (55.90) referent  
Age         
0-9 496 (37.43) 279 (37.70) 4.98 (2.38-10.40) <0.01 173 (29.03) 75 (46.58) 0.56 (0.23-1.33) 0.19  
10-19 223 (16.83) 32 (4.32) 19.51 (8.67-43.93) <0.01 68 (11.41) 12 (7.45) 1.37 (0.49-3.83) 0.55  
20-29 182 (13.74) 50 (6.76) 10.19 (4.64-22.39) <0.01 50 (8.39) 8 (4.97) 1.51 (0.50-4.59) 0.47  
30-39 167 (12.60) 67 (9.05) 6.98 (3.21-15.16) <0.01 70 (11.74) 9 (5.59) 1.88 (0.64-5.52) 0.25  
 40-49 97 (7.32) 68 (9.19) 3.99 (1.82-8.76) <0.01  51 (8.56) 13 (8.07) 0.95 (0.34-2.64) 0.92  
 50-59 77 (5.81) 79 (10.68) 2.73 (1.24-6.00) 0.01  55 (9.23) 14 (8.70) 0.95 (0.34-2.61) 0.92  
 60-69 41 (3.09) 68 (9.19) 1.69 (0.74-3.83) 0.21  45 (7.55) 9 (5.59) 1.21 (0.41-3.60) 0.74  
 70-79 32 (2.42) 69 (9.32) 1.30 (0.56-2.99) 0.54  55 (9.23) 14 (8.70) 0.95 (0.34-2.61) 0.92  
>80 10 (0.75) 28 (3.78) referent  29 (4.87) 7 (4.35) referent  
Seasonality         
Spring 316 (23.85) 165 (22.30) 1.02 (0.77-1.34) 0.90 147 (24.66) 33 (20.50) 0.61 (0.33-1.11) 0.10  
Summer 478 (36.08) 259 (35.00) 0.98 (0.76-1.26) 0.89  166 (27.85) 63 (39.13) 0.36 (0.21-0.62) <0.01  
Autumn 264 (19.92) 174 (23.51) 0.81 (0.61-1.07) 0.13  136 (22.82) 45 (27.95 0.41 (0.23-0.73) <0.01  
Winter 267 (20.15) 142 (19.19) referent  147 (24.66) 20 (12.42) referent  
Geographic area         









Urban 1161 (87.62) 686 (92.70) referent  544 (91.28) 149 (92.55)  referent  
Pig farm           
Present 1023 (77.21) 548 (74.05) 1.19 (0.96-1.46) 0.11  444 (74.50) 139 (86.34) 0.46 (0.28-0.75) <0.01 
Absent 302 (22.79) 192 (25.95) referent  152 (25.50) 22 (13.66) referent  
Mosquito1         
Present 314 (23.70) 265 (35.81) 0.56 (0.46-0.68) <0.01 104 (17.45) 39 (24.22) 0.66 (0.44-1.00) 0.05  
 Absent 1011 (76.30) 475 (64.19) referent  492 (82.55) 122 (75.78) referent  





Table 3.18: Meningitis and encephalitis associated with HIV positive cases in Taiwan from 1996-2008 
Cause of meningitis/encephalitis (case number) HIV positive 
Meningitis  
Cryptococcal meningitis (n=792) 21 
Syphilitic meningitis (n=13) 2 
Unspecified bacterial meningitis (n=2306) 2 
Tuberculous meningitis (n=1727) 1 




Encephalitis due to toxoplasmosis (n=6) 1 
Listeria encephalitis (n=37) 1 







Table 3.19: Trend analysis of the incidence of meningitis and encephalitis in Taiwan from 1996 to 2008 using the negative 
binomial regression 
Cases Estimate 95% CI P-value 
Meningitis cases -0.028 (-0.09 to 0.03) 0.40 
Unknown etiology -0.040 (-0.12 to 0.04) 0.32 
Known etiology 0.006 (-0.01 to 0.02) 0.55 
Encephalitis cases 0.021 (-0.01 to 0.05) 0.15 
Unknown etiology 0.025 (<0.01 to 0.05) 0.03 







Figure 3.1A: Map of urbanization levels in 329 townships in Taiwan. Urbanization is stratified into seven levels based on five 
indicators, as described in the methods section and, previously, by Liu*.  Level 1 represents the most heavily urbanized area, and 
level 7 represents the least urbanized area. Most urban townships are located on the west coast of Taiwan. 
*Liu CY, H. Y., Chuang YL, Chen YJ, Weng WS, et al. (2006). "Incorporating development stratification of Taiwan townships into sampling 




















Figure 3.1B: Map of urban and rural areas in Taiwan. Urbanization levels are further categorized into urban area (levels 1-3) 
and rural area (levels 4-7). Most of the urban areas are located on the western part of Taiwan, with Taipei city in the north, 











Figure 3.2: Distribution of pigs in Taiwan. The area of highest pig density was clustered in southern Taiwan, followed by central 















Figure 3.3: Distribution of Aedes aegypti mosquitoes in Taiwan. Aedes aegypti is distributed exclusively below the Tropic of 
Cancer. Townships (yellow) were categorized as having endemic Aedes aegypti mosquito density (Breteau index, BI) was >5% 
(level 2). The Breteau index is the number of positive containers for Aedes aegypti larvae per 100 houses inspected. Data source 















Figure 3.4: (A) Above, the incidence of meningitis in individual year from 1996-2008, ranging from 8.37 (year 2004) to 34.39 
(year 2001) per 100,000 population. One large outbreak of meningitis was observed in 2001. (B) Below, the incidence of 





































































Additional statistics information: 
Statistical model for counting data on cases of CNS infections in this study 
 
Temporal trends in cases of CNS infection are modeled using both Poisson and negative 
binomial regression models. When there is no over-dispersion, Poisson regression would be 
fitted between the dependent variable and co-variables. A negative binomial regression model 
would be fitted in the case of over-dispersion. 
The regression is modeled as: 
 
logλij = μ+ β1(time) , where λij is the disease occurrence for time i, μ is a grand mean, time is the 
effect of the year from 1996. 
 
As values of deviance and Pearson χ2 divided by the degree of freedom were appreciably greater 
than 1 in the Poisson regression model and close to 1 in the negative binominal regression model, 
the variance in the Poisson regression model is over-dispersed (i.e., the true variance is larger 
than μ), indicating inadequate fit of the Poisson model. Therefore, we use a negative binominal 






The average percentage change per year in the incidence was derived from the regression 
coefficients in the models. For example, the incidence rate ratios were obtained by 
exponentiation of the regression coefficients, and estimated average annual changes in the 
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Figure 4.1: Scan and analysis of microarrays. The microarrays are scanned by NimbleGen microarray scanner, and array images 
are generated. The left column shows the scanned picture of the microarrays. There are 24 microarrays on one slide. Over 66,000 
genetic probes are printed in one microarray. The picture in the right column shows a zoomed-in image of the selected array. The 







Accession taxid Description P_value q Probe_count/Total 
NC_006560 10317 Cercopithecine herpesvirus 2, complete genome. 3.74572978980651e-11 
 
192/1294 
NC_004812 10325 Cercopithecine herpesvirus 1, complete genome. 6.84626259287499e-10 
 
190/1315 
NC_007653 340907 Cercopithecine herpesvirus 16, complete genome. 5.20677520195196e-08 
 
191/1289 
NC_006151 10345 Suid herpesvirus 1, complete genome. 8.73166797798223e-07 
 
191/996 
NC_001806 10298 Human herpesvirus 1, complete genome. 9.73997263029271e-06 
 
213/1614 
NC_001798 10310 Human herpesvirus 2, complete genome. 1.29079422744542e-05 
 
221/1577 
NC_001847 10320 Bovine herpesvirus 1, complete genome. 3.7091340240379e-05 
 
182/1029 





Figure 4.2: Positive results identified by microarray. (a) Pathogens are considered positive by microarray given a p-value <10-5 
(above, yellow); (b) a schematic of the probe plot for human herpes virus 1. The probe is considered positive when the signal 
intensity is above the .9 quartile in the distribution of the raw intensities (below). 
 
 
 
